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8i Chapter 1 General Introduction and outline of the thesis
General introduction
Molecular tumorigenesis
Pathology is the medical discipline that diagnoses 
disease by investigation of tissues, cells and bodily 
fluids. The pathology diagnosis forms the basis of 
many medical treatments. Generally, tissue specimens 
obtained from a patient by small biopsies are formalin 
fixed in its entirety prior to further processing in tissue 
blocks, except when additional techniques require 
native material. In case of larger resection or excision 
specimens, preliminary examination and description 
by a pathologist is required, while preserving fresh 
samples for biobanking prior to formalin fixation. 
After fixation, further sampling of resection 
specimens (‘grossing’) is performed in order to 
select tissue parts in small cassettes for microscopic 
evaluation. The selected formalin fixed tissue parts 
are subsequently embedded in paraffin. The formalin 
fixed and paraffin embedded (FFPE) tissue blocks are 
sectioned on a microtome and the tissue sections 
of a few micrometers thick are glued on glass slides. 
After deparaffinization the sections are generally 
stained with hematoxylin and eosin (H&E) to obtain 
cellular and nuclear detail, which is evaluated 
by microscopic examination (histopathology). If 
needed, additional information can be obtained 
from the tissue sections by immunohistochemical 
stainings, which visualize the presence or absence 
of specific cellular or extracellular constituents. 
For tumor evaluation, traditional histopathology 
and immunohistochemistry is more and more 
complemented with molecular pathology (figure 1). 
Diagnostic molecular pathology aims at facilitating 
proper diagnosis, prognosis and/or treatment of 
patients with cancer or suspected cancer by analyzing 
aberrations in the nucleic acids DNA and RNA. This 
thesis will focus on DNA analysis.
 DNA (deoxyribonucleic acid) is a complex 
molecule that contains the information needed for 
development, functioning and reproduction of living 
organisms. Four different bases (adenine, thymine, 
guanine and cytosine) code this information; these 
bases are attached to a sugar-phosphate backbone, 
together called a nucleotide. Usually, DNA is organized 
as a double helix formed by two long strands of DNA, 
with bases from both strands joined as base pairs. 
Human DNA is organized into 23 chromosome pairs 
(one set inherited from each of the parents) that 
are located in the cell nucleus. Additionally a small 
Figure 1. Molecular pathology timeline. 
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amount of DNA is present in the mitochondria. 
Mitochondrial DNA (mtDNA) is circular, present in 
numerous copies per cell and is inherited solely from 
the mother. 
 The general human DNA sequence can be 
described by approximately 3 billion base pairs; this 
sequence is largely identical for all human beings. 
However, approximately 0.5% of the DNA sequence 
differs between two human individuals. Most of these 
variations are neutral, which means that they have no 
selective effect on the organism. The most common 
type of sequence variation is the single nucleotide 
polymorphism (SNP), which is a difference of one 
base in the DNA sequence that occurs in at least 1% 
of the population. DNA profiling (to distinguish one 
individual from another) is usually based on short 
tandem repeat (STR) analysis. STR are repetitions of 
short sequences of nucleotides with variable lengths 
that are present on many chromosomes. Multiple 
other types of genetic variation exist, including copy 
number variations and epigenetic variations.
 Cancers arise due to mutations in the 
DNA, which in contrast to neutral variants have a 
pathogenic effect. Tumor cells accumulate mutations 
as a result of genomic instability, with chromosomal 
and microsatellite instability as the most common 
mechanisms (figures 2 and 3). Chromosomal 
instability (CIN) is detected in the majority of tumors, 
and involves deletions or gains of whole chromosomes 
or parts of chromosomes. Microsatellite instability 
(MSI) is a type of genetic hypermutability, which is 
most pronounced in repeated sequences of DNA, the 
microsatellites. Other mechanisms resulting in DNA 
mutations include exposure to mutagens (smoking or 
ultraviolet light) and abnormal activity of enzymes that 
modify DNA (APOBEC) or of error-prone polymerases 
(POLE)1. During tumorigenesis, genomic instability 
mechanisms are considered to result in the activation 
of proto-oncogenes and the inactivation of tumor 
suppressor genes, leading to the transformation 
of a normal cell into a tumor cell. The mutated 
proto-oncogenes and tumor suppressor genes are 
drivers of the tumor and render oncogene addiction 
to the tumor cells. In addition to driver mutations, 
genomic instability will result in the occurrence of 
mutations without effect on the phenotype, the 
so-called passenger or hitchhiker mutations.  
 Most tumors are the result of somatic 
mutations, these mutations occur sporadically in 
any cell of the body. However, a minority of cancers 
arises in the context of a hereditary cancer syndrome, 
a disorder in which mutations are inherited from 
one of the parents. These inherited mutations are 
called germline mutations and are usually present 
in all cells of the affected individual. Most hereditary 
cancer syndromes are caused by germline mutations 
in tumor suppressor genes, which need a second hit 
before the gene is inactivated2 (figure 4). The presence 
of a germline mutation (the first hit) predisposes the 
affected individual to cancer development. 
Figure 3. Chromosomal or genetic changes due to mutations, 
chromosomal instability (CIN) and microsatellite instability (MSI).
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Figure 2. Tumorigenesis.
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Diagnostic molecular pathology
An overview of the routine molecular tests performed 
at the Erasmus MC department of pathology is shown 
in Table 1. The main reasons for testing for somatic 
DNA aberrations are:
To stratify patients for (targeted) therapy 
For some tumor types, the optimal 
treatment depends on the presence 
or absence of specific somatic DNA 
aberrations. Targeted therapies, for 
example, attack the tumor cells by 
specifically blocking mutated proteins or essential 
pathways that drive cell growth and proliferation. 
Molecular analysis reveals the driver mutations of 
tumors, and is therefore essential to stratify patients 
for the appropriate targeted therapy. 
Differential diagnosis 
Analysis of somatic DNA aberrations 
is also useful for differential diagnosis, 
to confirm or exclude a particular 
diagnosis. Some tumor types are 
characterized by the presence of 
certain genetic aberrations, for example a specific 
mutation in MYD88 is detected in up to 90% of 
Waldenström macroglobulinemia (WM)3. As this 
mutation is highly specific for WM, identification 
of a MYD88 mutation can help in diagnosing WM if 
histopathological evaluation is not conclusive. 
In the context of hereditary testing
Detection of somatic DNA aberrations 
in tumor cells can help in deciding 
whether or not a patient should 
be referred for germline testing, 
as some hereditary syndromes are 
characterized by specific somatic aberrations.
In the last five years, molecular pathology has 
become increasingly important in patient care. At 
the Erasmus MC, this is illustrated by the transition 
of the laboratory from semi-research to ISO certified. 
Furthermore, molecular results are no longer hidden 
in the ‘notepad’ of the laboratory information 
management system, but are now a prominent 
part of the pathology report. In 2013 an official 
2-year educational program for clinical scientist in 
molecular pathology (Klinisch moleculair bioloog in 
de pathologie) was established in the Netherlands. 
From 2014, all laboratories performing molecular 
testing in the Netherlands are required to employ a 
Clinical Scientist in Molecular Pathology, or at least 
have access to their expertise, as was described 
in guidelines introduced by the Dutch Society of 
Pathology (Nederlandse Vereniging voor Pathologie).
 Molecular pathology is a quickly evolving 
discipline: implementation of new research 
discoveries as well as new techniques into the 
routine diagnostic setting is constantly performed. 
Targeted treatment options increased rapidly the 
last several years for multiple tumor types, including 
lung adenocarcinoma, colorectal carcinoma and 
melanoma4-6. Additionally, multiple resistance 
mechanisms to these targeted treatments have been 
described, part of which are targets for treatment 
itself7,8. To detect all aberrations relevant for a specific 
tumor type, molecular tests need to be adapted 
continuously. 
 One of the most important changes in 
diagnostic molecular pathology over the past few 
years was the introduction of next generation 
sequencing (NGS)9-11. Multiple different platforms for 
NGS are currently available, of which the Ion Torrent 
?
Figure 4. Inactivation of a tumor suppressor gene with and 
without the presence of a germline mutation.
Germline mutation
No germline mutation
1 somatic hit
2 somatic hits
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Table 1. Overview of routine molecular tests performed at the Erasmus MC department of Pathology, Rotterdam (excluding in situ 
hybridization). Only the clinically most relevant genes are shown.
Tumor type Molecular abberations tested Reason for testing
Therapy Differential 
diagnosis
In the context 
of heriditary 
testing
Brain tumors IDH1/2, ATRX, TP53, EGFR, PTEN, TERT, 
CIC, FUBP1 mutations & copy number 
aberrations of chromosomes 1p, 7, 9, 10, 12 
and 19q
v v
MGMT methylation v
Colorectal carcinoma KRAS, BRAF, NRAS mutations v
MSI v v
MLH1 promoter methylation v
MMR gene mutations v
Desmoid tumors CTNNB1 mutations v
Gastro-intestinal stromal tumors KIT, PDGFRA, BRAF mutations v v
SDH gene mutations v
Langerhans cell histiocytosis BRAF mutations v
Melanoma BRAF, NRAS, KIT, GNAQ, GNA11 mutations v
Non-small cell lung carcinoma EGFR, KRAS, HER2, BRAF, MET mutations v
Ovarian carcinoma MSI, MLH1 promoter methylation v
MMR gene mutations v
FOXL2 mutations v
BRCA1/2 mutations v v
Pheochromocytoma, paraganglioma SDH gene, RET, VHL, NF1 mutations v
Thyroid carcinoma RET, KRAS, NRAS, HRAS, BRAF mutations v
Waldenström macroglobulinemia MYD88 mutations v v
Multiple tumor types: clonality 
determinations
Mutations & copy number aberrations in 
multiple genes
v
Multiple tumor types: tissue 
identification
Short tandem repeat analysis v
PGM (Life) and the MiSeq (Illumina) are predominantly 
used in molecular pathology laboratories in the 
Netherlands. Most diagnostic laboratories use 
targeted NGS, meaning that only a subset of genomic 
regions is screened, rather than the whole genome 
or exome. The basic principle of NGS is that, in 
contrast to Sanger sequencing, numerous small DNA 
fragments are amplified simultaneously. From each 
DNA fragment, hundreds to thousands of individual 
molecules are sequenced (‘massive parallel’)
(figure 5). Therefore, it is possible to analyze a 
multitude of genes even when only a limited amount 
of tissue is available, as often is the case in diagnostic 
molecular pathology. Because every single molecule 
results in a separate read (DNA sequence), NGS is 
more sensitive in mutation detection compared to 
Sanger sequencing. 
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Figure 5. Sanger sequencing versus targeted next generation sequencing.
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 Additionally, NGS can also be used for 
copy number detection, for example using SNPs. 
Informative SNPs, which are sequence variants that 
are present on one allele, but not on the other, can 
be used to discriminate between both alleles. If no 
copy number aberrations are present, all informative 
SNPs should be present in a 1:1 ratio (equal 
amount of both alleles). If however loss or gain of a 
chromosomal region is present, the ratio will diverge 
from 1:1 indicating a copy number change. Another 
way to detect copy number aberrations is using 
coverage analysis. The coverage of a DNA fragment 
represents the total number of reads that is detected 
for that fragment. NGS is based on a multiplex PCR, 
during which some DNA fragments amplify more 
efficient than others. The coverage of a specific DNA 
fragment relative to the total number of reads for 
that sample, is however quite stable. A high or low 
relative coverage therefore implies that there is gain 
or loss, respectively, of that particular chromosomal 
region.
Clonality determinations 
Some patients present with multiple 
tumors, either synchronous (at the 
same time) of metachronous (with 
time in between). These tumors can 
either be multiple primary tumors, or 
can be one primary tumor with one or more metastasis 
(metastatic disease). It is of prime importance to 
distinguish between these possibilities for patient 
care12, however, this is not always possible based on 
clinical and histopathological characteristics. 
 Each primary tumor has particular unique 
somatic genomic aberrations, and detection of 
these aberrations can facilitate proper diagnosis for 
these patients. If multiple tumors show similar DNA 
aberrations this suggest that they have a common 
origin, whereas different aberrations suggests 
multiple origins. An ideal clonality marker gives unique 
results for every single tumor tested (high predictive 
power). This is not limited to somatic aberrations, but 
can also be other unique characteristics of a cell, as 
long as they are helpful in discriminating one tumor 
from another. 
 Examples of unique markers are the highly 
diverse immunoglobulin gene rearrangements 
in B-cells. During lymphocytic development, a 
mechanism called V(D)J recombination occurs, 
which is the random rearrangement of variable (V), 
diversity (D) and joining (J) gene segments (figure 6). 
This mechanism results in a highly diverse repertoire 
of immunoglobulins for antigen detection. As B-cell 
lymphoma are clonal expansions of one particular 
B-cell, all lymphoma cells harbor the same V(D)
J rearrangement, which is highly unique for that 
particular tumor.
 Unfortunately, for most tumors unique 
markers are not available. For most clonality 
determinations in molecular pathology, tumors are 
therefore broadly screened for mutations as well as 
copy number aberrations. Genes frequently affected 
in a wide range of tumor types are for example 
oncogenes of the mitogen-activated protein kinase 
(MAPK) or PIK3CA pathway and tumor suppressor 
genes like TP53, PTEN and CDKN2a. Additionally, 
many tumors show loss of heterozygosity (LOH) of 
(part of) chromosomes. The predictive power of 
these aberrations for determining tumor clonality 
varies, as some aberrations are more unique than 
others, also depending on the tumor type in which 
they are detected. However, testing a combination of 
multiple markers, each of low predictive value, can 
also help in determining tumor clonality.
Molecular pathology 
in the context of hereditary testing 
Some tumors arise in the context of 
a hereditary syndrome; mutations 
in the germline can predispose 
for specific tumor types. In the 
Figure 6. V(D)J recombination during lymphocytic development.
D to J recombination
V to DJ recombination
V-segments D-segments J-segments Constant region
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Netherlands, patients suspected of being germline 
mutation carriers are counseled by the department 
of clinical genetics. This suspection can for example 
be based on a young age at diagnosis, the presence 
of multiple tumors, or family history. Some hereditary 
syndromes are characterized by specific somatic 
aberrations, as is the case for Lynch syndrome (LS). 
Patients with LS have germline mutations in one of 
the mismatch repair (MMR) genes or a germline 
deletion in EPCAM, which predispose for various 
types of cancer, including colorectal and endometrial 
cancer13-16. Tumors of LS patients have common 
somatic aberrations: MSI and aberrant MMR protein 
expression. If a patient is suspected of LS, screening 
of the tumor(s) for MSI and MMR protein expression 
helps to decide whether or not the patient should be 
referred for counseling17. 
 Additionally, testing for somatic aberrations 
can also complement hereditary testing during 
counseling. For tumor suppressor genes, germline 
mutations usually are only the first hit, and a second 
hit is needed to inactivate the gene and to drive 
tumorigenesis. This second hit is mostly loss of the 
wildtype allele (figure 4), which can be detected 
by somatic analysis of the tumor. When a germline 
variant of unknown significance is found in a patient 
suspected of a hereditary syndrome, somatic 
analysis can help in determining whether this variant 
might be pathogenic. For some patients suspected 
of a hereditary syndrome, no germline mutations or 
variants are detected in the specific genes known to 
be implicated in that particular syndrome. Detection 
of somatic aberrations in these genes suggests that 
these tumors have a sporadic origin and therefore 
facilitates proper diagnosis of these patients and 
their relatives18,19. 
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Outline of the thesis
In this thesis studies are described on the application 
of a variety of molecular analyses in solving diagnostic 
difficulties that remained unsolved based on clinical 
and histopathological characteristics. The first part, 
clonality determinations, focuses on the use of 
unique DNA markers or somatic DNA aberrations 
to define tumor origin or the clonal relationships 
between multiple tumors from one patient. The 
second part, molecular diagnostics in the context 
of hereditary testing, focuses on the interface of 
germline and somatic diagnostics by clinical genetics 
and pathology, respectively. The central theme of 
this thesis is the application of molecular analyses in 
a routine diagnostic setting. 
Part I - Clonality determinations
In chapter 2 a patient with a metastasis of a colorectal 
carcinoma in a transplanted liver is described. As 
a colonoscopy was negative for this patient, the 
diagnostic question was raised whether this tumor 
originated from the patient itself or from the donor. 
As somatic aberrations of the tumor are not helpful 
for this question, unique patient specific markers 
were tested to determine the origin of the metastasis.
 Clonality markers with a very high 
predictive power are immunoglobulin heavy (IGH) 
and Ƙ light chain (IGK) gene rearrangements in 
lymphoma. Occurrence of these rearrangements is 
not tumor-specific, all lymphocytes harbor unique 
immunoglobulin rearranged sequences. However, 
when a tumor originates from one of these 
lymphocytes, all lymphoma cells will harbor this 
unique rearranged sequence. Detection of these 
unique sequences can therefore help in discriminating 
multiple primary lymphomas from metastatic 
disease. In chapter 3 IGH and IGK rearrangements 
were studied in patients with successive B-cell 
lymphomas to determine whether these lesions 
were primary tumors and recurrences or unrelated 
multiple primary lymphomas.
 Most clonality assays focus on genomic 
DNA, however, human cells also contain multiple 
copies of mitochondrial DNA (mtDNA). Alterations 
in mtDNA have been described for multiple tumor 
types. In chapter 4 the potential use of the mtDNA 
D310 marker for tumor clonality determinations is 
discussed. 
 In the last years targeted NGS has been 
introduced into multiple molecular pathology 
laboratories, enabling the analysis of many genes 
simultaneously. The accuracy and additional value of 
targeted NGS for determining the clonal relationship 
between two lung lesions of a patient is discussed in 
chapter 5. 
 In chapter 6 the value of targeted NGS in the 
diagnostic workup of BRCA1/2 gene mutation carriers 
with more than one tumor location was evaluated, 
using a custom made primer panel for the detection 
of mutations as well as copy number changes.
Part II - Molecular diagnostics in the context of 
hereditary testing
Familial Adenomatous Polyposis (FAP) is an inherited 
disorder characterized by the onset of multiple 
polyps throughout the colon, which can give rise 
to colon cancer. FAP is caused by germline APC 
mutations. Desmoid tumors (soft tissue tumors) can 
occur sporadically or can be a first manifestation of 
FAP, however, germline APC testing is not routinely 
performed in children with desmoid tumors. The vast 
majority of these tumors are caused by mutations 
in APC or CTNNB1, which are mutually exclusive. 
In chapter 7 β-catenin immunohistochemistry and 
CTNNB1 mutation analysis were used to identify 
possible APC germline mutation carriers among 
children with desmoid tumors. 
 Diagnostic strategies for selection of patients 
for Lynch syndrome (LS) counseling include MSI 
testing and/or immunohistochemical analysis of the 
MMR proteins in tumor tissue. Chapter 8 discusses 
a pitfall in this screening strategy for a family with 
biallelic PMS2 mutations.
 Patients indicated as suspected of LS, 
based on the LS algorithm17, are tested for germline 
mutations in the MMR gene(s). However, in 35% of 
these patients no germline mutations in the MMR 
genes are detected20,21. In chapter 9 somatic MMR 
gene aberrations were studied in colorectal and 
endometrial cancers of suspected LS patients without 
germline MMR gene mutations. 
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Chapter 2
CASE REPORT
Donor-transmitted metastasis 
of colorectal carcinoma in a 
transplanted liver
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Abstract
A 62-year-old man with alcoholic liver cirrhosis underwent liver transplantation. The transplantation 
went uneventful and the ultrasound imaging of the liver performed after transplantation did not 
show any abnormalities. Eighteen months later, an intra-hepatic focal lesion was found on ultrasound. 
A contrast-enhanced ultrasound revealed a lesion with a malignant pattern of contrast uptake. The 
histopathological and subsequent molecular pathological analysis concluded a colorectal metastasis of 
donor origin. The donor had no history of malignancy but no complete autopsy had been performed which 
illustrates the importance of the meticulous donors‘ screening. Transplanted patients carry a high risk of 
developing malignancy in general but donor related-tumors are very rare. The therapeutic considerations 
differ substantially between recipient- and donor-related malignancies. Therefore, considering the possibility 
of donor-related tumor by raising suspicion of malignant lesion with appropriate imaging and distinction from 
recipient-related malignancy by molecular analysis are crucial for proper therapeutic decision. 
20i Chapter 2 Donor-transmitted metastasis of colorectal carcinoma in a transplanted liver
Introduction
Transmission of cancer from donor to recipient is 
a rare complication of solid organ transplantation. 
These donor-related tumors have been divided 
into two distinct entities, donor transmitted 
and donor derived tumors1. Donor transmitted 
tumors are defined as tumors present in the 
donor at the time of transplantation, in contrast 
to donor derived tumors that develop de novo in 
transplanted donor cells. To state the diagnosis of 
donor-related tumor, a good quality imaging and a 
molecular-pathological analysis are required. Here, 
we report a case of a donor transmitted metastasis 
of colorectal carcinoma in a liver transplant recipient 
in which the contrast-enhanced ultrasound (CEUS) 
directed further evaluation of a focal lesion detected 
in the transplanted liver. 
Clinical history and imaging – part I
A 62-years-old man with alcoholic liver cirrhosis was 
placed on the waiting list for liver transplantation. 
During the period on the waiting list, he developed 
two intra-hepatic localizations of hepatocellular 
carcinoma (HCC) that were treated with 
radio-frequency ablation. Three years later, he 
underwent a liver transplantation with a deceased 
donor liver from a 69-years old female patient 
who died of cerebral vascular event and without 
a history of malignancy. The explanted liver of the 
patient showed three localizations of hepatocellular 
carcinoma. There were no macroscopic abnormalities 
noticed of the donor liver and the ultrasound 
performed after transplantation showed no lesions. 
The post-transplantation period went uneventful 
with a good graft function and the only long-term 
complication was the development of de novo 
diabetes mellitus. 
 Ultrasound at 18 months after 
transplantation showed lesion in the liver
(Figure 1) of irregular shape, diameter of 5 cm and a 
homogenous hyperechogenic character. The overall 
aspect of the liver parenchyma and vasculature 
was normal. The differential diagnosis of this lesion 
was focal steatosis or recurrence of HCC. As a 
result of the patient‘s claustrophobia, a computed 
tomography (CT) scan instead of MRI was performed 
and showed the lesion with no characteristic 
features of malignancy. CEUS using 2.5 ml Sonovue 
revealed an enhancement pattern suspicious of 
malignancy with a rapid arterial enhancement and a 
wash-out in the late venous phase within 2–3 min 
after administration of contrast (Figure 2). Therefore, 
an ultrasound-guided biopsy of the lesion was 
performed, showing a small fragment of tissue 
possibly of colonic origin. Therefore, a colonoscopy 
was performed, but no abnormalities were revealed. 
A CT scan repeated two months later showed a 
growth of the focal lesion from 5 to 7 cm and a new 
adjacent lesion of 2.7 cm. The histological evaluation 
of the repeated biopsy showed an adenocarcinoma 
compatible with a metastasis of colorectal carcinoma. 
The colonic origin was confirmed by additional 
immunohistochemical staining, cytokeratin 20 and 
caudal related homeobox-2 (CDX-2) were both 
positive in the tumor cells, and cytokeratin 7 was 
Figure 1. Ultrasound performed 18 months after liver 
transplantation showing an irregularly shaped hyperechogenic 
lesion of 5 cm in segment 8 in the transplanted liver.
Figure 2. Contrast-enhanced ultrasound of the focal lesion in 
transplanted liver (a; B-mode) with a rapid arterial enhancement 
within few seconds after injection of 2.5 ml Sonovue contrast (b) 
and wash-out in the late venous phase at 2 min after contrast 
injection (c).
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negative (Figure 3). The repeated colonoscopy being 
negative, the suspicion of donor-transmitted tumor 
was raised and molecular analysis was performed. 
Molecular analysis
First, tumor and normal tissues were genotyped. 
DNA was extracted from formalin-fixed paraffin-
embedded (FFPE) tissues. A tissue area enriched 
for a high percentage of tumor cells and normal 
transplanted liver tissue were collected from sections 
by manual microdissection (Figure 4). Reference DNA 
was obtained from explanted FFPE liver tissue. 
 Genotyping was performed by short 
tandem repeat (STR) profiling using the Powerplex 
16 system (Promega). This system analyzes 15 STR 
loci and one sex chromosome marker. For each STR 
locus the number of repeats present was calculated 
using GeneMarker software (SoftGenetics). Results 
obtained with the green fluorescent labelled markers 
are shown in Figure 5. In Table 1, the repeat numbers 
are given for all samples examined. 
Comparison of the genotypes of tumor and 
explanted liver tissue showed that 13 markers display 
different number of repeats (Table 1). The major 
peaks of the transplanted liver tissue corresponded 
to the genotype of the tumor tissue and the minor 
peaks matched the genotype of the explanted tissue. 
These results strongly indicate that the tumor cells are 
Figure 3. Biopsy of the focal liver lesion showing a 
mucus-producing adenocarcinoma (PAS staining), with positive 
staining for cytokeratin 20 and CDX-2 and no staining for 
cytokeratin 7, compatible with metastasis of a primary colon 
tumor.
Figure 4. Tissue from the index patient (a), from which liver cells 
(b; transplanted liver) and tumor cells (c) were isolated.
Figure 5. STR profiles of six markers (D5S818, D13S317, D7S820, 
D16S539, CSF1PO, Penta D) for explanted liver tissue (a), tumor 
tissue (b) and transplanted liver tissue (c). The transplanted liver 
sample (c) shows a combined donor (yellow boxes) and acceptor 
(grey boxes) STR pattern. All alleles of the tumor sample (b) are 
present in the transplanted liver sample and (except the alleles 
from marker D13S317) not in the explanted liver (a), indicating 
that the tumor cells are of donor origin. Several donor derived 
alleles in the transplanted liver are not present in the tumor 
tissue demonstrating DNA loss in the neoplastic cells (with 
markers D5S818, D7S820, and D16S539). 
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of donor origin. To further establish the female origin 
of the tumor cells, fluorescent in situ hybridization 
(FISH) of the X and Y chromosomes was carried out 
using Satellite Enumeration probes (DXZ1 and DYZ3, 
Poseidon), following standard protocols 
All tumor cells as well as the transplanted 
liver cells showed either one or two X chromosomes, 
but no Y chromosome (Figure 6). The only cells 
harboring both an X and Y chromosome were 
infiltrating lymphocytes. These results underscore 
that the tumor cells are derived from female donor 
tissue. 
Clinical history and imaging – part II
Thus, 18 months after the transplantation, the patient 
was diagnosed with a donor-related metastasis of 
colorectal carcinoma in the transplanted liver. At 
further evaluation, no other localizations of this 
tumor were found. As a result of a recent myocardial 
infarction, cerebral stroke, and the development of 
psychiatric disorder with paranoid features, neither 
re-transplantation nor the local or systemic therapy 
could be offered. Patient died several months later, 
less than three years after the liver transplantation. 
Figure 6. Fluorescent in situ hybridization was performed for 
the X and Y chromosomes, which are labeled green and red, 
respectively. A group of tumor cells is shown, together with some 
detached tumor cells (white arrowhead) and lymphocytes (grey 
arrowhead). The tumor cells have two X chromosomes, which 
confirms their female origin.
Table 1. Repeat numbers at short tandem repeat loci for explanted liver tissue, tumor tissue and transplanted liver tissue. The alleles 
of the tumor tissue are similar to the major peaks of the transplanted liver tissue, and different from the explanted liver tissue. This 
indicates that the tumor cells were derived from donor tissue. 
Short tandem repeat locus Amelogenin D3S1358 TH01 D21S11 D18S51 Penta_E D5S818 D13S317
Explanted liver X, Y 15, 16 6,10 29, 30.2 12, 15 12, 17 10, 12 11
Tumor tissue X 16, 18 6, 9.3 28, 30 15a NA 11a 11
Transplanted 
liver     major peaks X 16, 18 6, 9.3 28, 30 15, 16 12, 19 11, 13 11
minor peaks Y 15 - 29, 30.2 - 17 10, 12 -
 Short tandem repeat locus D7S820 D16S539 CSF1PO Penta_D vWA D8S1179 TPOX FGA
 Explanted liver 12 12, 13 11, 12 12, 13 16, 17 8, 10 11 20, 21
 Tumor tissue 13a 11a 10 9, 10 17, 18 12, 15 8 21, 23
 Transplanted 
liver major peaks 9, 13 11, 12 10 9, 10 16, 18 12, 15 8 21, 23
minor peaks 12 13 - - 17 8, 10 11 20, 21
aLoss of one allele in the tumor tissue
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Discussion
We report a case of a donor-transmitted metastasis 
of colorectal carcinoma, identified 18 months after 
liver transplantation. This condition is very rare, the 
evaluation of the deceased donor-related tumor rate 
based on United Network for Organ Sharing (UNOS) 
registry (1994–2001) in almost 35 000 deceased 
donors being 0.04%1. Additional two cases of donor-
transmitted tumors (glioblastoma and melanoma) 
were reported in the UNOS registry of the period 
between 2000 and 20052. In the UNOS registry 
between 2005 and 2007, 15 tumors were confirmed 
in the solid organ transplantation and six recipients 
died as the result of a donor-transmitted disease3. 
The Israel Penn International Transplant Tumor 
Registry covering a period between 1965 and 2003 
reports only two cases of donor-transmitted colon 
cancer4. 
Interestingly, not every diagnosed malignant 
tumor in the donor is necessarily transmitted to the 
recipient; the UNOS registry (2005–2007)3 reporting 
one donor with proven colon cancer without 
transmission to the recipient. This case raises the 
question of the criteria for the donors‘ screening. 
The records of the donor showed no health problems 
but neither complete autopsy nor a CT scan have 
been performed as this is not part of the protocol. 
Two kidney recipients from the same donor have no 
signs of malignancy, which is not surprising given the 
specific metastatic pattern of colorectal carcinoma. 
Considering the still increasing age of donors and the 
high prevalence of colorectal carcinoma, the extent 
of the screening of the donors might need to be 
reconsidered with inclusion of a complete autopsy. 
Other aspect of this report is the value of a 
new imaging modality, contrast-enhanced ultrasound. 
At CEUS, the liver metastases are characterized by a 
predominant arterial blood supply but hypovascular 
metastases can also be seen, especially in metastases 
of adenocarcinomas5. In this case, CEUS showed 
neoplastic features with rapid arterial enhancement 
and wash-out. However, the question in this case 
was the distinction of a secondary lesion from the 
recurrence of HCC, the latter being clinically the most 
likely diagnosis. This distinction was not possible with 
the CEUS image which is also the generally observed 
limitation of this technique6; however, a rapid wash-
out of the contrast agent in a non-cirrhotic patient 
should raise the suspicion of a metastasis. 
Finally, the diagnosis was revealed by 
histopathological examination. The morphology of 
the tumor corresponded to an adenocarcinoma, 
intestinal type which was confirmed by the additional 
staining. The clinical setting of negative colonoscopy 
prompted further molecular analysis. The techniques 
used were the STR profiling and chromosome FISH. 
The STR profiling has high sensitivity and is generally 
accepted for genotyping in forensic medicine7. 
Concerning the treatment and the prognosis 
of donor-derived tumors, the experience is limited. 
From the five donor-derived (four proven, one 
possible) cases reported in UNOS registry in 2007, 
three patients were re-transplanted with favorable 
clinical outcomes. Provided that the extra-hepatic 
localization of the tumor has been excluded, re-
transplantation would be a curative treatment. 
As recipient-related metastatic malignancies or 
recurrence of HCC are much more common after 
liver transplantation and necessitate a different 
therapeutic approach, it is crucial to raise the 
suspicion of the donor-related malignancy and use 
molecular techniques to characterize the origin of 
the tumor. 
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Successive B-cell lymphomas 
mostly reflect recurrences rather 
than unrelated primary lymphomas
26i Chapter 3 Successive B-cell lymphomas mostly reflect recurrences rather than unrelated primary lymphomas
Abstract
Objectives: To address whether successive B-cell lymphomas, diagnosed within a 5- to 15-year interval, are 
recurrences or unrelated primary lymphomas. 
Methods: Immunoglobulin heavy and Ƙ light chain gene rearrangements were studied using multiplex 
polymerase chain reaction fragment assays and sequence analysis in 61 patients. 
Results: Clonal patterns of the multiple lymphomas from 36 patients were determined and classified 
accordingly: 30 recurrences, two possible recurrences, two different clones with a common origin, and two 
unrelated primary lymphomas.
Conclusions: Regardless of subtype, 89% to 94% of late B-cell lymphoma relapses were recurrences of 
the primary tumor. Therefore, routinely investigating the possible clonal relationship between successive 
lymphomas may not be warranted except for specific lymphoma subtypes such as diffuse large B-cell 
lymphomas. 
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Introduction
Malignant lymphomas are neoplasms of lymphocytes 
and their precursors. The main categories in the 
World Health Organization 2008 classification 
are Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL)1. After initial treatment, between 
25% and 85% of patients with malignant lymphomas, 
depending on the subtype, show relapses following 
a period of complete remission (CR)2-5. The second 
and subsequent occurrence is usually considered 
a recurrence of the original tumor, even after 
many years of CR. However, a second occurrence 
of malignant lymphoma may also be an unrelated 
primary malignant lymphoma, especially after a long 
period of CR. 
It is clinically relevant to differentiate between 
a recurrence and an unrelated primary lymphoma 
because the treatment strategy is usually different. 
Patients with recurrent lymphoma are usually 
treated aggressively, whereas patients with unrelated 
primary lymphomas generally receive the standard 
first-line therapies. Currently, little information is 
available with regard to the relative incidences 
of recurrent lymphoma and unrelated primary 
lymphoma. In previous studies, the percentage of 
patients with unrelated primary lymphomas rather 
than lymphoma recurrences ranged from 15% to 
100%6-12, as summarized in table 1. Limitations 
of these studies include their focus on particular 
lymphoma subtypes, the small sample sizes, or both. 
If the incidences of recurrences vs unrelated primary 
lymphomas were better documented, a better 
decision could be made on whether to perform 
molecular analysis to investigate the possible clonal 
relationship between successive lymphomas. To our 
knowledge, no such studies have been performed in 
a large clinical setting.
Using a single-center cohort consisting of 
all subtypes of B-cell lymphomas, we addressed 
whether successive B-cell lymphomas, diagnosed 
within a 5- to 15-year interval, are recurrences or 
unrelated primary lymphomas. Initially, 61 patients 
with multiple B-cell lymphomas were eligible for this 
study. Multiplex polymerase chain reaction (PCR) 
fragment assays were used to study rearrangements 
of the immunoglobulin heavy (IGH) and Ƙ light chain 
(IGK) genes in all lymphomas. Clonal patterns of 
the multiple lymphomas from 36 patients could be 
determined. When different fragment sizes were 
found in successive lymphomas of a patient, the 
rearrangements were sequenced to verify their 
different origin. 
Study Number 
of 
patients
Diagnosis primary 
lymphoma (number of 
patients)
Diagnosis relapse (number of 
patients)
Time 
interval 
(years)
(Suggested) 
recurrences
(Suggested) 
unrelated 
primary 
lymphomas
Percentage 
unrelated 
relapses
Ganzel et al6 6a HL (3), CLL (2), 
low-grade B (1)
HL (3), DLBCL (2), MZL (1) 0-25 0 5 100
Obermann et al7 22 HL (21), DLBCL (1) HL (21), DLBCL (1) 1-13 14 8 36
Lossos et al8 5 DLBCL (4), MCL (1) cerebral DLBCL 3-12 0 5 100
De Jong et al9 13 DLBCL DLBCL 4-17 11 2 15
Libra et al10 10 SLL (5), FL (3), MCL (2) SLL (5), MCL (3), FL (2) ≥3 8 2 20
Nishiuchi et al11 5 DLBCL (4), FL (91) DLBCL (3), FL (2) >5 3 2 40
Mao et al12 26b CLL DLBCL 0-4 18 5 22
aFor one patient, results were equivocal
bFor three patients, results were not available
CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; HL: Hodgkin lymphoma; MCL: 
mantle cell lymphoma; MZL: marginal zone lymphoma; SLL: small lymphocytic lymphoma
Table 1. Previous studies that examined successive b-cell lymphomas using molecular markers.
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Materials and Methods
Material selection
We studied a cohort of patients with a B-cell 
lymphoma, including HL, diagnosed between January 
1, 1985, and September 21, 2011, at the Erasmus 
Medical Center, Rotterdam, the Netherlands. Patients 
were selected using the pathology laboratory 
information system Sympathy (Tieto, Helsinki, 
Finland). Using the Dutch pathologic anatomy 
national automated archive (PALGA), all PALGA codes 
containing lymphoma and excluding bone marrow 
or containing Hodgkin and excluding lymphoma 
were selected. Within these groups, a total of 163 
patients had multiple lymphomas within a 5- to 15-
year interval, with the most recent lymphoma being 
diagnosed in 2000 or later. 
Subsequently, all patient histories were 
manually checked for the actual occurrence of 
multiple lymphomas and the availability of sufficient 
material for DNA analysis, resulting in the exclusion 
of 18 patients. Furthermore, patients with T-cell 
malignancies (n = 15) and patients treated outside 
the Erasmus Medical Center (n = 51) were excluded. 
The remaining 79 patients were categorized 
according to the diagnosis of the most recent 
lymphoma into one of the following groups: diffuse 
large B-cell lymphoma (DLBCL), follicular lymphoma 
(FL), primary cutaneous follicle center lymphoma 
(PCFCL), marginal zone lymphoma (MZL), mantle 
cell lymphoma, chronic lymphocytic leukemia (CLL), 
HL, or NHL not otherwise specified (NHL-NOS). 
Remission statuses were derived from the hospital 
records. These statuses were determined according 
to the internationally accepted criteria, the most 
recent from Cheson et al.13. 
Of these patients, all available lymphoma 
tissues were included in the analysis, also when 
diagnosed outside the specified interval. All diagnoses 
of lymphoma were reviewed by an experienced 
hematopathologist (K.H.L.). If necessary, additional 
immunohistochemistry was performed and patients 
were recategorized accordingly. Patients were 
excluded when stainings (n = 8) or formalin-fixed, 
paraffin-embedded (FFPE) tissue blocks (n = 8) were 
not available. Furthermore, another two patients 
were excluded because they eventually did not fulfill 
all selection criteria. In the end, a total of 61 (37%) 
of the initially selected 163 patients were included 
for analysis, resulting in 183 tissue samples in FFPE 
blocks. 
DNA isolation
From FFPE tissue blocks, 5 to 30 sections of 4 mm 
were cut depending on the size of the tissue. 
Tumor tissue was manually microdissected from 
5 to 15 hematoxylin-stained sections when the 
tumor percentage was below 5% or when multiple 
lymphomas were present in one tissue block. 
Additional DNA was isolated from frozen tissue 
or dissected from routine cytological specimens 
(if present) when distinct rearrangements were 
found in successive lymphomas of a patient. 
DNA was extracted using proteinase K (Roche 
Diagnostics, Indianapolis, IN) and 5% Chelex 100 resin 
(Bio-Rad, Hercules, CA), as previously described14.
Clonality analysis
To check the quality of the samples, we performed 
a multiplex control PCR as previously described15 
with undiluted DNA and 1:10 and 1:50 dilutions. 
The dilution with the best results in agarose gel 
electrophoresis was selected for further analysis. 
Multiplex BIOMED-2 PCR fragment assays 
were used to study rearrangements of the IGH and IGK 
genes in all samples. These assays were performed 
according to standardized protocols and primers15. 
IGH framework 1, 2, and 3 assays (IGH-A, IGH-B, and 
IGH-C) were used to detect Vh-Jh rearrangements, 
and IGH-D was used for the detection of incomplete 
Dh-Jh rearrangements. Vk-Jk rearrangements and 
functionally inactivating recombinations involving 
Kde (Vk-Kde or intron-Kde) were detected using IGK-A 
and IGK-B assays, respectively. The fragments were 
detected by GeneScan analysis on an ABI 3130XL 
genetic analyzer (Applied Biosystems, Foster City, CA), 
and data were analyzed with Peak Scanner Software 
version 2.1 (Applied Biosystems). Results were scored 
manually following recently described guidelines16. 
When different PCR product sizes were found within 
multiple lymphomas of a patient or when results 
were ambiguous, analyses were repeated. 
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Sequence analysis
When distinct rearrangements were found in 
multiple lymphomas of a patient, the fragments 
were sequenced to verify their different origin. The 
IGH or IGK gene rearrangements were amplified 
using unlabeled multiplex BIOMED-2 PCR assays15. 
Subsequently, heteroduplex analysis was performed 
to identify the presence of one or more clonal 
bands17. If a sample showed multiple homoduplexes 
or when a-specific bands were present, bands were 
cut from the polyacrylamide gel and eluted prior 
to sequencing. Single clonal PCR products were 
purified using ExoSAP-IT (Affymetrix, Santa Clara, CA) 
according to the manual. 
Sequencing was performed using the 
consensus Jh primer for IGH fragments, Jk1-4 and 
Jk5 primers for IGK-A fragments, and the Kde primer 
for IGK-B fragments. The BigDye Terminator version 
3.1 Cycle Sequencing Kit was used for sequencing, 
after which products were purified using the BigDye 
Xterminator Purification Kit (both from Applied 
Biosystems), according to the manuals. The labeled 
fragments were detected on an ABI 3130XL genetic 
analyzer (Applied Biosystems). Data were analyzed 
with CLC DNA workbench version 5.7 (CLC Bio, Aarhus, 
Denmark). The involved Vh or Vk family member 
was identified using the IMGT/V-Quest alignment 
tool, version 3.2.25 (www. imgt.org/IMGT_vquest/
vquest). Next, a Vh or Vk family primer was used to 
perform a monoplex PCR reaction from which the 
product was bidirectionally sequenced. 
When DNA quality was not sufficient to 
identify the Vh or Vk family member using a multiplex 
PCR approach, PCR reactions were performed with all 
V family primers in monoplex reactions. If necessary, 
multiplex or monoplex PCR products were cloned 
into a pGEM-T easy vector (Promega, Madison, WI). 
Single-colony PCR was performed on the positive 
clones; the PCR products were directly sequenced. 
Data analysis and classification of results
Multiple lymphomas with an interval of at least five 
years were classified as (a) recurrences, when two 
or more independent rearrangements showed the 
same fragment size; (b) possible recurrences, when 
only one interpretable marker showed identical 
sizes; (c) different clones with a common origin, 
when fragment size differences as well as similarities 
between the lymphomas were found; (d) unrelated 
primary lymphomas, when differences were found 
between the lymphomas in one or two markers, 
with at least two interpretable markers; or (e) non-
evaluable, if they did not fit the other categories. 
Results
A total of 61 patients with multiple lymphomas 
diagnosed within a 5- to 15-year interval were 
selected for analysis. Of these patients, all available 
lymphoma tissues were included in the analysis. 
Several of these additional lymphomas were 
diagnosed within the specified interval, shortening 
the remission time between two consecutive 
occurrences of lymphoma. Figure 1 shows a 
chronological overview of the multiple lymphomas 
for the 36 patients with evaluable results. For these 
patients, the interval between any two consecutive 
lymphomas ranged from 2 to 12 years. All CRs, partial 
remissions, and additional lymphomas for which no 
tissue was available, established within the intervals 
between the multiple lymphomas, are included as far 
as known based on the hospital records. 
IGH and IGK clonality analysis points 
to a high frequency of lymphoma recurrence
Rearrangements of IGH and IGK genes were analyzed 
in DNA isolated from 61 patients. In the first 11 
samples, all rearrangements involving the variable 
domains of IGH and IGK were tested using the 
BIOMED-2 IGH-A, IGH-B, IGHC, IGK-A, and IGK-B 
assays. Targets IGH-C and IGK-A gave the best results, 
with relative small product sizes of 100 to 300 base 
pairs (bp). This corresponded to the results of the 
control PCR, which showed that DNA quality was 
often compromised. Therefore, IGH-C and IGK-A 
were selected as the first targets to be tested in all 
other samples. However, targets IGH-C and IGK-A did 
not provide sufficient information to assess whether 
tissues were clonally related for 30 patients. In these 
patients, targets IGH-A and IGK were additionally 
analyzed, with product sizes between 210 and 390 
bp. For 15 patients, markers IGH-B and IGH-D were 
also analyzed, with product sizes between 110 and 
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Figure 1. Chronological overview of the multiple lymphomas in the 36 patients with evaluable results. Complete remissions (CR) 
and partial remissions (PR) established within the intervals between the multiple analyzed lymphomas are indicated. Additional 
lymphomas diagnosed within these intervals for which no tissue was available are indicated in gray. Fragment analysis results are 
indicated by the different colors. 
aNo information about CR and PR available D
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420 bp. Some samples showed ambiguous results 
due to suboptimal DNA quality, whereas other 
samples showed polyclonal patterns probably 
caused by a very low percentage of lymphoma cells 
in the tissue sample. These patients were regarded as 
non-evaluable after analyzing two, four or six markers 
(in 13, 9, and 3 patients, respectively). An overview 
of the number of non-evaluable patients for the 
different lymphoma subtypes is provided in Table 2. 
The samples of 18 patients showed IGH-C 
and IGK-A rearrangements of identical sizes (Figure 
2a-2d). After also analyzing IGH-A and IGK-B and 
subsequently IGH-B and IGH-D, six and five patients, 
respectively, showed rearrangements of identical 
size in at least two evaluable markers. All of these 
patients showed two independent rearrangements 
of identical size except for patient F17, who showed 
identically sized fragments only with primer sets 
IGH-B and IGH-C, which target the same IGH 
rearrangement. For two patients, only one of the 
six markers was evaluable, showing rearrangements 
of identical sizes. Five patients showed one or more 
targets with rearrangements of different sizes in their 
samples (Figure 2e-2h). For these patients, all markers 
were analyzed. Figure 1 shows for each lymphoma 
whether the clonal patterns were scored as identical 
(at least two rearrangements of identical fragment 
size), possibly identical (only one rearrangement with 
the same fragment size), different, or non-evaluable. 
The results of IGH and IGK clonality analysis for all 
patients are provided in Table 3.
Sequencing of differently sized 
fragments shows evidence for clonally related and 
unrelated lymphomas
From the five patients with differently sized 
immunoglobulin- rearranged products in their 
Figure 2. H&E stainings and clonality analysis results of IGH-C for the lymphomas of patients D17 and D8. Patient D17 presented with 
a DLBCL/aggressive CLL in 2003 (a) and a CLL in 1995 (b); both samples showed a fragment of 149 base pairs (c and d; DLBCL and CLL, 
respectively). Patient D8 presented with a DLBCL in 2004 (e) and WM in 1999 (f). These samples showed differently sized fragments 
of 149 (g; DLBCL) and 112 (h; WM) base pairs. H&E stainings are shown at 40 times. 
CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; IGH: immunoglobulin heavy chain; WM: Waldenström 
macroglobulinemia
Total No. Evaluable, No. (%) Non evaluable, No. (%)
DLBCL 24 14 (58) 10 (42)
FL 16 10 (63) 6 (37)
PCFCL 4 1 (25) 3 (75)
MZL/MALT 4 4 (100) 0
MCL 3 3 (100) 0
CLL 3 2 (67) 1 (33)
HL 6 1 (17) 5 (83)
NHL-NOS 1 1 (100) 0
CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell 
lymphoma; FL: follicular lymphoma; HL: Hodgkin lymphoma; 
MALT: mucosa-associated lymphoid tissue; MCL: mantle 
cell lymphoma; MZL: marginal zone lymphoma; NHL-NOS: 
non-Hodgkin lymphoma not otherwise specified; PCFCL: primary 
cutaneous follicle center lymphoma
Table 2. Evaluable and non-evaluable patients for the different 
lymphoma subtypes.
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Patient Diagnosis 
lymphoma
Tissue Year IGH-A IGH-B IGH-C IGH-D IGK-A IGK-B Result
DLBCL
D1 DLBCL FFPE 2003 119 IP Non evaluable
DLBCL FFPE 1992 b b
D2 DLBCL FFPE 2010 b b Non evaluable
DLBCL FFPE 2005 IP IP
D3 DLBCL FFPE 2004 319 253 118 210 144 (/151) 278 Differences 
found, additional 
analysis requiredDLBCL FFPE 2002
b (253) 118 b 144 (/149) b
DLBCL FFPE 1998 b b 118 115/137 144 (/151) b
FL FFPE 1998 b b 143 b 149 (/144) b
DLBCL Cytology 1998 319 253 118 141/245 144/151 278
DLBCL Frozen 1998 319 253 118 b 144 (/151) 278
D4 DLBCL FFPE 2010 b 264 142 b 151 228/280 (231) Differences 
found, additional 
analysis requiredDLBCL Frozen 2010 330 264 IP (/116) 178 (217/223?) 228/280 (/231/277)
FL FFPE 2009 331 265 IP 133/229 IP 228/280 (/231/277)
FL Cytology 2009 331 265 MP 178 152 229/280 (/231/277)
FL FFPE 2003 322 257 IP b IP 228/280 (/231)
D5 DLBCL FFPE 2010 b IP 148 279 Non evaluable
FL FFPE 2010 (336) IP 149 279
DLBCL FFPE 2009 b IP b 279
FL FFPE 2004 b b P b
D6 DLBCL FFPE 2008 143 150 Recurrences
DLBCL FFPE 2008 144 b
DLBCL FFPE 2007 b 150
DLBCL FFPE 2002 144 151
D7 DLBCL FFPE 2006 IP P MP Non evaluable
DLBCL FFPE 2000 136 (/153) NR 284/370
D8 DLBCL FFPE 2004 b (271) 149 240 149 209 Differences 
found, additional 
analysis requiredWM FFPE 2001 344 247 112
b 150 b
WM FFPE 1999 b b 112 b 149 b
WM Frozen 1999 312 247 111 257 150 402?
D9 DLBCL FFPE 2010 114 (/99) b Recurrences
PCFCL FFPE 2004 114 (/124) 152
PCFCL FFPE 2000 114 152
PCFCL FFPE 1998 114 (/153) 152
PCFCL FFPE 1998 114 152
PCFCL FFPE 1993 114 152
D10 DLBCL FFPE 2001 NE P 141/191 238 (/276) Recurrences
FL FFPE 2000 b b b b
FL FFPE 1991 b b 141 (/190) 238 (/276)
D11 DLBCL FFPE 2011 IP IP Non evaluable
DLBCL FFPE 2003 146 b
Table 3. Results of IGH and IGK clonality analysis for the multiple lymphomas of 61 patients a.
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D12 DLBCL FFPE 2008 b NE 152 283 Recurrences
DLBCL FFPE 1997 324 108 152 284
D13 DLBCL FFPE 2006 b b NR NR 149 215 /282 Possible recurrences
FL FFPE 2005 b b 87 b 150 b
FL FFPE 2003 b b NE b 149 b
FL FFPE 2001 b b 115/118 196 149 269
D14 DLBCL FFPE 2007 b b b b 141 276 Non evaluable
DLBCL FFPE 1993 (373) b b 186/281 NR b
D15 DLBCL FFPE 2003 NE b 139 150 279 Recurrences
DLBCL FFPE 1998 b b 139 150 b
D16 DLBCL FFPE 2004 b b IP 127 P 237/275 Non evaluable
DLBCL FFPE 1999 b b IP NR 150 275
D17
DLBCL or 
agressive 
CLL
FFPE 2003 336 271 149 145/195 272/276 Recurrences
CLL FFPE 2000 336 b 149 145/195 271/276
CLL FFPE 1995 336 b 149 145/195 272
D18 DLBCL FFPE 2008 b b P IP P P? Non evaluable
DLBCL FFPE 2003 b b P? 138/143 P? b
DLBCL FFPE 2003 NE b P 159 P? NE
DLBCL FFPE 2000 NE b 113 123/202 149/288 283
D20 DLBCL & HL FFPE 2008 b b (127/136) 149 b Non evaluable
DLBCL  FFPE 2003 b b IP IP b
D21 DLBCL FFPE 2002 b (267) IP 232 148 (217/277) Recurrences
DLBCL FFPE 1995 b b b 232 148 b
D22 DLBCL FFPE 2011 343 277 143 149/198 b Recurrences
MZL FFPE 2006 b b 143 149/198 IP?
MZL FFPE 1998 343 (277) 143 149/198 MP
D23 DLBCL FFPE 2010 332 265 123 262/281 b Recurrences
MZL FFPE 2000 123 149/263/281 b
D25 DLBCL FFPE 2010 b b P P NR Non evaluable
FL FFPE 2009 b b NR 143/147 227/278
FL FFPE 2005 (313) b IP P NR
D27 DLBCL FFPE 2004 316 251 MP b 149 b Recurrences
FL FFPE 1998 b 251 115 b 149 (212)
FL
F1 FL FFPE 2003 130 149/152 Recurrences
FL FFPE 1997 130 149
F2 FL FFPE 2011 119/P 288/P Non evaluable
HL FFPE 2003 MP NR
Patient Diagnosis 
lymphoma
Tissue Year IGH-A IGH-B IGH-C IGH-D IGK-A IGK-B Result
Table 3. Continued.
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F3 FL FFPE 2003 320 112 137/174/187 236/277/284 Recurrences
FL FFPE 2001 b NE NE b
FL FFPE 1998 b 112 137/174/187 236/277/284
F4 FL FFPE 2007 325 P 148 NR Recurrences
FL FFPE 2005 IP 
(/325?)
P 149 NR
FL FFPE 2001 325 P 150/P NR
FL FFPE 1998 326 IP 149 NR
F5 FL FFPE 2009 b 148 Non evaluable
FL FFPE 2002 P P
F7 FL FFPE 2003 P P Non evaluable
FL FFPE 1994 IP P
F8 FL FFPE 2000 b 130 144/149/194 281 Recurrences
FL FFPE 1998 b (123) 144/149/194 NR
FL FFPE 1993 IP P 145/149 281
F11 FL FFPE 2002 b NR NR b Non evaluable
FL FFPE 2001 b NR b b
FL FFPE 1990 b 109 NR b
F12 FL FFPE 2008 108 147/196 Recurrences
DLBCL FFPE 2005 IP 147/196
FL FFPE 2003 IP 147/196
FL FFPE 2001 108 147/196
F15 FL FFPE 2010 329 b 115 133 280 (/NR) b Differences 
found, additional 
analysis requiredFL Frozen 2010 329 257 115 134 280 237
FL FFPE 1995 b b NR b 145/151 b
FL Cytology 1995 329? IP 115 MP 151 (/281) 237
F16 FL FFPE 2009 IP IP Non evaluable
FL FFPE 2004 IP IP
F17 FL FFPE 2007 b b IP 245 P b Recurrences
FL FFPE 2005 318 NE IP MP P 209/377
FL FFPE 2004 MP NE IP 142 284/P 377
FL FFPE 2003 b 262 120 b P b
FL FFPE 1999 371 b IP 165 284/IP (/149?) 230/377
FL FFPE 1999 311/326 262 121 MP IP (/149?) IP?
FL FFPE 1991 b 262 121 184 IP (/149?) 229
F19 FL FFPE 2001 312 IP 139 218/238/274 Recurrences
FL FFPE 2000 313 124 /IP 139 b
FL FFPE 1994 313 IP 139 IP
F20 FL FFPE 2004 122/127 141/155 Non evaluable
FL FFPE 1998 b 104/148
FL FFPE 1998 (133) (149)
Patient Diagnosis 
lymphoma
Tissue Year IGH-A IGH-B IGH-C IGH-D IGK-A IGK-B Result
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F21 FL FFPE 2009 319 NE 121/148 282 Recurrences
FL FFPE 2002 319 P 121 (/149) 282
F23 FL FFPE 2000 b b NR (202/233) 149 235 Recurrences
FL FFPE 1997 325 259 118 b 149 238
FL FFPE 1997 b (259) NR b 149 b
FL FFPE 1994 325 259 117 b NR 238
FL FFPE 1986 b b 117 b b b
FL FFPE 1984 b b NR b b 238
PCFCL
P1 PCFCL FFPE 2004 325 259 IP 152 148/200 237/241 Recurrences
PCFCL FFPE 1997 324 258 124 b 148/200 b
PCFCL FFPE 1997 324 258 124 b 148/200 b
P2 PCFCL FFPE 2002 b MP NR 234 Non evaluable
PCFCL FFPE 1992 b b NR (319)
PCFCL FFPE 1992 325 146 148 238
PCFCL FFPE 1989 b MP b b
P3 PCFCL FFPE 2011 b NR NR b Non evaluable
PCFCL FFPE 2005 (308) NR NR b
P4 PCFCL FFPE 2007 328 IP NR 239/361 Non evaluable
PCFCL FFPE 1996 b IP NR b
MZL
Z1 MZL FFPE 2008 146/P 149/P (/198) Recurrences
MZL FFPE 2002 146 149/198
MZL FFPE 2002 146 149/198
Z3 MALT FFPE 2007 131 149/198 Recurrences
MALT FFPE 2005 131 149/198
MALT FFPE 2005 131 148/198
MALT FFPE 2004 131 149/197
MALT FFPE 2004 131 149/198
MALT FFPE 2000 131 149/197
MALT FFPE 1997 131 149/198
MALT FFPE 1996 131 149
Z4 MZL FFPE 2006 111 149/P Recurrences
MZL FFPE 2004 111 149/P
MZL FFPE 2000 111 149
Z5 MZL FFPE 2002 112 148 Recurrences
MZL or WM FFPE 1996 112 148
MCL
M1 MCL FFPE 1999 130 153 Recurrences
MCL FFPE 1999 130 153
Patient Diagnosis 
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MCL FFPE 1987 130 153
MCL FFPE 1985 130 153
M3 MCL FFPE 2011 b NE Recurrences
MCL FFPE 2011 146 149/198
MCL FFPE 2002 146 149/198
MCL FFPE 1997 146 149/198
M4 MCL FFPE 2008 335 133 b 150 b Recurrences
MCL FFPE 2000 334 133 b 149 (279)
CLL
C1 CLL FFPE 2005 118 151 Recurrences
CLL FFPE 2005 118 152
CLL FFPE 2005 117 152
CLL FFPE 2004 118 152
CLL FFPE 2001 117 152
CLL FFPE 1998 117 152
C2 CLL FFPE 2008 121/160 147/151 Recurrences
CLL FFPE 2007 121 b
CLL FFPE 2004 121/159 147/150
CLL FFPE 2001 121/160 147/150
C4 CLL FFPE 2003 b b Non evaluable
MZL FFPE 1994 105 150/155
MZL FFPE 1993 105 150/155
HL
H1 HL FFPE 2007 b b b b Non evaluable
HL FFPE 2006 b b NR b
HL FFPE 2005 b IP NR b
HL FFPE 2005 b IP NR b
HL FFPE 1997 b IP NR b
H3 HL FFPE 2009 IP IP Non evaluable
suspect HL FFPE 1999 b 149
H4 HL FFPE 2002 b b b b 197 (/NR) 237/278/285 Possible recurrences
DLBCL FFPE 1993 b b b b NR b
DLBCL FFPE 1993 b 279 142 250 197 b
H5 HL FFPE 2003 b NR NR 163 Non evaluable
HL FFPE 2000 b MP NR b
HL FFPE 1995 b b NR b
H7 HL FFPE 2005 (147) b Non evaluable
HL FFPE 1999 (135) b
H10 HL FFPE 2010 115 MP Non evaluable
HL FFPE 2000 (123) NE
Patient Diagnosis 
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NHL - NOS
O2 NHL-NOS Cytology 2000 b b 109 b b b Different clones 
with a common 
originNHL-NOS Cytology 2000 357
b 109/160/170 b 143/152/193/287 b
NHL-NOS Cytology 2000 b b (109) b IP b
NHL-NOS FFPE 1997 b b 109/160 IP 143/152/192 b
NHL-NOS Cytology 1997 357
251/
297/
303
109/160/170 b 143/152/193 
(/287)
264/284
NHL-NOS FFPE 1991 MP 296/303 124/160/170 184 143/192/287 234
aFragment sizes mentioned in parentheses are (additional) minor peaks
bNo fragment detected
CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FFPE: formalin fixed paraffin embedded; FL: follicular 
lymphoma; HL: Hodgkin lymphoma; IGH: immunoglobulin heavy chain; IGK: immunoglobulin k light chain; IP: irregular polyclonal; 
MALT: mucosa-associated lymphoid tissue; MCL: mantle cell lymphoma; MP: multiple peaks; MZL: marginal zone lymphoma; NE: 
non-evaluable; NHL-NOS: non-Hodgkin lymphoma not otherwise specified; NR: not reproducible; P: polyclonal; PCFCL: primary 
cutaneous follicle center lymphoma; WM: Waldenström macroglobulinemia
Patient Diagnosis 
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Tissue Year IGH-A IGH-B IGH-C IGH-D IGK-A IGK-B Result
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multiple lymphoma samples, DNA was isolated from 
additional FFPE, frozen, and cytological tissue if 
available. All six IGH and IGK targets were analyzed in 
these extra samples. To check whether the differently 
sized fragments in the patients represented 
independent rearrangements, we also sequenced 
the fragments (Table 4). 
Patient D3 showed an IGH-C fragment of 
143 bp in the FL from 1998, whereas the DLBCL from 
1998, 2002, and 2004 showed 118-bp fragments. 
After sequencing, the FL showed a dominant IGH-C 
fragment involving IGHV4-34 and a minor fragment 
involving IGHV3. This minor fragment was not visible 
during fragment analysis. All other samples from this 
patient showed only one fragment, identical to the 
IGHV3 rearrangement. The DNA from the FL was 
isolated from a tissue block containing a DLBCL/FL 
composite lymphoma. The minor fragment involving 
IGHV3 found in the FL is therefore most likely due 
to cells from the DLBCL. Because of the different 
rearrangements, this patient was classified as having 
unrelated primary lymphomas. 
Patient D4 showed IGH-A and IGH-B 
fragments of 322 and 257 bp, respectively, in the FL 
from 2003 compared with 330 and 264 bp for the 
FL from 2009 and the DLBCL from 2010. All samples 
had an IGH-A or IGH-B fragment involving IGHV3. 
However, the sequence of the FL from 2003 was 
different from that of the other samples, including 
a different junction, resulting in the observed size 
difference. This patient showed two identically sized 
rearrangements involving the Kde element in all 
samples. One of these rearrangements involving VK1 
was successfully sequenced in the FL from 2003 and 
the DLBCL from 2010 and turned out to be identical. 
Therefore, this patient was classified as having 
different lymphoma clones with a common origin. 
Patient D8 showed an IGH-C fragment of 
149 bp for the DLBCL from 2004, as well as 112-bp 
fragments for the Waldenström macroglobulinemia 
(WM) samples from 1999 and 2001. Sequencing 
revealed a fragment involving IGHV5- 51 for the 
DLBCL, and the WM samples showed a fragment 
involving IGHV3. All samples had an identically sized 
fragment of 150 bp with marker IGK-A. However, the 
DLBCL and WM rearrangements showed involvement 
of different V genes as well as different junctions. This 
patient was classified as having unrelated primary 
lymphomas. 
Patient F15 showed differences for target 
38i Chapter 3 Successive B-cell lymphomas mostly reflect recurrences rather than unrelated primary lymphomas
aFragment sizes mentioned in parentheses are (additional) minor peaks
bNo fragment detected
cdel 3’ VK (ins) del 5’ Kde
dTrp (W) not identified
Bp: base pair; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; IG: immunoglobulin; IGH: immunoglobulin heavy chain; 
IGK: immunoglobulin k light chain; IP: irregular polyclonal; MP: multiple peaks; ND: not determined; NR: not reproducible; WM: 
Waldenström macroglobulinemia
IGK-A, with a 280-bp fragment for the FL from 
2010 and a 151-bp fragment for the FL from 1995. 
Surprisingly, these samples showed an identically 
sized fragment on polyacrylamide gel and a nearly 
identical rearrangement involving Vk4-1. After 
reexamination of the fragment analysis results, a very 
low 281-bp peak was found for the FL from 1995. In 
addition, the samples showed identically sized IGH 
rearrangements. Therefore, these lymphomas were 
classified as clonally identical recurrences. 
Patient O2 showed multiple fragments 
in targets IGH-C and IGK-A, some of which were 
mutually exclusive between the NHL from 1991 and 
the NHL from 1997 and 2000. This was true for the 
124-bp and 109-bp fragments, respectively, for target 
IGH-C. For IGK-A, a 152-bp fragment was present in 
all samples except the NHL from 1991. However, in 
all samples, two and three additional identically sized 
fragments were found in targets IGH-C and IGK-A, 
respectively. Because of the complex rearrangement 
patterns, these samples were not sequenced. The 
patient was finally classified as having different 
lymphoma clones with a common origin. 
No obvious relation exists between occurrence 
of unrelated lymphomas and time interval
Overall, clonal patterns of the successive lymphomas 
from 36 patients could be determined and were 
Patient Diagnosis 
lymphoma
Year Clonality analysis Sequence analysis
IGH-A IGH-B IGH-C IGH-D IGK-A IGK-B IG Complete 
rearrangement 
found?
Involved V 
gene
Junction
D3 DLBCL
2004/ 
2002/ 
1998
319 253 118 NR 144 278 IGH yes, productive IGHV3 CARVRGSFSLDYW
FL 1998 b b 143 b 149 (/144) b IGH no IGHV4-34 ND
D4 DLBCL/ FL 2010/ 2009 330 264 IP 178 151
228/ 280 
(/231/ 277)
IGH yes, productive IGHV3 CATNTTIGPVSSSDHVSW
IGK-B
yes, 2 
rearrangements 
found
IGKV1-Kde 
(230 bp)
-21(10)-9c
IGKV3-Kde 
(281 bp)
-17(12)-4c
FL 2003 322 257 IP b IP 228/ 280 
(/231)
IGH yes, productive IGHV3 CAKNVTSPADLDCW
IGK-B yes IGKV1-Kde 
(230 bp)
-21(10)-9c
D8 DLBCL 2004 b (271) 149 240 149 209 IGH no IGHV5-51 ND
IGK-A yes, productive IGKV1-5 CQQYNSYPWTF
WM 2001/ 1999 NR 247 112 257 150 NR IGH yes, productive IGHV3 CARGGGAWDTS
d
IGK-A yes, productive IGKV1-17 CLQHDSYPRTF
F15 FL 2010 329 257 115 133 280 (/NR) b IGK-A no IGKV4-1 ND
FL 1995 329? IP 115 MP 151 (/281) 237 IGK-A no IGKV4-1 ND
Table 4. Results of IGH and IGK clonality and sequence analysis for patients with differently sized fragmentsa.
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classified accordingly: 30 recurrences, two possible 
recurrences, two different clones with a common 
origin, and two unrelated primary lymphomas. In 
both patients with unrelated primary lymphomas, 
the most recent lymphoma was diagnosed as a 
DLBCL. To study the possible association between 
occurrence of unrelated lymphoma and interval, we 
examined in more detail the intervals between the 
consecutive lymphomas. Of the 36 patients with 
evaluable results, two patients had an interval of more 
than 10 years between their consecutive lymphoma 
recurrences. Eighteen patients had an interval of 5 
to 10 years between two consecutive occurrences of 
lymphoma: 15 recurrences, one possible recurrence, 
and two different clones with a common origin. All 
other patients had an interval of less than five years 
between their consecutive lymphomas. 
Finally, we wanted to evaluate whether 
unrelated lymphomas occur in defined lymphoma 
subtypes. For two subtypes of lymphoma relapses, 
DLBCL and FL, we included at least 10 patients, 
with 14 and 10 patients with evaluable results, 
respectively. The DLBCL relapses were classified as 
follows: 10 recurrences, one possible recurrence, 
one different clone with a common origin, and two 
unrelated primary lymphomas. All FL relapses were 
recurrent lymphomas. 
Discussion
Our study shows that, regardless of the subtype, 89% 
to 94% of late B-cell lymphoma relapses diagnosed 
within a 5-to 15-year interval are recurrences of the 
primary tumor. Only 2/36 (6%) successive lymphomas 
actually concerned clonally unrelated primary 
lymphomas. In both cases (patients D3 and D8), the 
most recent lymphoma was diagnosed as a DLBCL. 
Although the most commonly used assay 
for determining whether two lymphomas are 
clonally related is fragment analysis of IGH and IGK 
rearrangements, there are some limitations to this 
approach. Ongoing somatic hypermutations are a 
common event in lymphomas, especially in FL. Only 
hypermutations resulting in deletions or insertions 
will be detected using fragment analysis. All FL in this 
study showed identical fragment sizes, suggesting 
that no deletions or insertions occurred in these 
lymphomas despite the large intervals. Differently 
sized fragments, however, can still represent the 
same rearranged fragment. In the current study, 
sequencing analysis was performed when differently 
sized fragments were found to see whether these 
differences truly reflect different tumor origins. 
The successive lymphomas of patient D4 showed 
differently sized IGH fragments both involving 
IGHV3 but with differences between the sequences 
and junctions. However, this patient showed two 
identically sized inactivating rearrangements involving 
the Kde element, one of which was confirmed by 
sequencing analysis. Despite the observed differences 
with the IGH marker, these lymphomas seem to have 
a common clonal origin. Furthermore, identically 
sized fragments found in two lymphomas can still 
represent two different rearrangements, as shown 
by Nishiuchi et al.11. The successive lymphomas of 
patient D8 showed an identically sized fragment 
with marker IGK-A. However, differently sized IGH 
fragments involving different V genes were found. 
The identically sized IGK fragment is due to the 
restricted IGK junctional heterogeneity, as different 
V genes and junctions were observed. Therefore, 
we suggest performing fragment analysis of at least 
two independent rearrangements when determining 
whether two occurrences of lymphoma are clonally 
related. 
The two patients in this study with unrelated 
primary lymphomas showed different rearranged 
IGH fragments between their successive lymphomas. 
As only one IGH rearrangement was found for each 
lymphoma, the question arises whether these 
lymphomas are really different or could have a 
common origin possibly represented by a second 
undetected IGH rearrangement. Furthermore, 
clonally distinct relapses can also be recurrences from 
a subclone in the primary lymphoma. Previously, 
FL and DLBCL recurrences have been described for 
which the mutation patterns of the rearrangements 
were nearly identical to that of minor subclones 
in the primary FL18,19. In this study, however, both 
patients with unrelated primary lymphomas 
showed involvement of different IGHV genes in their 
successive lymphomas, making it unlikely that the 
relapses were subclones of the primary lymphomas. 
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For both patients with clonally unrelated 
primary lymphoma relapses, the morphology of the 
clonally distinct relapse was different from that of 
the primary lymphoma. Patient D3 presented with 
a DLBCL/FL composite lymphoma in 1998 and with 
DLBCL relapses after four and six years. The FL was 
clonally distinct from the multiple occurrences of 
DLBCL, which were all related. Patient D8 presented 
with WM in 1999 and 2001. In 2004, the patient was 
diagnosed with a relapse suggestive of transformation 
of the lymphoma to a DLBCL. However, this relapse 
was not clonally related to the WM. In 6/10 patients 
with DLBCL recurrences, the primary tumor was 
also of a different morphology. These patients 
showed clonally related DLBCL recurrences from 
FL, CLL, or MZL. Histologic transformations of 
multiple lymphoma subtypes to DLBCL have been 
reported extensively20. Thus, a DLBCL relapse from a 
morphologically different primary tumor by itself is 
not an indication of unrelated primary lymphomas. 
Patient D17 presented with CLL in 1995 and 
2000, as well as DLBCL/aggressive CLL in 2003; these 
lymphomas were clonally identical recurrences. In 
situ hybridization was performed to detect Epstein-
Barr virus (EBV)–encoded RNA in the CLL and DLBCL 
samples of this patient, and a few positive nuclei 
were found. Because of the minimal amount of 
positive small nuclei, we are inclined to interpret this 
finding as a latent persistent EBV infection. However, 
we cannot exclude an oncogenic role in this respect, 
as other reports have demonstrated this21,22.
Previous studies reported higher frequencies 
of unrelated primary lymphomas instead of 
recurrences; however, these studies focused on 
subtypes of lymphoma. The single-center cohort 
used in the current study resulted in 36 patients with 
clonal patterns that could be determined, including 
multiple subtypes of lymphoma. The largest 
subgroups were DLBCL and FL relapses, consisting of 
14 and 10 patients, respectively. Within the subgroup 
of patients with DLBCL relapses, 2/14 patients had 
unrelated primary lymphomas. Correspondingly, 
de Jong et al.9 studied DLBCL recurrences after 4 to 
17 years; in 2/13 patients, they found evidence for 
clonally unrelated primary lymphomas. Nishiuchi et 
al.11 studied three patients with DLBCL recurrences, 
one of whom was suggested to have unrelated 
primary lymphomas. All FL relapses turned out to be 
recurrent lymphomas. Unrelated primary lymphomas 
were not found in any subtype of lymphoma relapses 
besides DLBCL. This is in contrast to previous studies 
that report a considerable number of patients 
with unrelated primary lymphomas rather than 
recurrences. High incidences of unrelated primary 
lymphomas were suggested in cases of HL relapses6,7 
and central nervous system relapses8. For these 
subtypes of lymphoma, we unfortunately do not have 
enough data available. Overall, our results and those 
of others suggest that the incidence of unrelated 
primary lymphomas varies between different 
subtypes of relapses and primary lymphomas. 
Even after a longer interval, we did not find a 
higher occurrence of unrelated primary lymphomas. 
Two patients had an interval of more than 10 years 
between their consecutive lymphomas; these 
patients were diagnosed with recurrences after 
a CR of 11 years. Furthermore, 18 patients who 
had an interval of 5 to 10 years between their 
consecutive lymphomas did not show unrelated 
primary lymphomas. The two patients with unrelated 
primary lymphomas had intervals of less than five 
years between their consecutive occurrences of 
lymphoma. It is also remarkable that one of these 
patients had only partial remission; apparently, this 
does not exclude the occurrence of a new unrelated 
primary lymphoma. 
Twenty-five patients who had ambiguous 
results were classified as non-evaluable. DNA was 
isolated from FFPE tissue blocks due to the high 
availability of this tissue. Unfortunately, DNA quality 
was compromised as a result of fixation artifacts. 
The highest percentages of non-evaluable patients 
were in the PCFCL and HL subgroups—for 3 of 4 and 
5 of 6 patients, respectively, clonal patterns of the 
successive lymphomas could not be determined. 
This could be explained by the combination of 
compromised DNA quality and the low amount of 
tumor cells in the tissues. The use of different patient 
tissues, especially for small-sized lymphomas, is 
therefore preferred. 
In conclusion, late relapses of lymphomas 
are mostly recurrences of the primary tumor. 
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Therefore, routine investigation of the possible clonal 
relationship between two successive occurrences of 
lymphoma is not warranted given the high costs of the 
molecular assays. However, for specific subgroups of 
lymphoma, additional extensive molecular analysis 
might be valuable, especially for DLBCL recurrences. 
To better document the incidence of 
unrelated primary lymphomas for specific lymphoma 
subtypes, a larger cohort is required, especially for 
lymphomas that are less common. Furthermore, it 
is important to perform sequencing analysis when 
differently sized fragments are found to confirm 
that these differences truly reflect independent 
rearrangements. To do this, it might be necessary 
to use patient tissues that are not formalin fixed to 
improve DNA quality. 
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Abstract
Patients with multiple tumors, either synchronous or metachronous, can have metastatic disease or suffer 
from multiple independent primary tumors. While proper diagnosis of these patients is important for 
prognosis and treatment, this can be challenging using only clinical and histological criteria. The aim of the 
present study was to evaluate the value of mitochondrial D310 mutation analysis in diagnostic questions 
regarding tumor clonality for a wide range of tumor types. Sanger sequencing of D310 was performed on 
a diagnostic cohort of 382 patients with 857 tumors that were previously analyzed using routine molecular 
analysis on genomic DNA. The D310 mononucleotide repeat was frequently somatically mutated (56/321, 
17%) in several tumor types, including breast, head and neck, gynecological, lung, colorectal, and skin tumors. 
For 84/327 (26%) patients, a D310 mutation was detected in at least one of their tumors; for these patients, 
D310 can be used to determine the clonal relationship between their multiple tumors. Clonality assessments 
based on mitochondrial DNA (mtDNA) and routine genomic DNA analysis were concordant in 52/73 (71%) 
patients. We conclude that D310 mutation status might aid in determining clonality of clinically challenging 
synchronous or metachronous tumors. To this end, next generation sequencing targeted genomic DNA assays 
should be complemented with mtDNA markers, such as the D310 repeat. 
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Introduction
When a patient presents with multiple tumors, 
either synchronous or metachronous, the question 
arises whether this is metastatic (recurrent) disease 
or, alternatively, the patient suffers from multiple 
primary tumors, as appears to be the case in 8% of 
cancer patients1. To distinguish between multiple 
independent primary tumors and metastatic disease 
is of prime importance for prognosis and treatment2 
but can be challenging, when only clinical and 
histological criteria are available. Since tumor cells 
differ from normal cells by the presence of clonal 
DNA aberrations, these can be used to determine 
whether or not a clonal relationship exists between 
multiple tumors within one patient2-4. 
Most molecular clonality assays focus 
on genomic DNA. Human cells, however, also 
contain numerous copies of mitochondrial DNA 
(mtDNA). Mutations in mtDNA initially result in 
heteroplasmic cells (cells with mutant and non-
mutant mitochondrial DNA molecules). Upon cellular 
expansion, these heteroplasmic cells can achieve 
mutant DNA homoplasmy (all mtDNA molecules 
within one cell harbor the same mutation), as has 
been demonstrated in tumor models, human tumors, 
and tumor cell lines5-8. Apparently, homoplasmic 
mtDNA aberrations have been frequently found in 
human tumors9, notably in a polymorphic cytosine 
mononucleotide repeat within the non-coding 
displacement loop (D-loop) region (D310)10. In several 
studies on different tumor types, mitochondrial 
DNA alterations have been used as a marker for 
clonality11-14. The aim of the present study was to 
evaluate for a wide range of tumor types whether or 
not D310 mutation analysis helps to solve diagnostic 
questions regarding tumor clonality. 
For this study, we selected patients with 
multiple synchronous or metachronous tumors, for 
which the question of a clonal relationship was raised 
leading to routine molecular analysis on genomic 
DNA. We addressed the following questions: (1) Do 
these tumors have mtDNA D310 mutations? (2) Are 
the tumors clonally related based on mtDNA analysis 
and does this correspond to the clonality status 
assessed by routine genomic DNA analysis? 
Materials and methods
We studied a cohort of patients with synchronous 
or metachronous tumors for which routine 
molecular clonality analysis on genomic DNA had 
been performed between January 2006 and April 
2013 at the Erasmus Medical Center, Rotterdam, 
The Netherlands. All cases concerned patients for 
which pathologists or clinicians had previously 
submitted a request for molecular analysis in view 
of questions regarding diagnosis, prognosis, and/
or patient treatment. For routine analysis, normal 
and tumor DNA had been extracted from formalin-
fixed paraffin-embedded (FFPE) tissue blocks using 
proteinase K and, for extractions from 2009 onwards, 
5% Chelex 100 resin, as previously described15. 
DNA was used in accordance with the Code of 
Proper Use established by the Dutch Federation of 
Medical Scientific Societies (https://www.federa.
org/sites/default/files/digital_version_first_part_
code_of_conduct_in_uk_2011_12092012.pdf). On 
these tumors, depending on the amount of tissue 
available and the tumor type, different combinations 
of routine molecular analyses had been performed, 
among which loss of heterozygosity (LOH) analysis, 
TP53 mutation analysis following abnormal p53 
immunohistochemical staining, and/or mutation 
analysis for other genes. 
Of 466 patients eligible for inclusion in the 
study, 63 were excluded because no archival normal 
or tumor DNA was available, 17 because the original 
report was unavailable, and four because this was 
incomplete. In total, 857 tumors from 382 patients 
were included. Supplementary Table 1 shows an 
overview of all tumor details. Consecutive tumors in 
any single patient included have been numbered T1 
to T7, in chronological order with T1 being the first 
diagnosed; in most cases this was the primary tumor. 
PCR amplification of D310 was performed 
with normal and tumor DNA using Kapa 2G robust 
hotstart readymix (Kapa Biosystems, Woburn, MA) 
and M13-tailed custom-made primers (forward TGT 
AAA ACG ACG GCC AGT - TTG AAT GTC TGC ACA GCC 
AC and reverse CAG GAA ACA GCT ATG ACC - GGG 
GTT TGG CAG AGA TGT G). After purification using 
Exonuclease I and FastAP Thermosensitive Alkaline 
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Phosphatase (Fermentas, Thermo Fisher Scientific, 
Waltham, MA), PCR products were sequenced with 
M13 primers using the BigDye Terminator v3.1 kit 
(Applied Biosystems, Foster City, CA). Fragments were 
detected on a ABI 3730xl genetic analyzer (Applied 
Biosystems). D310 repeat length (nucleotide position 
303–309) was evaluated by visual inspection using 
Mutation Surveyor v.3.24 software (SoftGenetics, 
State College, PA). An altered D310 repeat length in 
tumor DNA compared to patient-matched normal 
DNA was classified as a D310 mutation (either deletion 
or insertion). To exclude genomic DNA amplification, 
DNA isolated from mtDNA-less cells was used as a 
negative control (143B/206 ρ0, a kind gift of Dr. G.P. 
Comi, Dino Ferrari Centre, Neuroscience Section, 
Department of Pathophysiology and Transplantation 
(DEPT), University of Milan, Milan, Italy). 
Results
Detailed results on the analysis of D310 in 857 
synchronous or metachronous tumors of 382 patients 
are shown in Supplementary Table 1. Corresponding 
normal DNA could be evaluated in 332 patients and 
showed D310 repeat lengths of 6, 7, 8, or 9 cytosines 
(for 1, 187, 123, and 21 patients, respectively). Both 
normal DNA and DNA from the first tumor (T1) could 
be evaluated in 321 patients. A D310 mutation was 
found in 56/321 (17%) of T1, of which 11/85 (13%) 
in breast, 11/62 (18%) in head and neck, 4/35 (11%) 
in gynecological, 5/26 (19%) in lung, 8/25 (32%) in 
colorectal, and 3/19 (16%) in skin tumors (Figure 1). 
In 35/56 (63%) tumors, an insertion of one, two, or 
three nucleotides was found (in 25, 7, and 3 tumors, 
respectively); 21/56 (37%) tumors showed a deletion 
of one, two, or multiple nucleotides (18, 2, and 1 
tumors, respectively). Of the 327 patients for whom 
D310 status could be determined, 243 (74%) showed 
tumors without D310 aberrations, while in 84 (26%) a 
D310 mutation was detected in one or more tumors 
(Table 1). 
Of the 84 patients with a D310 mutated 
tumor, 29 (35%) had clonally related tumors and 55 
(65%) had multiple primary tumors based upon D310 
mutation status. For 73 of these 84 patients, a final 
clonality status assessed by genomic DNA molecular 
clonality analysis was available, and in 52 (71%), 
mtDNA and genomic DNA results were concordant 
(Figures 2, 3 + Supplementary Table 2). 
Discussion
We found that the D310 mononucleotide repeat 
in mtDNA is somatically mutated in 13% of breast 
tumors, 18% of head and neck tumors, 11% of 
gynecological tumors, 19% of lung tumors, 32% of 
colorectal tumors, and 16% of skin tumors. These 
results are in close agreement with previous studies 
in which D310 mutations were found in 11–28% of 
breast tumors, 0–16% of head and neck tumors, 
3–26% of ovarian tumors, 0–13% of lung tumors, and 
8–36% of colon tumors10. 
The identified D310 mutations were (nearly) 
homoplasmic, indicating that these mutations are 
present in the majority of the neoplastic cells and 
as a consequence must have occurred early during 
oncogenesis. Heteroplasmic D310 mutations have 
been reported in normal cells, achieving homoplasmy 
in tumor cells6,12. This suggests that D310 mutation 
status might provide an ideal marker for tumor 
clonality. We found in 84/327 (26%) patients with 
synchronous or metachronous tumors, for which the 
question of a clonal relationship was raised, a D310 
mutation in at least one of the tumors. In such cases, 
D310 mutation status can be used to determine the 
possible clonal relationship between the tumors. In 
a large majority of patients (71%), clonality status 
assessed by mtDNA analysis and routine genomic 
Figure 1. Percentage of D310 mutations in the chronologically 
first diagnosed tumors of all patients. The tumors are categorized 
by tumor type; after each tumor type, the number of tumors 
with an evaluable result is shown between parentheses.
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Figure 2. Routine genomic DNA and mitochondrial DNA results for patient 352, who was diagnosed with synchronous tumors of the 
right (T1) and the left lung (T2). (a) Both tumors were diagnosed as adenocarcinomas with a bronchioloalveolar growth pattern; T1 
shows absence of p53 staining, whereas T2 shows clear nuclear p53 staining. Scale bars represent 50 μm. (b) Routine genomic DNA 
analysis was performed on DNA isolated from normal (N) and both tumor tissues (T1 and T2). LOH analysis of marker D17S786 (TP53) 
showed loss of the large allele in T1 and loss of the small allele in T2, indicated by arrowheads. The horizontal axis indicates the size of 
the DNA fragments in base pairs; the vertical axis indicates signal intensity. (c) Routine Sanger sequencing of TP53 showed a p.Gln52* 
mutation only in T1, and a p.Ser127Tyr mutation only in T2, both indicated by arrowheads. (d) Sanger sequencing of mitochondrial 
DNA marker D310 showed an 8-cytosine repeat in normal DNA, no aberrations in T1, and a 1-bp deletion in T2, as indicated by the 
arrowhead. The results of routine genomic DNA and mitochondrial DNA analysis both indicate that T1 and T2 represent two primary 
tumors.
H&E: hematoxylin and eosin stain 
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DNA analysis were concordant. 
Discordant results between clonality status 
assessed by mtDNA and genomic DNA analysis were 
found in 21/73 (29%) patients. Clonality assays on 
multiple tumors often result in some markers with 
concordant results but also markers with discordant 
results between the different tumors. Close scrutiny 
of individual markers is then necessary to decide 
whether the tumors are clonally related or not 
in view of the notion that genomic DNA analysis 
generates a likelihood that multiple tumors might 
be clonally related, but does not provide a definitive 
result. For 11 of our patients with discordant results, 
a highly likely diagnostic result was obtained because 
the tumors had a mutation in common, had mutually 
exclusive mutations, or the first tumor had a mutation 
that was not found in consecutive tumor(s). For these 
patients, the discordant mtDNA result was probably 
incorrect. Possible explanations are firstly that 
two primary tumors by chance may have acquired 
identical D310 mutations, secondly that de novo 
D310 mutations acquired during tumor progression 
result in clonally related tumors with different 
D310 mutations, and thirdly that intercellular or 
intracellular heterogeneity (heteroplasmy) in regard 
of D310 mutations is maintained during tumor 
development. For five patients, a likely diagnostic 
result was obtained because a mutation was only 
present in a consecutive tumor or the tumors showed 
common or different LOH status of five or more loci. 
For another five patients, the diagnostic result was 
weak, based on common or different LOH status of 
less than five loci. To reliably classify such tumors as 
clonally related or not, more informative genomic 
and/or mtDNA markers would be necessary. 
Although D310 mutations are the most 
common mtDNA mutations in human cancer, other 
mtDNA deletions, insertions, and point mutations 
have been described9. Recently, next generation 
sequencing assays for mitochondrial DNA have 
become available16. The use of such assays for 
clonality analysis would result in the detection of more 
mutations and probably result in a higher predictive 
value. However, approximately 1.8 point mutations 
in somatic mtDNA have been found in only 60% 
of cancers10, emphasizing the necessity to include 
analysis of genomic DNA as well. Mitochondrial DNA 
markers might be helpful when only a small number 
of cells are available, in view of the high number of 
mtDNA copies per cell compared to genomic DNA. 
This study also has some limitations. Even 
though mtDNA is present in numerous copies per 
cell, facilitating amplification and analysis of a 
minute number of cells, no or an ambiguous D310 
mutation analysis result was obtained for 55/382 
(14%) patients. This was mostly due to an insufficient 
amount of DNA. For 11/84 (13%) patients with 
D310 mutations, a final clonality status assessed by 
genomic DNA analysis was not available, and for 
these patients, we were unable to compare mtDNA 
with genomic DNA results. 
We conclude that D310 mutation status 
might aid in clonality determinations of clinically 
challenging synchronous or metachronous tumors, 
but as a single assay, has limited predictive value. 
To further evaluate the potential contribution of 
mtDNA markers to assessment of tumor clonality, 
we propose to include in existing next generation 
sequencing targeted genomic DNA assays mtDNA 
markers, such as the D310 repeat.
Supplementary material on the internet
Supplementary Table 1. Mitochondrial DNA results 
for all patients.
http://www.niekgeurts.nl/proefschrift/Chapter 4 
-Supplementary Table 1.xls
Supplementary Table 2. Routine genomic versus 
mitochondrial DNA results for 84 patients with 
a D310 mutation in at least one of their tumors. 
http://www.niekgeurts.nl/proefschrift/Chapter 4 
-Supplementary Table 2.xls
Figure 3. Clonality status assessed by mitochondrial DNA 
(mtDNA) results compared to routine genomic DNA results for 
73 patients with a D310 mutation in one or more of their tumors.
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Abstract 
Histological and molecular subtyping of non-small cell lung cancer (NSCLC) is important for predicting 
survival and drug response in these patients. Up to 8% of NSCLC are multifocal and these tumor foci are 
often clonally related. Multiple foci can however also represent different primary tumors, with prognostic 
and therapeutic consequences. We describe a patient with multifocal NSCLC from which we obtained tissue 
from two separate lesions. With routine conventional molecular determinations, the clonal relationship 
between the two lesions was determined. In addition, targeted next generation sequencing with the Ion 
Torrent Personal Genome Machine (PGM) was performed to explore the accuracy and additional value of 
this relatively new technique. The two tumors of this patient showed different activating epidermal growth 
factor receptor (EGFR) mutations, EGFR amplification status, TP53 mutation status, and loss of heterozygosity 
patterns. With the PGM, all conventional detected mutations were confirmed, and an additional variant 
of unknown significance in ATM was detected in one of the tumors. The multifocal NSCLC of this patient 
represents two unrelated primary tumors. Our results suggest that multifocal NSCLC should be considered as 
potentially multiple primary tumors. As the presence of activating EGFR mutations has important therapeutic 
consequences, EGFR testing should be performed on all tumor foci present. In the present case, targeted next 
generation sequencing using the PGM appeared to be accurate and comparable with conventional molecular 
determinations. However, the application of the PGM in routine pathology molecular diagnostics needs 
validation in larger series of cases. 
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Introduction
Lung cancer, with non-small cell lung cancer (NSCLC) 
as the most common type, is the leading cause 
of cancer mortality1. Histological and molecular 
subtyping of NSCLC is important for predicting survival 
and drug response. Patients with NSCLC harboring 
activating epidermal growth factor receptor (EGFR) 
mutations have a longer progression-free survival 
when treated with tyrosine kinase inhibitors 
(TKIs) compared to conventional chemotherapy2. 
Conversely, conventional chemotherapy is superior 
to TKI treatment in NSCLC patients without EGFR 
mutations. 
Up to 8% of NSCLC are multifocal3-6. 
These tumors occur either synchronous (detected 
simultaneously) or metachronous (detected with 
a time interval). Multifocal lung tumors can be 
clonally related, but they can also represent multiple 
unrelated primary tumors. Previous studies showed 
that 7 to 64% of multifocal lung tumors are unrelated 
primary tumors5-8. This large range can be explained 
by inclusion of different subtypes of lung cancers 
and inclusion or exclusion of metachronous tumors. 
Furthermore, different combinations of molecular 
techniques were used to determine the clonal 
relationship between the tumors among which loss 
of heterozygosity (LOH) analysis and EGFR, KRAS, 
and TP53 mutation determinations. Discriminating 
clonally related tumors from multiple primary tumors 
is of prime importance for appropriate treatment 
of the individual patient. It has been reported that 
patients with multifocal clonally distinct tumors may 
have a better outcome than patients with multifocal 
clonally related tumors7. Multifocality of a single 
primary NSCLC is probably an indication of the 
expanding or malignant potential of the lesion. 
In the current study, we describe a patient 
with synchronous multifocal NSCLC. We addressed 
the question whether these foci are clonally related 
using routine molecular analysis. Furthermore, 
targeted next generation sequencing was performed 
to explore the accuracy and additional value of this 
relatively new technique in diagnostic questions 
regarding tumor clonality. 
Clinical history
At the age of 69, the index patient was diagnosed with 
a multifocal lung tumor. The patient was a formerly 
healthy smoker (45 pack years) and presented with 
chest pain and weight loss. On a CT scan, we found 
three subpleural, nodular lesions; two in the left 
upper lobe and one in the right middle lobe of the 
lung. On a CT-guided cytologic biopsy, we did not 
succeed to get an adequate tumor sample so she was 
scheduled to have a video-assisted thoracoscopic 
procedure. A local excision of both tumors in the apex 
of the left lung was performed; a tumor of 15 mm in 
diameter was located at the ventral side (tumor 1) 
and a tumor of 17 mm in diameter was located at 
the dorsal side (tumor 2). At inspection of the pleural 
cavity, a diffuse nodular pattern was seen on both 
visceral and parietal pleura. Excision of the tumor in 
the right lung was not possible. Pathology revealed 
that both tumor foci of the left lung had comparable 
adenocarcinoma histology and both were TTF1 
positive (Figure 1b), indicating their pulmonary origin. 
Patient was staged to have a pT4N0M1 NSCLC9. When 
molecular analyses showed two different EGFR exon 
19 deletions in the two tumor foci, the patient was 
started on gefitinib (TKI). She showed a complete 
response which currently persists 32 months after 
start of the gefitinib treatment. CT scan 30 months 
after surgery showed no recurrence of disease.
Materials and methods 
Normal and tumor tissues were manually 
microdissected from 5 to 15 hematoxylin-stained 
sections (4 μm) of formalin-fixed paraffin-embedded 
(FFPE) tissue blocks. DNA was extracted using 
proteinase K and 5% Chelex 100 resin, as previously 
described10. 
P53 and TTF-1 immunohistochemistry was 
performed with the mouse monoclonal antibodies 
Do-7 (Dako, Glostrup, Denmark) and SPT24 (Monosan, 
Uden, The Netherlands), respectively, according to 
standard protocols. To establish whether the EGFR 
locus was amplified in the tumor tissue, fluorescent 
in situ hybridization (FISH) was performed using 
EGFR/SE 7 probes (Kreatech, Amsterdam, The 
58i
Chapter 5 Molecular diagnostics of a single multifocal non-small cell lung 
cancer case using targeted next generation sequencing
Netherlands), according to standard protocols. 
Sequence analysis of KRAS codons 12, 13, 61, 
and 146, EGFR exons 18–21, and TP53 exons 4–9 was 
performed with M13-tailed custom-made primers on 
tumor DNA. PCR amplification was performed with 
Kapa 2G robust hotstart readymix (Kapa Biosystems, 
Woburn, MA) according to the manual. PCR products 
were purified with Exonuclease I and FastAP 
Thermosensitive Alkaline Phosphatase (Fermentas, 
Thermo Fisher Scientific, Waltham, MA). The 
products were sequenced with M13 primers using 
the BigDye Terminator v3.1 kit (Applied Biosystems, 
Foster City, CA). Labeled fragments were detected on 
an ABI 3730xl genetic analyzer (Applied Biosystems). 
Data were analyzed with Mutation Surveyor v3.24 
software (SoftGenetics, State College, PA). When 
variants were detected, normal DNA was sequenced 
to see whether the variants were tumor specific. 
Snapshot analysis of EGFR was performed 
with the SNaPshot multiplex kit (Applied Biosystems) 
and custom made primers and probes to detect all 
EGFR hotspot mutations and deletions. The snapshot 
protocol was previously described11. 
LOH analysis was performed using normal 
and tumor DNA. FAM-labeled primers for the 
following microsatellite markers were used: D1S199, 
D3S1038, D3S1300, D5S421, D5S433, D8S133, 
D9S157, D9S1748, PTENCA, D10S541, D13S153, 
D13S263, D17S855, D17S1353, D17S786, D18S474, 
and D19S412. PCR amplification was performed 
as described for the mutation analysis. Labeled 
fragments were detected on an ABI 3730xl genetic 
analyzer (Applied Biosystems). Data were analyzed 
with Genemarker v1.85 software (SoftGenetics). 
Ion semiconductor sequencing on the Ion Torrent 
Personal Genome Machine (PGM) was performed 
with the Ion AmpliSeq Cancer Panel on normal 
and tumor DNA according to the manufacturer’s 
protocols. In short, libraries were made using the 
Ion AmpliSeq Library Preparation Kit. Template was 
prepared using the Ion OneTouch Template Kit and 
sequencing was performed with the Ion Sequencing 
Kit v2.0 on an Ion 316 chip. Data were analyzed with 
Variant Caller v2.2.3-31149 (all Life Technologies, 
Figure 1. Hematoxylin and eosin (HE) stainings, TTF-1 and p53 
immunohistochemistry and EGFR fluorescent in situ hybridization 
(FISH) results for tumor 1 (upper panels) and tumor 2 (lower 
panels). (a) HE stainings; the non-small cell lung cancer is indicated 
by arrows, normal lung tissue is indicated by arrowheads. Both 
tumor foci were diagnosed as adenocarcinomas. (b) TTF-1 
staining was positive in both tumors, indicating their pulmonary 
origin. (c) p53 staining was absent in most cells of tumor 1; 
tumor 2 showed clear nuclear staining. (d) EGFR FISH shows the 
EGFR locus with red spots and the centromere of chromosome 
7 with green spots. Two copies of EGFR were present in the cells 
of tumor 1, whereas tumor 2 showed amplification of the EGFR 
locus. 
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Carlsbad, CA). Variants were called when the position 
was covered at least 500 times. Sequences of all 
primers and probes are available on request. 
Results 
Tumor 1 showed a heterogeneous p53 staining; 
most cells were negative but some scattered single 
cells showed slightly positive nuclear staining (Figure 
1c). Tumor 2 showed positive nuclear p53 staining in 
almost all tumor cells, suggestive of a TP53 mutation. 
EGFR FISH showed two copies of the EGFR locus in 
tumor 1 and EGFR amplification in tumor 2 (Figure 
1d). 
The molecular data for both tumor samples 
are summarized in Table 1. Sequencing analysis 
showed EGFR deletions in exon 19 in both tumor 
samples. Tumor 1 harbored a p.E746_A750del 
(c.2235_2249del15) and tumor 2 a p.L747_T751del 
(c.2240_2254del15) (Figure 2a). These deletions 
were confirmed by SNaPshot analysis (data not 
shown) and with the PGM (Figure 2b). Both tumor 
samples were wild type for KRAS. TP53 exons 4 to 9 
were sequenced in both tumor samples; tumor 1 was 
wild type and tumor 2 showed a p.S215I (c.644G>T) 
mutation in exon 6 (Figure 2c). This mutation was 
confirmed with the PGM (Figure 2d). Tumor 2 also 
showed LOH of marker D17S786, which is located 
near the TP53 locus (Figure 3b). LOH analysis of 
ten chromosomes showed different LOH patterns 
between T1 and T2 at four chromosomes, including 
the TP53 and APC loci (Figure 3). Furthermore, 
a variant of unknown significance (VUS) in ATM 
(p.Q3014X, c.9040C>T) was detected in a minority of 
the PGM reads of sample T2 (position covered 1,351 
times of which 94 reads showed the variant). No 
other variants were detected with the PGM. 
Discussion 
The multifocal NSCLC of the index patient represents 
two unrelated primary tumors. The two tumors 
showed different activating EGFR mutations, which 
are early somatic mutations in NSCLC12. Several other 
differences were observed between the tumors, 
including EGFR amplification status, TP53 mutation 
status, and LOH patterns, supporting that these 
tumors are different and unrelated entities. 
In the present case, targeted next generation 
sequencing using the PGM is accurate; all mutations 
found by conventional molecular techniques were 
confirmed by the PGM. An additional VUS in ATM 
was detected in tumor 2 which, to our knowledge, 
has never been described before. This variant 
introduces a premature stop at codon 3014, leading 
to the truncation of 42 amino acids. The functional 
relevance of this variant is yet unknown. The variant 
was only found in a minor subset of the PGM reads, 
indicating molecular heterogeneity within this tumor. 
PGM sequencing can be of additional value in 
tumor clonality determinations compared to routine 
Gene/locus Tumor 1 Tumor 2
Mutation analysis
KRAS WT WT
EGFR p.E746_A750del p.L747_T751del
TP53 WT p.S215I
LOH analysisa
D1S199 ROH ROH
D3S1038 LOH (short) LOH (short)
D3S1300 LOH (short) LOH (short)
D5S421 LOH (short) ROH
D5S433 LOH (short) ROH
D9S157 LOH (short) LOH (short)
D9S1748 LOH (short) ROH
D13S153 LOH (long) LOH (long)
D13S263 LOH (short) LOH (short)
D17S855 ROH LOH (short)
D17S786 LOH (short) LOH (long)
D18S474 LOH (long) LOH (long)
D19S412 ROH LOH (long)
FISH
EGFR Not amplified Amplified
PGM - additional variant detected
ATM WT p.Q3014Xb
aOnly informative markers are shown 
bDetected in 94 out of 1,351 reads 
FISH: fluorescent in situ hybridization; LOH: loss of heterozygosity; 
PGM: Ion Torrent Personal Genome Machine; ROH: retention of 
heterozygosity; WT: wild type 
Table 1. Summary of the molecular data for both tumors of the 
index patient. 
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Figure 2. Sequencing analysis and Ion Torrent Personal Genome Machine (PGM) results for EGFR exon 19 and TP53 exon 6. For the 
PGM data, each gray line represents an individual read; only aberrations from the wild type sequence are indicated. (a) Both tumors 
had an EGFR deletion, tumor 1 harbored a p.E746_A750del and tumor 2 a p.L747_T751del. (b) These deletions were confirmed with 
the PGM, the deletion is indicated by the black lines. (c) TP53 sequencing revealed a p.S215I missense mutation only in tumor 2 
(position is indicated by arrows). (d) This mutation was also confirmed with the PGM, shown in reverse complement.
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molecular analyses, especially when no mutations 
are detected using routine molecular techniques. 
Due to the low amount of DNA input necessary, the 
PGM can provide information about multiple genes 
even in cytology or small biopsy specimens. With only 
10 ng of input DNA, the Ion Ampliseq Cancer Panel 
can detect 739 hotspot mutations in 46 oncogenes 
and tumor suppressor genes. Furthermore, PGM 
sequencing can successfully be performed with 
DNA retrieved from routine pathology FFPE tissue. 
Another advantage of the PGM is the high coverage, 
which enables the detection of variants down to 
5% allele frequency. For conventional sequencing, 
a sample with 40 to 50% tumor cells is necessary 
for accurate detection of mutations, while for the 
PGM, 10% tumor cells in a background of normal, 
non-neoplastic cells, is sufficient. Additionally, a 
high coverage enables the detection of variants that 
are only present in a subpopulation of the tumor 
cells. This could be important in tumor clonality 
determinations, as a mutation present in one tumor 
might only be present in a subpopulation of the 
cells from the other tumor and would have escaped 
detection by conventional sequencing. However, 
the application of the PGM in routine pathology 
molecular diagnostics needs validation in a large 
cohort. 
The index patient presented with two 
unrelated primary NSCLC, which raises the question 
whether the patient could be predisposed for 
developing this malignancy. The patient had a 
smoking history of 45 pack years. Warth et al.7 
reported that extensive smoking may increase the 
risk to develop multifocal, unrelated NSCLC. Although 
not significant, they found that patients with clonally 
unrelated NSCLC had higher numbers of pack years 
of smoking than patients with clonally related 
NSCLC. The genetic background can also predispose 
to the development of multiple lung tumors. It can 
be expected that next generation sequencing of 
constitutional DNA of NSCLC patients will aid in the 
identification of genetic risk factors. 
Earlier studies reported that a high 
percentage of multifocal lung tumors are actually 
unrelated primary tumors5,7,8. In a recent study of 
Warth et al.7, including 78 patients with synchronous, 
multifocal NSCLC, 28 patients (36%) are suggested 
to have separate primary tumors based on their 
unique molecular profiles. Our results and those 
of others indicate that multifocal NSCLC should be 
considered as potentially multiple primary tumors. 
Molecular testing is valuable to establish whether 
the tumors are clonally related. As the presence of 
activating EGFR mutations has important therapeutic 
consequences, it is indicated to perform EGFR testing 
on all tumor foci present. 
Multifocal tumors consisting of multiple 
primary tumors possibly also have different EGFR 
mutation statuses. This poses a problem, as NSCLC 
harboring an activating EGFR mutation respond well 
to TKIs, whereas NSCLC without these mutations 
Figure 3. Loss of heterozygosity (LOH) results for the APC and 
TP53 loci (markers D5S421 and D17S786, respectively). The 
alleles are indicated by gray lines, LOH is indicated by arrows. 
The horizontal axis indicates the size of the DNA fragments (in 
base pair); the vertical axis indicates signal intensity. (a) LOH of 
APC was detected in tumor 1; tumor 2 showed retention of both 
alleles. (b) LOH of TP53 was detected in both tumors; tumor 1 
showed loss of the short allele and tumor 2 showed loss of the 
long allele.
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respond better to conventional chemotherapy2. 
More research is necessary to establish whether 
NSCLC patients with a combination of EGFR mutated 
and EGFR wild type lung tumors will benefit from TKI 
treatment. 
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Abstract
Female BRCA1/2 mutation carriers affected with breast and/or ovarian cancer may develop new tumor deposits 
over time. It is of utmost importance to know the clonal relationships between multiple tumor localizations, 
enabling differentiation between multiple primaries or metastatic disease with consequences for therapy and 
prognosis. We evaluated the value of targeted next generation sequencing (NGS) in the diagnostic workup 
of BRCA1/2 mutation carriers with ≥2 tumor localizations and uncertain tumor origins. Forty-two female 
BRCA1/2 mutation carriers with ≥2 tumor localizations were selected. Patients with inconclusive tumor 
origin after histopathological revision were ‘cases’; patients with certain tumor origin of ≥3 tumors served 
as ‘controls’. Tumors of cases and controls were analyzed by targeted NGS using a panel including CDKN2A, 
PTEN and TP53, hotspot mutation sites for 27 different genes and 143 single nucleotide polymorphisms for 
detection of loss of heterozygosity (LOH). Based on prevalence of identical or different mutations and/or LOH 
patterns, tumors were classified as ‘multiple primaries’ or ‘one entity’. Conventional histopathology yielded 
a conclusive result in 38/42 (90%) of patients. Four cases and 10 controls were analyzed by NGS. In 44 tumor 
samples, 48 mutations were found; 39 (81%) concerned TP53 mutations. In all four cases, the intra-patient 
clonal relationships between the tumor localizations could be unequivocally identified by molecular analysis. 
In all controls, molecular outcomes matched the conventional histopathological results. In most BRCA1/2 
mutation carriers with multiple tumors routine pathology work-up is sufficient to determine tumor origins 
and relatedness. In case of inconclusive conventional pathology results, molecular analyses using NGS can 
reliably determine clonal relationships between tumors, enabling optimal treatment of individual patients.
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Introduction
Female BRCA1/2 mutation carriers have a cumulative 
lifetime risk of developing breast cancer of 55-85% 
by the age of 701-4. The cumulative lifetime risk of 
developing ovarian cancer varies between 15-60% 
for BRCA1 and 10-35% for BRCA2 mutation carriers1-4. 
Moreover, susceptibility for other cancers also seems 
to be increased in BRCA1/2 mutation carriers5,6. 
 It has been reported that BRCA1-associated 
breast cancers more frequently develop visceral 
metastasis and fewer bone metastases7,8 and BRCA2-
associated breast cancers tend to develop more 
lymph node metastases compared with sporadic 
breast cancer8. Metastatic sites of sporadic ovarian 
cancer mostly confine to the intraperitoneal cavity9,10, 
whereas it has been described that BRCA1/2-
associated ovarian cancer patients frequently (74%) 
present with visceral metastases to liver, lung and 
spleen11. Although this can be of some help, the non-
specific metastatic patterns in BRCA1/2-associated 
breast and ovarian cancer patients impede careful 
differentiation between breast cancer, ovarian 
cancer and other tumor origins when multiple cancer 
localizations occur in one patient. It is of clinical 
importance, however, to make this distinction, as it 
guides surgical and chemotherapeutic treatment and 
determines prognosis12,13. 
 A potentially helpful tool in determining 
clonal relationships between multiple tumors is 
DNA next generation sequencing (NGS)14. With NGS, 
selected genes known to be frequently mutated in 
specific tumor types can be analyzed. Additionally, 
single nucleotide polymorphisms (SNPs) can be 
analyzed to detect any DNA copy number changes 
present in the tumor cells. Identical molecular 
aberrations of different tumor localizations indicate 
a common tumor origin (e.g. metastatic disease), 
whereas different mutations and/or copy number 
changes in different tumor samples indicate two 
primary malignancies. 
 The aim of the current study was to evaluate 
the value of NGS in the diagnostic workup of BRCA1/2-
associated breast and ovarian cancer patients with 
multiple tumor localizations.
Materials and methods
Patient selection: cases and controls
Patients at increased risk of breast and/or ovarian 
cancer visiting the Family Cancer Clinic of the Erasmus 
Medical Center Cancer Institute for counseling and 
surveillance programs are registered in an institutional 
ongoing database. All women provide written 
informed consent for registration of their clinical 
data and storage of genetic material (if relevant) for 
research purposes. From this database, we selected 
all female germline BRCA1 or BRCA2 mutation 
carriers with ≥2 synchronous or metachronous tumor 
localizations of which tumor material had been 
obtained by fine needle aspiration (FNA), biopsy or 
surgical excision. Tumor localizations of which no 
suitable material was available for histopathological 
or molecular analysis were excluded. Included were 
BRCA1/2 mutation carriers with multiple tumors of 
which at least one was located in the breast or ovary. 
Inclusion and exclusion criteria are depicted in Table 1.
 If possible, the origin of the tumor 
localizations was identified based on H&E staining. 
If tumor histology did not provide a conclusive 
diagnosis, immunohistochemical (IHC) staining was 
applied. Patients for whom the origin of one or 
more tumor localizations remained uncertain after 
histological and IHC evaluation were selected for NGS 
molecular analysis (‘cases’). Patients with ≥3 tumor 
localizations of conclusive origin, based on histology 
and IHC, served as ‘controls’. Controls were selected 
for NGS, as well, to validate the versatility of the NGS 
approach for tumor clonality determinations.
Conventional diagnostics
Tumor histology
Formalin-fixed paraffin-embedded (FFPE) tumor 
tissues were collected from the Department of 
Pathology of the Erasmus Medical Center Cancer 
Institute and from regional hospitals. Two pathologists 
specialized in breast and gynecological cancer (C.v.D., 
P.v.D.) independently reviewed haematoxylin and 
eosin (H&E) stained tissue sections of the tumor 
localizations for histology, with a subsequent 
consensus discussion. 
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Immunohistochemistry
IHC tissue markers were chosen according to the 
institutional protocol and depended on clinical and 
histological differential diagnosis of the origin of the 
various tumor localizations. Estrogen receptor (ER) 
was used as a breast cancer marker. IHC markers 
used for differentiation of ovarian cancer were 
cancer antigen 125 (CA125), Wilms’ tumor 1 (WT1) 
and PAX-8, all known to be frequently expressed in 
ovarian cancer15-17. To differentiate with primary lung 
carcinoma, TTF-1 was used18.
Molecular analysis
For cases and controls, p53 IHC was performed on 
all tumor tissues if FFPE tissue blocks were available. 
Nuclear expression of p53 in tumor cells was scored 
as either heterogeneous (no indication for TP53 
mutation), strong in all tumor cells (indication for 
missense TP53 mutation) or absent in all tumor 
cells (indication for frameshift, nonsense, or splice 
site TP53 mutation). For NGS analysis, normal and 
tumor tissues were manually microdissected from 
haematoxylin-stained tissue sections of FFPE tissue 
blocks or if unavailable, from original routine H&E, 
IHC stained sections or cytological preparations. DNA 
was extracted using proteinase K and 5% Chelex 
resin, as previously described19; DNA concentrations 
were measured with the Qubit 2.0 Fluorometer. To 
assess the quality of DNA amplification a multiplex 
control PCR was performed as previously described20; 
PCR products were analyzed on an agarose gel. All 
DNA samples were screened with the Ion Torrent 
Personal Genome Machine (PGM), with supplier’s 
materials and protocols (Life Technologies, Carlsbad, 
CA, USA). A custom made primer panel was used, 
designed using Ion AmpliSeq Designer 2.2.1, for 
diagnostic use in clonality determinations of various 
tumor types including breast and ovarian cancer. 
Because this panel was designed for analysis of 
a broad range of tumor types, it includes genes 
frequently mutated in breast and ovarian cancer, as 
well as genes rarely mutated in these tumors. The 
panel targets almost the entire open reading frame of 
CDKN2A, PTEN and TP53 (coverage 95-99%), multiple 
hotspot mutation sites for 27 different genes and 143 
SNPs at 15 different loci for the detection of loss of 
heterozygosity (LOH, see Supplementary Table 1 for 
primer details). In total, the panel consisted of 254 
amplicons with a mean amplicon size of 160 base 
pairs. With this panel, libraries were created using the 
Ion AmpliSeq 2.0 Library Kit. Template was prepared 
using the Ion OneTouch 2 with the Ion OneTouch 
200 Template Kit v2 DL or using the IonChef with the 
Ion PGM Hi-Q Chef Kit. Sequencing was performed 
on an Ion 318v2 chip with the Ion PGM sequencing 
200 kit v2 or the Ion PGM Hi-Q sequencing kit. 
Data was analyzed with Variant Caller v4.0 or 
v.4.4.2.1. Annotation of the variants was previously 
described21. For mutation detection, all exonic and 
splice variants with a variant percentage ≥20% were 
reported, excluding synonymous single-nucleotide 
variants and variants present in patient-matched 
normal tissue. Variants with a total coverage of ˂100 
Inclusion
•	 Women with a proven BRCA1 and/or BRCA2 mutation
•	 With ≥ 2 synchronous or metachronous tumor localizationsa
•	 Tumor material available for next generation sequencing analysis 
•	 (obtained by fine needle aspiration, histological biopsy or 
surgical excision) 
•	 One of the 4 clinical scenarios:
1. Breast cancer and ovarian cancer
2. Breast cancer and second other tumor
3. Ovarian cancer and second other tumor
4. Breast cancer, ovarian cancer, and third or additional 
other tumor localizations
Exclusion criteria for ‘other tumor localization’
•	 Hematological malignancies
•	 Dermatological malignancies (ie. melanomas, basal cell carcino-
mas)
•	 Ipsilateral lymph node metastases in the presence of breast 
cancer
•	 Premalignant lesions, such as ductal carcinoma in situ
•	 Contralateral breast cancer or second ipsilateral breast cancer, 
except in the presence of a third tumor localization
•	 Peritoneal tumor localization in the presence of ovarian cancer
- If reported that the ovarian cancer was growing per 
continuum into the peritoneal cavity
- Confining to the ipsilateral adnexa
aIsolated site of invasive cancer as diagnosed by radiological 
examination, intra-operatively or during pathological examination
Table 1. Inclusion and exclusion criteria.
68i
Chapter 6 Molecular determination of the clonal relationships between multiple tumors in 
BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant
reads, reference coverage ˂ 10 reads, and/or a variant 
coverage of ˂ 5 reads for either the forward or reverse 
strand were excluded. For LOH analysis, SNPs with a 
total coverage of ˂100 reads or a strand bias (ratio 
forward:reverse reads not between 1:10 and 10:1 
for reference and/or variant reads) were excluded. 
If a mutation was detected in one or more tumor 
samples of a patient, the specific locus was manually 
checked using the integrative genomics viewer (IGV) 
in normal DNA as well as all tumor samples of that 
patient. Furthermore, TP53 was manually checked 
for mutations if no mutation was detected and IHC 
showed aberrant staining or was unavailable.
 Samples for which the control PCR showed 
no signal for amplicons larger than 100 base pairs 
and for which NGS analysis showed ˂70% of reads 
on target and/or ˂70% of amplicons with at least 
100 reads were defined low quality samples. For 
low quality samples with more than three variants, 
we focused on variants present in other tumors of 
the patient, or if not present, on TP53 variants. For 
all low quality samples, mutations were confirmed 
by Sanger sequencing or by a second NGS run. For 
Sanger sequencing, primers from the AmpliSeq 
design were extended with M13 tails. PCR protocol 
was previously described22, data was analyzed using 
Mutation Surveyor v.4.0 software (SoftGenetics). 
Results
Patients
Fifty-six BRCA1/2 mutation carriers with multiple 
tumor localizations were selected. Fourteen were 
excluded due to missing or unsuitable tumor 
material, leaving 42 women (39 BRCA1, 3 BRCA2) 
for analyses. Clinical classification of tumor origins 
was ‘breast cancer + ovarian cancer’ in 31 patients, 
‘breast cancer + other’ in nine, ‘ovarian cancer + 
other’ in one, and ‘breast cancer + ovarian cancer 
+ other’ in one woman (data not shown). Median 
number of tumor localizations was 2 (range 2-5), and 
median time from first to last cancer diagnosis was 5 
years (range 0-23).
Conventional diagnostics
For 21/42 women (50%) the origin of the tumor 
localizations was conclusive based on histology only. 
In an additional 17 (40%) a conclusive diagnosis was 
reached after IHC for relevant markers. Ten of 38 
women with conclusive outcomes based on histology 
and/or IHC had ≥3 tumor localizations (controls; eight 
BRCA1 and two BRCA2 mutation carriers). 
 In four women (10%) one or more tumor 
localizations remained of uncertain origin after 
histological and IHC evaluation (cases; all BRCA1 
mutation carriers). 
 Case no. 1 presented with tumors in the right 
and the left breast, and a tumor in the lung seven 
years later. Both breast tumors were diagnosed IDC 
of the breast based on HE staining. The lung tumor 
was diagnosed non-small cell carcinoma, however, 
conclusive diagnosis regarding the origin of the tumor 
was not possible based on HE and IHC (see Figure 1a 
for details).
 Case no. 2 presented with a tumor in the 
ovary and a tumor in the breast six years later. The 
tumor of the ovary was diagnosed serous carcinoma 
of the ovary based on HE staining. The breast tumor 
was diagnosed adenocarcinoma based on cytological 
preparations; however, no tissue was available for 
IHC. Therefore, tumor origin could not be determined. 
 Case no. 3 presented with a tumor in the 
breast and peritonitis carcinomatosa 10 years later. 
The tumor in the breast was diagnosed IDC of the 
breast based on HE staining. The tumor cells found 
in the ascites were diagnosed adenocarcinoma based 
on cytological preparations. CA-125 and WT-1 IHC 
performed on de-stained cytological preparations 
was not conclusive, therefore, determining the site 
of the origin of this tumor was not possible. 
 Case no. 4 presented with a tumor in the 
breast and tumors in the retroperitoneal lymph nodes 
as well as in the ovary and uterus three years later. 
The tumor in the breast was diagnosed IDC of the 
breast and the tumor in the ovary and uterus serous 
carcinoma of the ovary, both based on HE staining. 
The tumor in the retroperitoneal lymph nodes was 
classified as a large cell carcinoma based on the HE 
staining. However, only a small biopsy was available, 
from which no tissue was left in the FFPE tissue block 
for additional analyses.
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Figure 1. Conventional diagnostics and molecular analysis results for case no. 1, who presented with tumors of the right (T1) and the 
left (T2) breast, and a tumor in the lung seven years later (T3). (a) Both tumors in the breast (T1 and T2) could be conclusively diagnosed 
invasive ductal carcinoma of the breast based on haematoxylin and eosin (H&E) stainings only. Additionally, ER and HER2NEU stainings 
are shown, which were negative in both tumors. Conclusive diagnosis regarding the origin of the non-small cell carcinoma in the lung 
(T3) based on HE stainings and immunohistochemistry (IHC; P63 and TTF1 both negative) was not possible.
As part of the molecular analysis p53 IHC was performed, showing strong nuclear expression in the tumor cells of T1 and T3, and 
absent expression in the tumor cells of T2. Scale bars represent 50 μm. (b) Targeted next generation sequencing results of TP53 exon 
6 for DNA isolated from normal and tumor tissues of the patient. Each grey line represents an individual read; only aberrations from 
the wildtype sequence are indicated. Sequencing results are shown in reverse complement, which means that TCG is actually CGA. 
T1 and T3 show an identical PT53 missense mutation (c.646G>A; p.V216M), whereas T2 shows a different TP53 nonsense mutation 
(c.637C>T; p.R213*). (c) Loss of heterozygosity (LOH) was analyzed using single nucleotide polymorphisms (SNPs); the variant allele 
frequencies of 17 SNPs at five different loci (chromosome 8p, PTEN, BRCA2, BRCA1 and SMAD4) are shown for the three tumor 
samples. Loss of the reference allele is indicated in red and loss of the variant allele in green; a more intense color (either red or green) 
indicates a higher tumor percentage. As expected for a BRCA1 germline mutation carrier, all tumor samples show loss of the same 
BRCA1 allele. For all other loci shown, T1 and T3 show corresponding LOH patterns (both tumors show either red or green), whereas 
T2 shows a different LOH pattern.
Chr: chromosome
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Characteristics and outcomes of tumor histology 
and IHC of cases and controls are outlined in Table 2. 
Median age at first cancer diagnosis was 41.5 years 
(range 33-59). Median year of first cancer diagnosis 
was 1997 (range 1983-2012). Clinical classification of 
tumor origins was breast cancer + ovarian cancer in 
11, breast cancer + other in two, and breast cancer + 
ovarian cancer + other in one woman. 
Molecular analysis
Outcomes of molecular analysis are depicted in Table 
2. The FFPE tissues used for DNA isolation were 
relatively old, ranging from 2 to 32 years old at time 
of isolation. Six out of 38 (16%) DNA samples isolated 
from FFPE tumor tissue were of low quality (see 
Supplementary Table 2 for quality parameters). For 
six tumors no FFPE tissue was available and DNA was 
isolated from original routine HE and/or IHC sections 
or from cytology preparations. Four out of 6 (67%) 
DNA samples isolated from original sections were of 
low quality.
 In total, 167 tumor-specific variants were 
detected in the 44 analyzed tumors (Supplementary 
Table 3). Up to 27 variants were detected in the low 
quality tumor samples, compared to only one or two 
variants for good quality tumor samples. Additionally, 
some multinucleotide changes were incorrectly 
reported as two or three separate variants. Finally, 
48 mutations were either detected in good quality 
samples or confirmed in low quality samples. In 
the majority of tumors (n=34, 77%), one mutation 
was found; seven tumors harbored two mutations. 
Thirty-nine (81%) of all 48 variants concerned a 
mutation in the TP53 gene; in 39/44 tumors (89%) 
a TP53 mutation was found. Other variants included 
PTEN, PIK3CA and STK11 mutations in tumors located 
in the breast; a CAPZB mutation in tumors in the 
uterus and cervix; a FBXW7 mutation in tumors in 
the ovary and uterus; and a BRAF mutation in a lung 
lesion (Table 2). Parallel to molecular analysis, p53 
IHC was conducted and showed results consistent 
with molecular outcomes (Table 2). In two low 
quality samples with aberrant p53 staining, no TP53 
mutation was detected, probably due to insufficient 
coverage of TP53 (<100 reads for 8/19 amplicons 
for control no. 2, T1) or the type of TP53 mutation 
Figure 1. Continued.
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Figure 2. Loss of heterozygosity (LOH) analysis. Variant allele frequencies (VAF) for single nucleotide polymorphisms (SNPs) at 15 
different loci on 11 different chromosomes (indicated on the y-axis) for the tumors samples of all patients analyzed are shown. 
The VAF for the different SNPs are indicated by different colors. The example (bottom right) shows an A/T SNP, A representing the 
reference allele and T the variant allele. For any informative SNP without LOH, a VAF of 0.5 is expected (grey). If there is loss of the 
reference allele, a VAF >0.5 is expected (red). Alternatively, loss of the variant allele would result in a VAF <0.5 (green). A more intense 
color, either red or green, represents a VAF deviating further from 0.5, indicating a higher tumor percentage. Regardless of the actual 
nucleotides, green represents the reference allele and red the variant allele for all SNPs. Non-informative SNPs or SNPs with a strand 
bias or coverage <100 reads are not shown. If multiple tumors of a patient show largely concordant LOH patterns (all tumors show 
either red or green), this indicates that these tumors are most likely clonally related. Alternatively, differences in the LOH patterns 
between multiple tumors of one patient indicate multiple primary tumors. 
Twelve patients (all patients except control no. 4 and 9) are BRCA1 mutation carriers. 10/12 patients show a concordant LOH pattern 
for the BRCA1 locus in their multiple tumors. Control no. 2 shows an equivocal LOH pattern, which is probably due to the low quality 
of the data. For case no. 3 only one informative marker is available which does not show clear LOH for T1 (VAF of 0.41). Control no. 4 
and 9 are BRCA2 mutations carriers. Control no. 9 shows a concordant LOH pattern for the BRCA2 locus for the three analyzed tumor 
samples. Control no. 4 shows a concordant LOH pattern for samples T2 and T3, a different LOH pattern for sample T1 and no LOH for T4. 
Chr: chromosome
(possible intronic mutation or homozygous deletion 
for control no. 1, T1). 
 As further shown in Table 2, based on the 
molecular analysis, all tumor localizations analyzed 
could be classified into one or more entities 
concerning their origins. Additional LOH analyses of 
the 143 SNPs at 15 different loci were confirmative 
of the classifications made in 8/14 patients (Figure 
2 + Supplementary Table 4 showing all SNP data). In 
the group of cases, where conventional histology and 
IHC were not conclusive, molecular outcomes were 
decisive for all tumors (see Figure 1 for an example). 
In the group of controls, all molecular outcomes 
matched the diagnosis given by conventional 
histopathological diagnostics. 
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Discussion
For 38/42 (90%) BRCA1/2 mutation carriers 
with multiple tumor localizations, conventional 
histopathological analyses (histology, IHC) were 
sufficient to determine tumor origins. Results 
obtained by NGS provided decisive information in all 
four cases with inconclusive results from conventional 
diagnostics, enabling accurate differentiation 
between a second primary or metastatic cancer. 
NGS conducted on 10 control cases with ≥3 tumor 
localizations, unequivocally showed the same results 
as obtained by conventional histopathology, and 
indicate that NGS analysis of multiple tumors within 
one patient is a versatile procedure to determine 
clonal relationships between the lesions. NGS analysis 
can be useful in case of ambiguous histopathology 
results, or if no FFPE tissue block is available for IHC.
 As an illustration, the results of two patients 
are discussed below. First, case no. 2 comprises 
ovarian cancer followed by thoracic wall and axillary 
lymph node metastases three years later. There were 
no signs of breast cancer, suggesting that the ovarian 
cancer had metastasized to the thoracic wall and the 
axilla. After another three years, synchronously with 
progressive metastatic disease, a small breast cancer 
was detected. After extensive diagnostic work-up it 
was concluded that thoracic wall and axillary lesions 
actually were metastases of this formerly subclinical 
primary breast cancer and the patient was treated 
accordingly. However, retrospectively, our findings 
of identical TP53 variants in the ovarian cancer and 
breast cancer strongly suggest that the breast cancer 
was actually metastatic ovarian cancer. Unfortunately, 
no suitable material of the thoracic wall and axillary 
lesions was left for molecular analysis in this study. 
Since the primary tumor origin determines the 
therapy of choice for metastatic disease, it is essential 
to have no doubt about the origin of the metastases. 
The above-mentioned case is an example of how NGS 
can be decisive. 
 Second, control no. 1 comprises two ipsilateral 
breast cancers with a 13-year interval, both classified 
as invasive ductal carcinoma by histopathology, and 
ovarian cancer six years later. Histopathological 
analysis is not always able to differentiate between 
local recurrent and second primary breast cancer. 
The location of the breast cancer may help, but in 
this case, the first breast cancer was located in the 
medial upper quadrant while the second breast 
cancer was located centrally, leaving both options 
open. Some data suggest that BRCA1/2 mutation 
carriers, especially when young (<40 years), show 
longer intervals to local recurrent breast cancer23,24. 
However, since the prognosis of a second ipsilateral 
breast cancer occurring <5 years is worse than after 
>5 years, late-recurring breast cancer are probably 
more often second primary tumors25,26 and it is 
justifiable that they are treated accordingly. It is likely 
that the recurrent breast cancer after 13 years in this 
case was a second primary breast cancer. Molecular 
analysis confirmed that these tumors were two 
different entities.
 LOH -patterns were supportive of the results 
obtained by variant analysis in more than half of 
cases and controls (Figure 2). Almost all cases and 
controls showed corresponding LOH of BRCA1 or 
BRCA2 in all tumors, representing the ‘second hit’ 
of the functioning BRCA wild-type allele. For BRCA1 
mutation carriers, exceptions were case no. 3 with no 
clear LOH of BRCA1 for the breast cancer and control 
no. 2 with no evaluable LOH results. For BRCA2 
mutations carriers, an exception was control no. 4 
with four primary tumors showing loss of one allele 
of BRCA2 in the larynx tumor, loss of the other allele 
in both the lung tumor and the uterus/omentum 
tumor, and no loss of BRCA2 in the breast tumor. 
So far, BRCA2 mutation carriers are not associated 
with elevated risk of lung cancer and an increased 
risk of laryngeal carcinoma seems improbable27-30. 
Additional Sanger sequencing showed loss of the 
mutated BRCA2 allele for the tumor located in the 
larynx and loss of the wild-type allele for the lung 
lesion and the uterus/omentum tumor localizations 
(data not shown). The laryngeal carcinoma therefore 
is most likely a sporadic tumor. Loss of the wild-
type BRCA2 allele in the lung tumor may indicate 
either sporadic or BRCA2-related carcinogenesis. 
Furthermore, it has been described that LOH causes 
the second hit in only 80% of BRCA1-associated and 
in 60-70% of BRCA2-associated breast cancer31-33, 
fitting with the fact that we did not find (clear) LOH 
in two breast tumors. Possible alternative ‘second 
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hit’ mechanisms include mutations and deletions of 
the wild-type allele. Epigenetic silencing as a second 
hit, to our knowledge, is rare in germline BRCA1/2 
mutation carriers and therefore not a plausible 
explanation31.
 The diagnostic panel used in this study 
covered the exonic regions of the genes CDKN2A, 
PTEN and TP53 almost completely, multiple hotspot 
mutation sites for 27 genes, and SNPs (Supplementary 
Table 1). In the majority of cases and controls a 
conclusive diagnosis concerning tumor site clonality 
could be made based on different or similar TP53 
variants. A PTEN mutation was only found once and 
none of the tumors harbored CDKN2A mutations. 
Up to 97% of all high grade serous ovarian cancer, 
typically occurring in BRCA1/2 germline mutation 
carriers, harbor somatic TP53 mutations12,34. TP53 is 
affected in 16% to 84% of BRCA1/2-associated breast 
cancer, and in up to 97% of BRCA1-associated basal-
like breast cancer35,36. Our finding of TP53 mutations 
in 93% of all tumors (39/44 confirmed and 2/44 based 
on p53 IHC) is in line with the high percentages found 
in the literature. It suggests that molecular diagnostic 
workup may simply consist of TP53 analysis, rather 
than NGS of an entire panel. However, in two tumors 
without TP53 mutations, we found mutations in 
other genes (PIK3CA and STK11), providing also a 
conclusive diagnosis for these tumor localizations. 
Additionally, LOH analysis was not only confirmative 
of the classifications made for most of the patients, 
but was also helpful if ‘hotspot’ TP53 mutations were 
found. An example is control no. 10, for which both 
T2 and T3 harbor a TP53 R175H mutation. Since 
according to somatic mutation databases this is a 
common TP53 mutation these tumors potentially 
could still be different primary tumors. However, 
because LOH patterns were identical, we were able 
to reliably classify these tumors as one entity.
 IHC tissue markers were chosen according 
to institutional protocol depending on clinical and 
histological differential diagnosis of the tumor 
origin. Various different IHC markers of breast cancer 
have been investigated, such as GATA3, GCDFP, 
mammaglobin and SOX10. Although of potential 
value for differentiating breast cancer, as yet, their 
applicability seems limited or has not been validated 
well enough in triple negative breast cancer 37-39.
 A limitation of our study was that 10/44 
tumor samples analyzed with NGS were of low 
quality, mostly due to fixation artefacts or a low 
amount of starting material, resulting in less reliable 
variant calling. Variants in low quality samples were 
therefore confirmed by Sanger sequencing or by a 
second NGS run. Furthermore, LOH analysis of these 
samples was difficult, resulting in non-evaluable LOH 
data in two patients with one or more tumor samples 
of low quality. Nevertheless, using a combined 
approach of multiple molecular analyses resulted 
in reliable classification of the tumors into one or 
more entities for all patients. Another limitation was 
that, due to the specific selection criteria, the study 
sample size was small.
In conclusion, during diagnostic workup of BRCA1/2-
associated breast cancer and ovarian cancer patients 
with multiple tumor localizations, analysis of tumor 
histology and IHC by a specialized pathologist may be 
sufficiently conclusive in most cases. However when 
routine pathology is inconclusive, molecular analysis 
using NGS can reliably determine the relationships 
between the tumor localizations and as such guide 
the most appropriate treatment for each individual 
patient.
Supplementary material on the internet
Supplementary Table 1. Next generation sequencing 
primers.
http://www.niekgeurts.nl/proefschrift/Chapter 6 - 
Supplementary Table 1.xlsx
Supplementary Table 2. All variants detected for the 
44 tumors analyzed by next generation sequencing 
(NGS).
http://www.niekgeurts.nl/proefschrift/Chapter 6 - 
Supplementary Table 2.xlsx
Supplementary Table 3. Quality parameters.
http://www.niekgeurts.nl/proefschrift/Chapter 6 - 
Supplementary Table 3.xlsx
Supplementary Table 4. All single nucleotide 
polymorphism (SNP) data.
http://www.niekgeurts.nl/proefschrift/Chapter 6 - 
Supplementary Table 4.xlsx
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Abstract
Objective: Desmoid tumors are rare mesenchymal tumors with unpredictable progression and high recurrence 
risk. They can occur sporadically or in association with Familial Adenomatous Polyposis (FAP), which is 
caused by germline APC mutations. The Wnt/β-catenin pathway has a central role in the pathogenesis of 
desmoid tumors. These tumors can occur due to either a somatic CTNNB1 or APC mutation but can also 
be the first manifestation of FAP. Because germline APC analysis is not routinely performed in children with 
desmoid tumors, the diagnosis FAP may escape detection. The aim of this study is to form guidelines for the 
identification of possible APC germline mutation carriers among children with desmoid tumors, based on 
CTNNB1 mutation analysis and immunohistochemical analysis (IHC) for β-catenin. 
Patients and methods: We performed IHC of β-catenin and mutation analysis of CTNNB1 and APC in 18 
pediatric desmoid tumors, diagnosed between 1990 and 2009 in the Erasmus MC, Rotterdam. 
Results: In 11 tumors, IHC showed an abnormal nuclear β-catenin accumulation. In this group a CTNNB1 
mutation was detected in seven tumors. In two tumors with an abnormal nuclear β-catenin accumulation and 
no CTNNB1 mutation, an APC mutation was identified, which appeared to be a germline mutation. 
Conclusions: Aberrant staining of β-catenin in pediatric desmoids helps to identify children at risk for FAP. We 
recommend to screen pediatric desmoid tumors for nuclear localization of β-catenin and consequently for 
CTNNB1 mutations. For patients with nuclear β-catenin expression and no CTNNB1 mutations, APC mutation 
analysis should be offered after genetic counselling.
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Introduction
Desmoid tumors (also named aggressive 
fibromatosis) are rare mesenchymal tumors which 
can occur sporadically or in association with Familial 
Adenomatous Polyposis (FAP). These tumors are 
characterized by unpredictable progression and high 
recurrence rate and therefore are difficult to treat. 
The occurrence of desmoid tumors in children is low, 
with an estimated incidence of 2–4 new diagnoses 
per million per year1. Currently, no general guidelines 
are available for genetic analysis of pediatric patients 
with desmoid tumors. 
The Wnt/β-catenin signaling pathway is 
recognized as having a central role in the pathogenesis 
of desmoid tumors. The β-catenin protein is a key 
effector of the pathway, affecting cellular decisions 
such as stem cell maintenance and cell proliferation 
through modulating the expression of specific target 
genes. In normal cells, β-catenin is involved both in 
cell adhesion, when located at the cell membrane, 
and in transcriptional regulation, when present in the 
nucleus2,3. Several members of the Wnt/β-catenin 
signaling pathway form an intracellular multiprotein 
complex, composed of APC, β-catenin, AXIN1, 
AXIN2 and GSK3b. APC binds to β-catenin at the so-
called 15 and 20 amino acid binding sites2,3. AXIN1/
AXIN2 activates casein kinase I alpha, that catalyses 
a priming phosphorylation on S45 of β-catenin, 
thereby providing a signal for glycogen synthase 
kinase 3 to promote the sequential phosphorylation 
of T41, S37 and S33, which subsequently induces 
the degradation of β-catenin thereby preventing its 
signaling activity. 
In several tumor types, this pathway is 
constitutively activated due to ‘loss of function’ 
mutations of the APC gene leading to inefficient 
β-catenin degradation and its intracellular 
stabilization. In case the APC gene is intact, pathogenic 
CTNNB1 mutations, encoding β-catenin, are found at 
the N-terminal phosphorylation sites interfering with 
its proteolytic degradation2,3. Either APC or CTNNB1 
mutations can lead to an abnormal intranuclear 
accumulation of β-catenin. The aberrant β-catenin 
stabilization is thought to constitutively activate 
downstream Wnt/β-catenin target genes and trigger 
a genetic program resulting in tumor formation. 
Several studies identified somatic CTNNB1 
mutations in desmoid tumors in a frequency varying 
between 52% and 87%4-8, including one study 
focusing on pediatric desmoid tumors7. Somatic APC 
mutations were found in several cases of desmoid 
fibromatosis, lacking CTNNB1 mutations8,9. In Familial 
Adenomatous Polyposis (FAP), caused by germline 
APC mutations, 10–15% of the patients are affected 
by desmoid tumors, representing a more than 800-
fold increased risk in comparison with the general 
population10,11. FAP is a hereditary predisposition to 
develop hundreds to thousands of colorectal polyps 
ultimately leading to colorectal cancer. Untreated, 
the risk of colorectal cancer in FAP patients is 100%. 
The average age when colorectal polyps are detected 
is 15 years12. Colonoscopy, started at the age of 10–12 
years, and surgery in adolescence prevent colorectal 
cancer formation in FAP. When FAP is diagnosed in 
time, health benefits and increased life expectancy 
can be achieved. 
In children, a desmoid tumor can occur 
due to either a somatic CTNNB1 or APC mutation, 
but importantly can also be the first manifestation 
of FAP. This is of importance for the management 
of the child, but might also have implications for 
other (asymptomatic) family members. Currently, 
no established procedure is available to identify FAP 
carriers among children with this tumor type. Here, 
we present an immunohistochemical and mutational 
analysis on 18 pediatric desmoid tumors, based on 
which we formulate guidelines to identify possible 
APC germline mutation carriers. 
Materials and methods
Patients
Between January 1990 and June 2009, 20 desmoid 
tumors were operated in 19 patients under the age 
of 21 years in the Erasmus MC, University Medical 
Centre, Rotterdam. Ten tumors were localized in the 
head and neck region, five in the extremities, three 
in the abdominal wall and two in the back (Table 1). 
All tumors were classified as deep fibromatoses. The 
medical records and family history of these patients 
were analyzed. Tissues were obtained from the 
initial operative procedure and embedded in paraffin 
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after formalin fixation. All tissues were revised by a 
pathologist and confirmed as being desmoid tumors. 
Unfortunately, two samples (D14 and D18) were not 
suitable for molecular analysis. 
Immunohistochemistry (IHC)
Immunohistochemical analysis for β-catenin (1:100 
dilution of clone 14, BD Transduction Laboratories) 
was performed basically as previously described13. 
All sections were evaluated under a light microscope 
after Mayer hematoxylin counterstaining. 
DNA isolation
Normal and tumor DNA was extracted from 
Formalin-Fixed, Paraffin-Embedded (FFPE) tissue 
fragments using proteinase K and 5% Chelex 100 
resin, as previously described14. For the identification 
of germline APC mutations, DNA isolated from 
peripheral blood cells was used. Isolation of this DNA 
was performed according to standard procedures. 
CTNNB1 mutation analysis
Sequence analysis of CTNNB1 exon 3, encoding the 
mutational cluster region (MCR) of β-catenin was 
performed on tumor DNA as previously described14. 
To test for complete or partial deletions of CTNNB1 
exon 3, a PCR was performed using primers flanking 
exon 3. 
APC mutation analysis
As the MCR of APC in desmoid tumors is located in 
exon 15 between codons 1324 and 1567, this region 
was chosen for sequence analysis8,15,16. The APC 
MCR was amplified in four overlapping fragments 
according to standard procedures.
  For the identification of germline APC 
mutations, DNA isolated from peripheral blood 
cells was used. All coding exons and intron–exon 
boundaries of APC were sequenced according to 
standard procedures. In addition, Multiplex ligation-
dependent probe amplification (MLPA) analysis was 
performed using the SALSA MLPA kit P043 (MRC 
Patient no. Tumor Gender Age at diagnosis (years) Tumor localization Family history
1 D1 M 2.4 Mandible
2 D2 M 8.2 Spina iliaca posterior superior left
3 D3 F 1.4 Upper extremity
4 D4 F 4 Neck
5 D5 F 5 Mandible
6 D6 F 12.3 Lower extremity
7 D7 M 1.4 Trunk (back, subcutaneous) Sister with a fibrous hamartoma of infancy
D8 Upper extremity
8 D9 M 5.7 Mandible
9 D10 F 14.8 Abdominal wall (intraabdominal)
10 D11 F 15.3 Abdominal wall This patient and her father diagnosed with FAP
11 D12 M 0.8 Neck
12 D13 F 0.6 Neck (parotid)
13 D14 M 0, Congenital Upper extremity
14 D15 F 2 Mandible
15 D16 M 0.8 Trunk (groin)
16 D17 M 1 Trunk (back, subcutaneous)
17 D18 F 6 Neck
18 D19 F 1.3 Earlobe
19 D20 M 1.5 Parotid gland Father diagnosed with FAP after diagnosis of 
the desmoid tumor in the patient
Table 1. Clinical characteristics of the 19 children with desmoid tumors.
M: male; F: female
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Holland, Amsterdam, The Netherlands) as previously 
described17.
LOH
Loss of heterozygosity (LOH) analysis of the APC locus 
was performed using DNA isolated from normal 
and tumor tissues. Three microsatellite markers 
(D5S433, D5S656, D5S421), mapping to chromosome 
5q21.2-5q22.2 were selected. PCR amplification was 
performed as described above for CTNNB1 mutation 
analysis with FAM-labelled primers. The FAM-
labelled PCR fragments were run on an ABI 3130xl 
genetic analyzer (Applied Biosystems) and data were 
analyzed with Genemarker version 1.8 software 
(SoftGenetics, State College, PA). Peak heights of the 
alleles were compared between normal and tumor 
DNA samples. If one of the alleles showed relative 
loss in the tumor sample this was considered to be 
due to LOH (scored manually). 
Sequences of all primers are available on 
request. 
Results
Eighteen desmoid tumors from 17 patients could 
be included in the study (Table 1 and 2). Patient 7 
showed two localizations of desmoid tumors (D7 and 
D8). His sister had a fibrous hamartoma of infancy. 
In patient 10 there was a prior family history of FAP. 
The father of patient 19 was known with polyposis. 
After diagnosis of a desmoid tumor in patient 19 
at 1.5 years of age, we could identify a germline 
APC mutation in the father as well as in the child 
during subsequent counselling. The youngest age at 
diagnosis was 0 years (a congenital desmoid tumor) 
and the oldest patient was 15 years. The latter was 
the patient from the previously known FAP family. 
The mean age was 4.4 years. The male: female ratio 
was almost equal (1:1.1). 
Immunohistochemistry
Immunohistochemistry succeeded in all 18 tumors. 
Eleven tumors (61%) showed strong nuclear staining 
for β-catenin (Table 2 and Figure 1a and c). No nuclear 
Sample IHC β-catenin CTNNB1 analysis APC analysis Effect of APC mutation LOH of APC
D1 MS wt wt No
D2 IS c.121A>G; p.T41A – –
D3 LIS wt wt No
D4 LIS – – –
D5 IS c.104T>G; p.I35S wt No
D6 IS c.121A>G; p.T41A wt No
D7 CS wt wt –
D8 IS wt wt –
D9 LIS – – –
D10 IS c.134C>T; p.S45F wt –
D11 IS wt c.4216C>T; p.Q1406* Nonsense (heterozygous) No
D12 IS c.134C>T; p.S45F wt No
D13 IS c.122C>T; p.T41I wt No
D15 IS c.133T>C; p.S45P wt No
D16 LIS, LCS wt wt No
D17 CS wt – –
D19 IS wt wt No
D20 IS wt c.4348C>T p.R1450* Nonsense (hemizygous) Yes
In samples D14 and D18, IHC of β-catenin and DNA-isolation did not succeed due to low cellular density and the poor quality of FFPE 
stored tumor samples (no sequences obtained).
Wt: wild type; ‘–‘: no informative result; IS: intranuclear staining; MS: membranous staining; LIS: light intranuclear staining; CS: 
cytoplasmic staining; LCS: light cytoplasmic staining
Table 2. Results of immunohistochemical analysis (IHC) and mutation analyses of CTNNB1 and APC.
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expression of β-catenin was present in normal cells 
in these tissues. In seven other tumors at most a 
light nuclear, membrane or cytoplasm staining was 
present (Figure 1b and d). 
CTNNB1 mutation analysis
Sequence analysis of exon 3 of CTNNB1 succeeded 
in 16/18 tumors. No data were obtained from the 
remaining two samples due to poor quality DNA 
within these samples. In 7/16 tumors (44%) point 
mutations were found (Table 2 and Figure 2a). Six 
mutations were situated in the expected positions 
(residues S45 and T41). One mutation was detected 
at position 35 (p.I35S), which has been described 
previously18,19. Analysis for exon 3 deletions revealed 
no obvious deletions, but small deletions could have 
been missed, due to the relative large size of the 
residual product and poor quality of DNA extracted 
from FFPE material. All oncogenic CTNNB1 mutations 
were identified in tumors showing a strong nuclear 
accumulation of β-catenin (7/11). 
APC mutation analysis
Mutation analysis of the APC MCR succeeded in 
14/ 18 tumors. An APC mutation was found in two 
samples (14%), both causing a premature stop 
codon (Table 2 and Figure 2b). Both mutations were 
also found in the germline DNA of the patients. Ten 
samples harbored the heterozygous c.4479G>A 
change, known as polymorphism (data not shown). 
No APC mutation was detected in the CTNNB1 
mutation positive samples. Both desmoid tumors in 
which we identified the APC mutation also showed a 
strong accumulation of nuclear β-catenin (2/11). 
LOH analysis
To further study the possible involvement of APC 
in the development of the desmoid tumors, LOH 
analysis of the APC locus was performed in all tumors. 
Only one tumor, i.e. D20 in which we had previously 
identified the p.R1450X germline mutation, showed 
LOH of the APC locus (Figure 3). 
Figure 1. Microscopy and immunohistochemistry. (a) and 
(b), hematoxylin and eosin (HE) stained section of two 
desmoid tumors. The same tumors were used for β-catenin 
immunohistochemistry: (c) note the strong nuclear accumulation 
of β-catenin in the tumor cells whereas the accompanying normal 
cells are negative; (d) note the absence of nuclear staining and 
the presence of membranous staining of β-catenin in the tumor 
cells. The blood vessels show a normal positive membranous and 
cytoplasmic β-catenin staining.
Figure 2. (a) Sequence analysis of CTNNB1 (D12) showing hetero-
zygosity for the p.S45F mutation; (b) sequence analysis of APC 
(D11) showing heterozygosity for the p.Q1406X mutation.
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Discussion
We analyzed 18 pediatric desmoid tumors for 
aberrations in the Wnt/β-catenin signaling pathway. 
Immunohistochemical analysis for β-catenin indicated 
that deregulation of this pathway was involved in the 
development of 11 tumors, of which two harbored 
point mutations in the APC gene (D11, D20, Table 
2). These were confirmed as being a germline APC 
mutation. Patient 10 was a member of a known FAP 
family. The father of patient 19 was known with 
polyposis. During the following genetic counselling, 
we identified both father and son as being a carrier of 
the p.R1450X germline APC mutation. We identified 
loss of the remaining wild type allele (LOH of APC) in 
the desmoid tumor of patient 19. This is in line with 
Knudson’s two-hit hypothesis20-22, further supporting 
that the germline APC mutation underlies formation 
of this tumor. 
The results of the molecular and 
immunohistochemical analyses of the desmoid 
tumors of patient 10 and 19 indicate that these 
analyses can lead to the identification of FAP carriers. 
Mutations in CTNNB1 and APC have been 
shown to occur in a mutually exclusive manner in all 
tumor types studied so far. As germline oncogenic 
CTNNB1 mutations are not compatible with adult life, 
the identification of such a mutation provides direct 
evidence of the sporadic nature of the tumor. CTNNB1 
mutations are more common than APC mutations in 
adult desmoid tumors, suggesting that most desmoid 
tumors are of sporadic origin4-8. Recently, Bo et al.7 
showed that CTNNB1 is also frequently mutated 
in pediatric desmoid tumors (25/32), but FAP 
patients were excluded in their study. We observed 
a somewhat lower overall mutation frequency than 
previous reports, which may be explained by the 
limited number of cases in our cohort. However, the 
less frequent involvement of Wnt signaling pathway 
in pediatric desmoid tumors has been previously 
described as well23. Also in our set, no simultaneous 
APC mutations were detected in the tumors with a 
somatic CTNNB1 mutation, and as such these tumors 
can be considered as sporadic tumors. 
Interestingly, we observed two samples with 
intranuclear staining for β-catenin in which neither 
CTNNB1 nor APC mutations were detected. However, 
we still do suspect an involvement of the Wnt/β-
catenin signaling pathway in these samples. An APC-
Figure 3. (a) Sequence analysis of APC in the tumor (D20), showing hemizygosity for the c.4348C>T p.R1450X mutation; (b) 
Identification of the germline APC mutation in patient no 19, showing heterozygosity for the c.4348C>T p.R1450X mutation; (c) Loss 
of heterozygosity (LOH) analysis in tumor D20, showing loss of heterozygosity of the APC locus (marker D5S656). The arrow indicates 
the loss of one allele in the tumor DNA.
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mutation localized outside the analyzed region cannot 
be excluded. Alternatively, these samples could 
contain an alteration of other Wnt-related genes, 
such as AXIN1 or AXIN2, although mutations in these 
genes have not been reported in desmoid tumors 
previously. Also epigenetic alterations may play an 
important role in these tumors. Recently, Okpanyi et 
al.24 showed activation of the Wnt/ β-catenin pathway 
in pediatric germ cell tumors due to APC promoter 
methylation and LOH of APC. In colorectal cancer an 
epigenetic inactivation of secreted frizzled related 
proteins (SFRPs), which normally suppresses Wnt 
signaling, has been suggested to contribute to colon 
cancer formation25. As the epigenetic mechanisms in 
desmoids tumors are not well understood, it should 
be investigated in the future. 
In four desmoid tumors, neither nuclear 
β-catenin staining nor CTNNB1 or APC mutations 
were detected. At this moment we have no evidence 
of Wnt/β-catenin pathway involvement in these 
tumors, and the aetiology of these tumors remains 
unclear. Previous studies described a lack of CTNNB1 
and APC gene mutations in superficial fibromatoses26. 
However, since all tumors in our cohort were classified 
as deep fibromatoses, this feature represents an 
unlikely explanation for the lack of mutation in these 
mutation-negative tumors. Interestingly, patient 7 
developed two desmoid tumors with both presence 
and absence of intranuclear staining of β-catenin in 
different tumors. His sister had a fibrous hamartoma 
of infancy. Previously it has been reported that 
Wnt/β-catenin pathway plays an important role in 
desmoid formation, but does not appear to play a role 
in the pathogenesis of other myofibroblastic lesions 
in children27. Pathological diagnosis of fibroblastic 
lesions can be challenging. As such, it cannot be 
entirely excluded that some of the immuno-negative 
lesions might not be desmoid tumors, although 
central review by an experienced pathologist has 
been performed. 
Despite the limited size of our cohort, our 
data support current ideas about the molecular 
background in desmoid tumors and illustrate that a 
combination of IHC of β-catenin and the mutation 
analysis of CTNNB1 and APC can help to identify 
APC carriers among the children with desmoid 
tumors. This may be especially valuable in de novo 
APC mutation carriers, with a negative family history 
for FAP. It is known that approximately 20–25% of 
individuals with FAP have a de novo APC mutation28. 
Unfortunately, not in all our FFPE samples sufficient 
DNA quality could be obtained, most likely due to the 
well-known problems associated with over-fixation 
and long-term storage in paraffin. To this aim, we 
recommend that fresh frozen tissue of the desmoid 
sample is stored specifically for DNA isolation, in 
addition to the FFPE sample. The latter is still required 
for a proper histological evaluation and for β-catenin 
IHC, as it is not possible to detect nuclear β-catenin 
in frozen sections29. 
In conclusion, children with desmoid tumors 
can be carriers of a germline APC mutation. Therefore, 
we recommend to analyze the lesions for nuclear 
staining of β-catenin by IHC to identify the desmoid 
tumors with an underlying defect in β-catenin 
signaling. If consequently pathogenic CTNNB1 
mutations are detected, this makes an increased risk 
of FAP in the patient unlikely. If, however, CTNNB1 
screening turns out negative, genetic counselling 
of such children and their parents is warranted and 
germline APC analysis should be offered. These 
recommendations should be evaluated by future 
studies in larger cohorts. 
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Abstract
Heterozygous germline mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 cause 
Lynch syndrome. Biallelic mutations in the MMR genes are associated with a childhood cancer syndrome 
[constitutional mismatch repair-deficiency (CMMR-D)]. This is predominantly characterized by hematological 
malignancies and tumors of the bowel and brain, often associated with signs of neurofibromatosis type 1 
(NF1). Diagnostic strategies for selection of patients for MMR gene analysis include analysis of microsatellite 
instability (MSI) and immunohistochemical (IHC) analysis of MMR proteins in tumor tissue. We report the 
clinical characterization and molecular analyses of tumor specimens from a family with biallelic PMS2 germline 
mutations. This illustrates the pitfalls of present molecular screening strategies. Tumor tissues of five family 
members were analyzed for MSI and IHC. MSI was observed in only one of the analyzed tissues. However, 
IHC analysis of brain tumor tissue of the index patient and his sister showed absence of PMS2 expression, 
and germline mutation analyses showed biallelic mutations in PMS2: p.Ser46IIe and p.Pro246fs. The same 
heterozygous mutations were confirmed in the father and mother, respectively. These data support the 
conclusion that in case of a clinical phenotype of CMMR-D, it is advisable to routinely combine MSI analysis 
with IHC analysis for the expression of MMR proteins. With inconclusive or conflicting results, germline 
mutation analysis of the MMR genes should be considered after thorough counselling of the patients and/or 
their relatives. 
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Introduction
Heterozygous germline mutations in mismatch 
repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 
cause Lynch syndrome1-5. Carriers of heterozygous 
MMR gene mutations are at high risk for developing 
colorectal carcinomas (CRCs) and extracolonic 
neoplasias such as endometrial, small bowel, ureter, 
renal pelvis, stomach, ovarian and brain tumors. In 
Lynch syndrome carriers, these malignancies usually 
develop during the fourth and fifth decade of life. 
Biallelic mutations in MMR genes lead to a childhood 
cancer syndrome. This is predominantly characterized 
by hematological malignancies, brain tumors and 
gastrointestinal tumors in early childhood. Carriers 
of biallelic MMR gene mutations often show signs 
of neurofibromatosis type 1 (NF1), mainly café au 
lait (CAL) spots. This childhood cancer syndrome is 
often referred to as constitutional mismatch repair-
deficiency (CMMR-D). To our knowledge, a total 
of 107 cases of children with CMMR-D have been 
reported in the literature6-10. 
Diagnostic strategies for fast selection 
of patients with an MMR gene defect suspected 
for Lynch syndrome include analysis of MSI and 
immunohistochemical (IHC) analysis of tumor tissue 
for expression of MMR proteins11-13. However, the 
sensitivity of molecular tests in tumor tissue of 
patients with CMMR-D is unclear. MSI and absent 
MMR protein staining have been described in 
gastrointestinal tumors of patients with CMMR-D9. 
In contrast, tumor tissue of most reported CMMR-D 
patients with brain tumors did not show MSI8,14. 
Here, we report a family with childhood 
brain tumors and early-onset colorectal cancer 
with biallelic germline mutations in the PMS2 gene 
that underscores pitfalls of the present molecular 
screening strategy. 
Case report
Family data
At age 7, the index patient was diagnosed with an 
anaplastic glial brain tumor (Figure 1: pedigree, 
individual IV.2). His older sister (individual IV.1) had 
died from a primitive neuroectodermal brain tumor 
(PNET) at 4 years of age. Both children had multiple 
large CAL spots (Figure 2) and the index patient 
showed freckling. The younger sister of the index 
patient (individual IV.3) showed one CAL spot. Both 
non-consanguineous parents were of Dutch origin 
and showed no signs of neurofibromatosis type I (NFI). 
At the time of counseling, the family history of both 
parents was not suggestive of Lynch syndrome. One 
maternal uncle had been diagnosed with colorectal 
cancer (individual II.5) at age 62. The parents of 
the index patient declined endoscopic screening. 
However, within 2 years of the diagnosis of the brain 
tumor of our index patient, the father was diagnosed 
with colorectal cancer at age 43 (pT4N2M1, Dukes 
stage D). The paternal mother (individual II.2) was 
diagnosed with colorectal cancer during the same 
period of time at age 84. The mother of our index 
patient then underwent surveillance colonoscopy 
and one adenoma with low-grade dysplasia was 
removed.
MSI and IHC analyses 
Tissues of five family members including CRC tissues 
from the father and his mother, the colonic adenoma 
from the mother and brain tumor specimens from 
the index case and his sister were analyzed for MSI 
Figure 1. Pedigree of the reported family. Patient details on 
malignancy, adenomas and age of diagnosis in years are given. 
→ index patient;     male;    female;    males and females; 
CRC, coloretal cancer;       brain cancer; / deceased.
6
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and IHC aberrations (Table 1). MSI analysis was 
performed on DNA retrieved from paraffin-embedded 
tumor tissues, using five mononucleotide repeat 
MSI markers (Promega pentaplex) as previously 
described14,15. As controls, normal leukocyte DNA 
from the index patient, DNA from paraffin-embedded 
normal tissue from the father (III.2), DNA from paraffin 
embedded normal tissue from the grandmother 
(II.2), and unrelated normal DNA were used. The 
MSI marker profiles of all these normal DNA samples 
(three family members, one unrelated normal DNA) 
were identical, demonstrating the absence of MSI 
in normal tissues. IHC analysis was performed for 
four MMR proteins: MLH1, MSH2, MSH6 and PMS2, 
according to the standard procedure15. 
The brain tumor of the index patient showed 
an MSI pattern with additional fragments of increased 
size of markers NR-21 and BAT-26. Surprisingly, 
microsatellite stability (MSS) was observed, in the 
brain tumor of the sister of the index patient (Figure 
3a). IHC analysis of brain tumor tissues from both 
children showed absence of PMS2 expression in the 
tumor and normal cells. Tumor specimens from all 
other family members were MSS and showed normal 
expression of the MMR proteins in the tumor and 
normal tissue. 
Germline mutation analysis 
Mutation analysis of the NF1 gene was performed 
in the index patient but a mutation could not be 
identified. Mutation analysis in a blood sample 
of the index patient identified the compound 
heterozygous mutations, p.Pro246fs and p.Ser46IIe. 
Figure 2. Café au lait spots of the index patient.
Case Malignancy Age at 
diagnosis 
(years)
Skin lesions NF1 gene 
mutation
Analysis 
of MSI 
IHC LOH 
analysis 
PMS2
PMS2 gene mutation
II.2 Adenocarcinoma of the rectum 84 ND ND MSS Normal ND None
III.2 Adenocarcinoma of the transverse colon 43 None ND MSS Normal no LOH Heterozygous p.Ser46IIe
III.3 One adenoma (low-grade dysplasia) 45 None ND MSS Normal ND Heterozygous p.Pro246fs
IV.1 PNET 4 CAL spots >6, hemangioma leg ND MSS 
PMS2 
absent ND
Compound heterozygous 
Pro246fs, p.Ser46IIe
IV.2 Anaplastic glial brain tumor 7 CAL spots >6, axillary 
melanotic freckling
None MSI-H PMS2 absent ND 
Compound heterozygous 
Pro246fs, p.Ser46IIe
Table 1. Summary of results of the molecular and IHC analyses of tissues from the studied family.
CAL: café au lait; IHC: immunohistochemistry of MLH1, MSH2, MSH6 and PMS2; LOH: loss of heterozygosity analysis by sequencing; 
ND: not determined; MSI: microsatellite instability; MSI-H: microsatellite instability-high; MSS: microsatellite stable; PNET: primitive 
neuroectodermal brain tumor
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Both mutations were also found in DNA derived from 
the brain tissue from his sister. No mutation analysis 
was performed in the younger sister of the index 
patient. The heterozygous mutations p.Ser46IIe and 
p.Pro246fs were confirmed in the father and mother, 
respectively, indicating the compound heterozygous 
pattern in the index patient and his sister. The 
paternal grandmother appeared not to carry the 
p.Ser46IIe mutation, as present in the father of the 
index patient. 
In both the index patient and his father, no 
germline mutation was detected in the MLH1, MSH2 
and MSH6 gene. 
Additional molecular analysis: 
loss of heterozygosity (LOH)
To assess whether the tumor from the father of the 
index patient was caused by the PMS2 germline 
mutation, LOH analysis was performed (Figure 3b). 
For that purpose, DNA extracted from normal and 
tumor tissue of the father was sequenced, according 
to a previously described method14. No LOH of the 
PMS2 locus was found, while the tumor percentage 
was high enough to detect LOH, which was indicated 
by the presence of LOH at the TP53 and APC loci 
(Figure 3c). 
Discussion
The above-mentioned family displays a CMMR-D 
phenotype in the presence of compound 
heterozygous PMS2 mutations (p.Ser46IIe and 
p.Pro246fs). MSI was only found in the brain tumor 
of the PMS2 compound heterozygous index patient. 
The brain tumor of his compound heterozygous sister, 
as well as the CRCs of the father and his mother and 
the colorectal adenoma of the mother, were MSS. 
IHC analysis showed absence of PMS2 staining in 
both the brain tumor and normal tissue of the index 
patient and his sister, but not in the analyzed CRCs of 
their father and grandmother. 
PMS2 is considered a tumor suppressor 
gene5. In tumors of carriers of a heterozygous PMS2 
mutation, MSI and absence of IHC staining of PMS2 
can be expected as a result of the loss of the wild-
type allele. In case of a biallelic germline mutation, 
MSI and especially absence of PMS2 expression can 
be expected already in normal tissue, as well as in 
tumor tissue. 
Both parents of the index patients were 
found to carry a heterozygous PMS2 mutation. The 
p.Pro246fs mutation of the mother (individual III.3) 
is a previously described pathogenic frameshift 
mutation16. The p.Ser46Ile missense germline 
mutation of the father (individual III.2) has been 
found in seven cases in a cohort of 400 selected 
Dutch patients suspected to have an MMR gene 
defect. In contrast, this mutation was not detected in 
927 controls (unpublished data of the Department of 
Human and Clinical Genetics, LUMC). Also, the amino 
acid involved in this mutation, is positioned in a highly 
conserved small helix domain (codon 35–48) and in 
addition serine and isoleucine have very different 
physical and chemical properties. In the literature, 
there is a clear overrepresentation of p.Ser46Ile 
in patients with PMS2 negative tumors17-21. These 
findings support the pathogenicity of this mutation. 
Surprisingly, no MSI and IHC aberrations were 
found in the CRC of the father. Eight additional CRCs 
in heterozygous carriers of the p.Ser46Ile mutation 
have been reported (Table 2). Unfortunately, only 
data on the MSI status of the tumor tissues of three 
of these eight patients were available, all displaying 
MSI. Absence of PMS2 expression was found in all 
described tumors in contrast to our observations in 
the CRC of the father. Because additionally no LOH 
of the PMS2 locus was detected in the tumor of the 
father, a role of PMS2 in the development of the early-
onset CRC of the father cannot be demonstrated 
at the moment. It is possible that other colorectal 
cancer susceptibility genes are involved. As the tumor 
tissue of the father’s CRC was found to be MSS, it is 
unlikely, however, that this concerns the other MMR 
genes. Also, germline mutation analyses of MLH1, 
MSH2 and MSH6 revealed no aberrations in the 
father. Nevertheless, other unknown susceptibility 
genes cannot be excluded. In view of this, first-
degree relatives of the father, who test negative for 
the familial PMS2 mutation, should in our opinion 
still be offered colorectal surveillance. 
The results of MSI and IHC analysis of the 
tissue of the paternal grandmother are in agreement 
with analysis of sporadic colorectal cancer. This 
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Figure 3. Microsatellite instability (MSI) analysis of the brain tumors of the index patient and his sister (individual IV.2 and IV.1) and 
loss of heterozygosity (LOH) analysis of the father of the index patient (individual III.2). (a) Promega pentaplex MSI results of unrelated 
normal control DNA (C), index patient’s normal leukocyte DNA (N), index patient’s brain tumor DNA (T1) and his sister’s brain tumor 
DNA (T2). MSI (markers NR-21 and BAT-25, instability indicated by arrows) is only observed in the tumor of the index patient and not 
in his sister’s tumor. (b) Sequencing results of exon 2 of the PMS2 gene, showing the heterozygous p.Ser46Ile (c.137G>T) mutation in 
normal tissue (N) and colorectal carcinomas (CRC) (T) of the father. No LOH is detected in tumor tissue (T). (c) Result of LOH analysis 
with a dinucleotide polymorphic microsatellite at the TP53 locus in normal tissue (N) and CRC (T) of the father. Arrows indicate the 
relative loss of the larger allele in the CRC compared to the normal DNA. 
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finding is in concordance with her not being a carrier 
of the familial PMS2 mutation. 
The index patient and his sister inherited 
both PMS2 germline mutations from their parents, 
explaining their CMMR-D phenotype. However, MSI 
was found in only one of the two brain tumors. In 
gastrointestinal tumors, MSI analysis seems to 
be a reliable tool to diagnose MMR deficiency. In 
the literature, results of molecular analyses in 21 
patients with gastrointestinal malignancies and 
biallelic MMR gene mutations have been reported. 
Nineteen patients were diagnosed with CRC and two 
patients with duodenal cancer. In all tumors, MSI was 
detected. Additional IHC analysis showed absence 
of immunostaining of the corresponding affected 
MMR proteins in 19/21 analyzed gastrointestinal 
tumors8,17,18,20,22-34. In addition to the gastrointestinal 
patients, 43 patients (mean 8 years, range 4–17, 88% 
male) with biallelic MMR gene mutations and brain 
cancer have been reported. In 8 of these 43 cases, 
brain tumor specimens were analyzed for MSI and 
in 5 of these cases IHC analysis of MMR proteins 
was performed (Table 3; 8,14,17,25,35-38). Germline 
mutation analysis showed one patient with MLH1, 
one with MSH2, four with MSH6 and two with PMS2 
mutations. In six of the analyzed eight cases, no MSI 
was found in brain tumor tissue. A hypothesis to 
explain the lack of MSI in brain tumors from germline 
biallelic PMS2 mutant patients is that in brain tissue a 
PMS2 deficiency could lead to tumorigenesis through 
a different mechanism than the MMR pathway8,14,17. 
Also, the extent and pattern of MSI may differ 
between CRCs and brain tumors, making the MSI 
analysis that is routinely used for CRC less reliable for 
brain tumors8,14. 
IHC analysis showed the absence of 
immunostaining of PMS2 in the brain tumor cells as 
well as in normal cells in the specimens of our index 
case and his sister. This is in accordance with the 
absence of expression of the affected MMR protein 
in all five investigated brain tumors of germline 
biallelic mutant MMR gene patients described in the 
literature8,14,17,35,36. From the literature and our own 
data, it can be concluded that MMR and IHC analysis 
may be more sensitive than MSI analysis to detect 
MMR deficiency in brain tumors. 
The third child in this family (IV.3) is also 
at risk of being a heterozygous or compound 
heterozygous carrier of the familial PMS2 mutations. 
Because single CAL spots are a frequent finding in the 
general population and this child is 8 years past the 
age of onset of the brain tumors in her siblings, we 
estimate her risk for CMMR-D to be lower than the 
theoretical 25%. However, her risk is not excluded. 
No guidelines are available yet for the surveillance of 
children at risk for CMMR-D. In this family, we think 
regular clinical surveillance by a pediatric oncologist 
including colonoscopy and possibly brain magnetic 
Patient Case Malignancy Age at diagnosis of 
malignancy (years)
Analysis of MSI IHC References
1 1 CRC: cecum 32 NA PMS2 absent Senter et al., 200820
2 2 CRC: cecum 47 NA PMS2 absent Senter et al., 200820
3 3 CRC: sigmoid 44 NA PMS2 absent Senter et al., 200820
4 5 CRC: transverse 43 NA PMS2 absent Senter et al., 200820
5 6 CRC: sigmoid 62 NA PMS2 absent Senter et al., 200820
6 Patient 1 CRC 31 MSI-H PMS2 absent Nakagawa et al., 200419
7 66603/current report: III.2 CRC 43 MSS Normal Van der Klift et al., 201021
8 74028 CRC 70 MSI-H PMS2 absent Van der Klift et al., 201021
9 74055 CRC 54 MSI-H PMS2 absent Van der Klift et al., 201021
CRC: colorectal carcinoma; IHC: immunohistochemistry; NR: not reported; MSI: microsatellite instability; MSI-H: microsatellite 
instability-high; MSS: microsatellite stable
Table 2. Genetic and clinical summary of nine reported cases (including our case) of patients with CRC and the heterozygous PMS2 
mutation: c.137G>T; p.Ser46IIe.
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resonance imaging (MRI) can be considered. Because 
of behavioral and psychological problems of the third 
child, she and her mother declined genetic testing for 
the PMS2 mutations and surveillance at the moment. 
In conclusion, the results of molecular 
analyses in this family display the diagnostic 
challenges in PMS2-mutation families. In case of a 
clinical phenotype of CMMR-D, it is recommended to 
routinely combine MSI analysis with IHC analysis for 
the expression of MMR proteins. With inconclusive 
or conflicting results, mutation analysis of the 
MMR genes should be considered after thorough 
counselling of the patients and their relatives. 
CAL: café au lait; IgA: immunoglobulin A; IHC: immunohistochemistry; NA: not available; MMR: mismatch repair; MSI: microsatellite 
instability; MSI-H: microsatellite instability-high; MSS: microsatellite stable; NHL: non-Hodgkin’s lymphoma
Family Case Gene Malignancy Age at 
diagnosis of 
malignancy 
(years)
Signs of NF1 Analysis of MSI IHC References
1 Patient1 PMS2 
Glioblastoma, colonic  
adenomas, NHL of the 
rectum
4 CAL spots MSI-H NA Hamilton et al., 199525
2 IV.2 MSH2 Glioblastoma 4 NR MSS NA Bougeard et al., 200335
3 III.1 PMS2 
Giant cell glioblastoma, 
duodenal cancer, 
colonic adenomas
17 CAL spots 
MSS (glioblastoma), 
MSI-H (duodenal 
cancer)
PMS2 absent in 
glioblastoma. MSH6 and 
PMS2 absent in duodenal 
tumor tissue
Agostini et al., 
200517
4 V.4 MSH6 Oligodendroglioma, rectosigmoid cancer 10 CAL spots MSS 
MSH6 absent in CRC, 
MSH6 present in 
oligodendroglioma
Menko et al., 
20048
5 IV.3 MSH6 Glioblastoma 
multiforme
8 CAL spots, axillary freckling MSI-H NA 
Hegde et al., 
200537
6 Patient1 MSH6 Astrocytoma 9
CAL spots, axillary 
freckling, IgA 
deficiency
NA MSH6 absent Ostergaard et al., 200538
7 I MLH1 Glioblastoma, Wilms tumor 4 CAL spots MSS 
MLH/PMS2 absent in 
brain tissue
Poley et al., 
200714
8 I.2 MSH6 Glioblastoma 
multiforme 
9
Hyper and 
hypopigmentation 
skin
MSS MSH6 absent, MSH2 expression reduced
Etzler et al., 
200836
Table 3. Results of analysis for MSI and IHC analysis of patients with brain cancer from families with biallelic MMR mutations.
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Abstract
Lynch syndrome (LS) is caused by germline mutations in mismatch repair (MMR) genes, resulting in 
microsatellite-unstable tumors. Approximately 35% of suspected LS (sLS) patients test negative for germline 
MMR gene mutations, hampering conclusive LS diagnosis. The aim of this study was to investigate somatic 
MMR gene aberrations in microsatellite-unstable colorectal and endometrial cancers of sLS patients negative 
for germline MMR gene mutations. Suspected LS cases were selected from a retrospective Clinical Genetics 
Department diagnostic cohort and from a prospective multicenter population-based study on LS in The 
Netherlands. In total, microsatellite-unstable tumors of 40 sLS patients (male/female 20/20, median age 57 
years) were screened for somatic MMR gene mutations by next-generation sequencing. In addition, loss of 
heterozygosity (LOH) of the affected MMR genes in these tumors as well as in 68 LS-associated tumors and 
27 microsatellite-unstable tumors with MLH1 promoter hypermethylation was studied. Of the sLS cases, 
5/40 (13%) tumors had two pathogenic somatic mutations and 16/40 (40%) tumors had a (likely) pathogenic 
mutation and LOH. Overall,
LOH of the affected MMR gene locus was observed in 24/39 (62%) tumors with informative LOH markers. Of 
the LS cases and the tumors with MLH1 promoter hypermethylation, 39/61 (64%) and 2/21 (10%) tumors, 
respectively, demonstrated LOH. Half of microsatellite-unstable tumors of sLS patients without germline 
MMR gene mutations had two (likely) deleterious somatic MMR gene aberrations, indicating their sporadic 
origin. Therefore, we advocate adding somatic mutation and LOH analysis of the MMR genes to the molecular 
diagnostic workflow of LS.
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Introduction
Lynch syndrome (LS) is an autosomal dominant 
hereditary condition that predisposes to various 
types of cancer and accounts for about 3% of 
all colorectal cancers (CRCs) and about 2% of all 
endometrial cancers (ECs)1,2. The increased risk 
for malignant lesions in LS is due to an inactivating 
germline mutation in one of four mismatch repair 
(MMR) genes, MLH1, MSH2, MSH6 and PMS2, or a 
germline deletion in EPCAM3,4. The final diagnosis 
of LS is based on the identification of the germline 
mutation in one of these genes5. 
MMR genes are classical tumor suppressor 
genes and bi-allelic inactivation results in 
tumorigenesis. The tumors of LS patients are 
characterized by a microsatellite instability (MSI) 
phenotype and absence of expression of one or more 
MMR proteins, both indicating DNAMMR deficiency. 
As a result of the LS testing algorithm6, patients are 
indicated as suspected of LS (sLS) or non-suspected 
of LS, after which germline testing of the affected 
MMR gene(s), as indicated by immunohistochemistry 
(IHC), is performed in the sLS cases. Germline testing 
leads to identification of a MMR gene mutation 
or of a variant of unknown significance (VUS) in 
about 65% of the sLS patients, as was shown in a 
prospective multicenter population-based study in 
The Netherlands, in which all consecutive CRC and 
EC patients≤70 years were screened for LS7,8. The 
lack of identification of mutations in the remaining 
35% severely hampers conclusive diagnosis (LS or 
not LS) for these patients and their relatives. An 
existing germline mutation could have been missed 
by germline analysis or they could have a sporadic 
tumor caused by bi-allelic somatic MMR gene 
inactivation. The prevalence of somatic mutations in 
the MLH1, MSH2 and MSH6 genes in sporadic CRC 
is 16%, 10% and 6%, respectively9,10; however, not 
all of the tumors included in these analyses showed 
MSI. More recently, somatic aberrations of the MLH1 
and MSH2 genes were studied in CRCs and ECs with 
MSI, but negative for both MMR germline mutations 
and promoter hypermethylation11,12. Sourrouille et 
al.11 performed mutation analysis of 18 CRCs and 
detected two somatic mutations in each of four 
tumors. Mensenkamp et al.12 combined mutation 
and LOH analysis in 25 CRCs or ECs and identified two 
somatic hits in 13 tumors. Both studies concluded 
that these double somatic hits indicated bi-allelic 
somatic inactivation and sporadic occurrence of the 
tumors. 
Reliable LS diagnosis is important for 
both patients with malignancies and their healthy 
relatives at risk of carrying a MMR gene germline 
mutation, as surveillance and preventive options can 
provide substantial health benefits in the case of a 
pathogenic MMR germline mutation13-16. In addition, 
the exclusion of LS in patients suspected of LS can also 
lead to health benefits, since these patients and their 
relatives may be released from further surveillance, 
additional genetic testing and emotional distress. 
The aim of the present study was to improve LS 
diagnostics by the determination of somatic MMR 
gene aberrations in microsatellite-unstable tumors of 
sLS patients tested negative for germline MMR gene 
mutations. 
Materials and methods
Patient selection and DNA isolation 
Patient selection is described in Figure 1; unexplained 
tumors from sLS patients were included in the study. 
sLS patients were defined as patients: (a) with 
microsatellite-unstable CRC, EC or ovarian cancer; 
(b) without MLH1 promoter hypermethylation when 
MLH1 was the affected MMR gene as indicated by 
IHC; and (c) tested negative for germline mutations 
and VUS in the affected MMR gene (mutation analysis 
of entire genes, including analysis of large intragenic 
deletions) and negative for EPCAM deletions. If blood 
was not available as the source of constitutional DNA 
because the patient was deceased at the time of 
germline mutation analysis, one or more first-degree 
relatives were analyzed. 
A retrospective series of 22 tumors (including 
one adenoma) of sLS patients were screened for 
MMR gene aberrations; these patients or their 
relatives were counselled at the Clinical Genetics 
Department of Erasmus MC, University Medical 
Centre, Rotterdam, during 2000–2012. Furthermore, 
18 tumors of sLS patients that were previously 
involved in a prospective multicenter population-
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Figure 1. Patient selection flowchart. All unexplained tumors (without germline mutations) from a retrospective series of suspected 
Lynch syndrome (sLS) patients counselled at the Clinical Genetics Department of Erasmus MC during 2000–2012 (1. CLINIC) as well 
as from sLS patients previously involved in a prospective, multicenter, population-based study in The Netherlands (2. LIMO) were 
included.
CRC: colorectal cancer; EC: endometrial cancer; LS: Lynch syndrome; MMR: mismatch repair; MSI: microsatellite instability; MSS: 
microsatellite-stable; n: number of patients
MSI analysis and MMR immunohistochemistry
MSS and normal 
MMR protein expression:
not LS associated
MSI and/or absent MMR protein expression 
MLH1 deficient
MLH1 promoter methylation analysis of normal 
and tumor tissue
MLH1 promoter 
methylated only
in tumor: 
sporadic tumor
MLH1 promoter 
methylated in 
normal & tumor: 
LS
MLH1 promoter 
not methylated
Suspected LS: germline mutation analysis
If the patient is deceased, one or more first degree
relatives are analysed
MSH2, MSH6 or 
PMS2 deficient
Clinical geneticist
-Bethesda guidelines
-Other clinical suspicion of LS
Pathologist
-CRC or EC < 50 years
-CRC + CRC or other 
LS-associated tumor < 70 years
1. CLINIC 2. LIMO
-CRC or EC < 70 years
1. CLINIC 
     
Unexplained tumors from patients 
counseled in the clinic between 2000 - 2012
N=22 (median age 46, IQR 23)
2. LIMO
        
Unexplained tumors from patients included 
in the prospective LIMO study
N=18 (median age 60, IQR 12)
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based study in The Netherlands (LIMO) were 
included7,8. As controls, 68 tumors of LS patients 
with an identified pathogenic MMR gene germline 
mutation (male/female 35/33; median age 50 years; 
IQR 14) and 27 sporadic tumors with MLH1 promoter 
hypermethylation (male/female 9/18; median age 
64 years; IQR 8) were analyzed. Of all 135 cases, 
formalin-fixed and paraffin-embedded (FFPE) normal 
and tumor tissues were manually microdissected 
from five to ten hematoxylin-stained sections. DNA 
was extracted using proteinase K and 5% Chelex 100 
resin, as previously described6. 
MSI analysis, MMR protein IHC and MLH1, MSH2 
and MSH6 promoter hypermethylation assay 
These analyses were performed as previously 
described6 (for additional details, see Supplementary 
Methods). 
LOH analysis and copy number detection of the 
MMR genes 
LOH analysis was performed for the affected MMR 
gene (for sLS patients, as indicated by IHC) using 
the SNaPshot multiplex kit (Applied Biosystems, 
Foster City, CA, USA) on normal and tumor DNA, 
as previously described17. Single and multiplex PCR 
assays were designed to detect six to nine single-
nucleotide polymorphisms (SNPs) in or adjacent to 
each of the MMR genes (Figure 2) (see Supplementary 
Methods). Classification of SNP results per gene was 
as follows: LOH, at least one SNP with LOH, no SNP 
with retention of heterozygosity (ROH); ROH, at least 
one SNP with ROH, no SNP with LOH; partial LOH, 
both SNP(s) with LOH and ROH; NI, all SNPs were 
non-informative (homozygous). To establish the copy 
number of the affected MMR gene, fluorescence 
in situ hybridization (FISH) was performed, using a 
commercial probe to detect MSH2 and custom-made 
probes to detect MLH1, MSH6 or PMS2 (all Kreatech, 
Amsterdam, The Netherlands), according to standard 
protocols. Control probes targeting the centromere 
or a locus on the opposite chromosomal arm were 
included for each gene. 
Mutation analysis of the MMR genes and BRAF 
All tumor samples of sLS patients were screened for 
somatic mutations of MLH1, MSH2, MSH6 and PMS2, 
using the ion torrent personal genome machine 
(PGM) with the supplier’s materials and protocols 
(Life Technologies, Carlsbad, CA, USA). A custom 
primer panel targeting the open reading frame 
including the exon–intron boundaries of the MMR 
genes was designed using Ion AmpliSeq Designer 
1.2. This panel consisted of 150 amplicons covering 
100%, 92%, 97% and 79% of MLH1, MSH2, MSH6 
and PMS2, respectively. Mean amplicon size was 155 
(range 124–174) base pairs (bp). All variants in the 
coding regions and the splice sites were reported, 
excluding synonymous single-nucleotide variants 
and known bona fide SNPs. All variants detected with 
the PGM were confirmed by Sanger sequencing in 
tumor and normal DNA, as previously described18. 
For four MLH1-deficient tumors (sLS-1, sLS-2, sLS-
9 and sLS-10), conventional Sanger sequencing of 
the exonic regions of MLH1 was performed instead 
of PGM analysis. All previously identified germline 
mutations in LS patients were confirmed in normal 
and tumor tissue if possible. Additionally, all tumor 
samples were screened for BRAF mutations by 
Sanger sequencing and with mutation-specific PCR 
for BRAF V600E and V600K, using FAM-labelled 
primers. Details of the PGM and Sanger sequencing 
analyses and data processing are provided in the 
Supplementary Methods. 
Predicting pathogenicity for somatic MMR variants 
Frame-shift, nonsense and splice site mutations were 
Figure 2. Locations of the SNPs used to screen for LOH of the 
MMR genes in four multiplex assays. Vertical black lines represent 
the positions of the SNPs targeted by SNaPshot probes.
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assumed to be pathogenic. For all missense variants 
and in-frame deletions, InSIGHT classification19,20, 
multiple in silico tools and a literature search were 
used to predict pathogenicity (for more details, see 
Supplementary Methods). Finally, all variants were 
classified as: 1, benign; 2, likely not pathogenic; 
3, uncertain; 4, likely pathogenic; or 5, definitely 
pathogenic. 
Results
All results for sLS patients, confirmed LS patients 
and patients with sporadic tumors are shown in 
Supplementary Table 1. 
Somatic MMR aberrations in sLS patients
The tumors of 40 sLS patients negative for MMR gene 
germline mutations were screened for somatic MMR 
mutations and for LOH of the affected MMR gene, as 
indicated by IHC (Table 1, Figure 3). This led to the 
detection of 49 somatic MMR gene variants, 31 in 
MLH1, 11 in MSH2, six in MSH6 and one in PMS2. 
Details about PGM coverage and the classification of 
missense variants and in-frame deletions are shown 
in Supplementary Tables 1 and 2, respectively. Two 
(5%) of the 40 patients, both deceased and with 
first-degree relatives negative for germline MMR 
mutations, showed a pathogenic mutation in both 
tumor and normal tissues. For all other patients, DNA 
from normal tissue showed no aberrations. Twenty-
one out of 40 (53%) tumors showed either two 
pathogenic mutations (5) or one (likely) pathogenic 
mutation and LOH (16) (Figure 4). In 12 of the 
tumors with a mutation and LOH, Sanger sequencing 
confirmed loss of the wild-type allele. Five of the 
40 (13%) tumors showed a VUS combined with a 
pathogenic mutation or LOH. In 9/40 (23%) tumors, 
only one somatic aberration was detected and 1/40 
(3%) tumors showed only a likely benign variant. Two 
(5%) of 40 tumors showed no aberrations, including 
the tumor from patient sLS-38, for which no mutation 
analysis results were available. In total, two VUS 
and four likely benign variants, but no pathogenic 
mutations, were detected in non-affected MMR 
genes, as indicated by IHC. 
LOH analysis 
All tumors were screened for LOH of the affected 
MMR gene (for sLS patients, as indicated by IHC) 
by SNaPshot analysis and/or Sanger sequencing. 
Finally, 39/40 tumors from sLS patients, 61/68 
tumors from LS patients and 21/27 sporadic tumors 
showed evaluable and informative results. Of those, 
24/39 (62%) tumors of sLS patients, 39/61 (64%) LS-
associated tumors and 2/21 (10%) sporadic tumors 
Figure 3. Somatic aberrations for the tumors of 40 suspected Lynch syndrome patients. The different colors indicate the deficient 
mismatch repair gene, as indicated by immunohistochemistry.
LOH: loss of heterozygosity; VUS: variant of unknown significance
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Figure 4. Somatic aberrations for patient sLS-4, who was diagnosed with a moderately–poorly differentiated adenocarcinoma of the 
colon. (a) Tumor cells show absence of MLH1 and PMS2 expression and normal MSH2 and MSH6 expression (filled arrowheads), 
stromal cells show expression of all four proteins (open arrowheads); scale bar=50 μm. (b) Microsatellite instability (MSI) analysis 
shows MSI of six markers (NR-21, BAT-26, BAT-25, NR-24, MONO-27 and Penta C) in the tumor (lower panel) compared to normal 
(upper panel); the MSI shifts are indicated by arrowheads. (c) A nonsense mutation (c.298C>T) in MLH1 was detected with the ion 
torrent personal genome machine. (d) Sanger sequencing confirmed the presence of the mutation (arrowhead) in tumor tissue (lower 
panel) and shows the absence of the mutation in normal tissue (upper panel). At the location of the mutation, loss of the wild-type 
allele was detected. (e) LOH was confirmed by SNaPshot analysis; one marker in TRANK1 and one marker in ITGA9 (arrowheads) are 
heterozygous in normal tissue (upper panel) and show LOH in tumor tissue (lower panel). (f) Copy number analysis by fluorescence 
in situ hybridization shows two copies of the MLH1 locus (red signal) and two copies of a control locus on the opposite arm of 
chromosome 3 (green signal) in the tumor cells (open arrowhead).
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showed LOH of (part of) the affected gene (Figure 
5). For the tumors of sLS patients, LOH was detected 
in 15/23 (65%) and 9/12 (75%) of the MLH1- and 
MSH2-deficient tumors, respectively. For 36 variants 
detected in tumors of sLS patients, both PGM data 
and LOH results by Sanger sequencing were available; 
for these variants, the percentage of variant reads 
by PGM was compared to LOH results by Sanger 
sequencing (Table 1); 15/36 variants showed LOH 
by both PGM and Sanger sequencing, 20/36 showed 
ROH by both PGM and Sanger sequencing, and one 
showed LOH by PGM (81% variant reads) but ROH by 
Sanger sequencing. Interestingly, the tumor of this 
patient (sLS-8) did show LOH by SNaPshot analysis. 
For the LS-associated tumors, LOH was detected in 
13/21 (62%), 10/13 (77%), 11/21 (52%) and 5/6 (83%) 
of the tumors of MLH1, MSH2, MSH6 and PMS2 
germline mutation carriers, respectively. Overall, 
seven tumors showed partial LOH by SNaPshot 
analysis and another eight tumors showed LOH by 
SNaPshot analysis but ROH by Sanger sequencing, 
with at least one variant.
Copy number analysis 
All tumors were screened with FISH to detect MMR 
gene copy number variations: 121 tumors showed 
two copies of the affected MMR gene; two tumors 
showed only one copy; one tumor showed polysomy; 
nine tumors showed non-evaluable results; and 
for two tumors copy number by FISH could not be 
determined. Both tumors with only one copy of 
the affected MMR gene (patients LS-27 and LS-56) 
showed LOH by SNaPshot analysis. 
BRAF mutation analysis 
All tumors were screened for BRAF mutations, using 
a sensitive mutation-specific PCR to detect V600E 
and V600K mutations and Sanger sequencing. For 
127 tumors BRAF analysis had evaluable results. 
Combining the results from both assays, BRAF 
mutations were detected in 5/34 (15%) tumors of 
sLS patients, 1/67 (1%) LS-associated tumors and 
22/26 (85%) sporadic tumors. V600E mutations were 
detected in three tumors of sLS patients and in 22 
sporadic tumors, a K601E mutation was detected 
in the tumor of a sLS patient and a BRAF D594G 
mutation was detected in both a LS-associated tumor 
and the tumor of a sLS patient.
Discussion 
Somatic MMR gene aberrations were investigated 
in 40 tumors of sLS patients negative for germline 
mutations in the affected MMR gene(s), as indicated 
by IHC; final conclusions are shown in Figure 6. Two 
Figure 5. Percentages of tumors with LOH or ROH for suspected Lynch syndrome (sLS) patients, Lynch syndrome patients and 
patients with sporadic tumors; different colors indicate the affected mismatch repair genes (for sLS patients, as indicated by 
immunohistochemistry).
LOH: loss of heterozygosity; ROH: retention of heterozygosity
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somatic and (likely) deleterious aberrations of the 
affected MMR genes were detected in 21/40 (53%) 
of these tumors, 16/24 for MLH1 and 5/12 for MSH2 
(Figure 4). In addition, 5/40 (13%) patients showed 
a variant of unknown pathogenicity combined 
with a pathogenic mutation or LOH. No pathogenic 
mutations were detected in the non-affected MMR 
genes, as indicated by IHC. This suggests that 
secondary mutations in the non-affected MMR genes 
are uncommon. Furthermore, 19/21 (91%) tumors 
with MLH1 promoter hypermethylation showed 
ROH for the MLH1 gene, which is in accordance with 
the notions that microsatellite-unstable tumors are 
generally chromosomally-stable21 and that MLH1 
promoter hypermethylation affects both alleles22. 
Focusing on the MLH1- and MSH2-deficient 
tumors, 21/36 (58%) tumors had two somatic and 
(likely) deleterious aberrations. This is comparable to 
the study of Mensenkamp et al.12, who identified two 
somatic aberrations in 13/25 (52%) MLH1- or MSH2-
deficient tumors. In the current study, 5/36 (14%) 
of the tumors showed two pathogenic mutations 
and 16/36 (44%) showed a combination of a (likely) 
pathogenic mutation and LOH. For the study of 
Mensenkamp et al.12, this was 5/25 (20%) and 8/25 
(32%) respectively; the slightly lower proportion of 
tumors with a pathogenic mutation and LOH could 
be explained by the fact that for 10/25 tumors, LOH 
Figure 6. Suspected Lynch syndrome patient details and final conclusions based on tumor analysis; numbers of patients (median age, 
IQR) are shown for all patient groups.
MMR: mismatch repair; n: number of patients
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analysis was not informative. We did not observe 
a different percentage of likely sporadic tumors for 
CRCs (55%, 18/33) compared to ECs (60%, 3/5). 
Mensenkamp et al.12 showed that 48% (11/23) of 
CRCs and 100% (2/2) of ECs were likely of sporadic 
origin. Although both studies showed that EC can 
be caused by two somatic aberrations, the numbers 
of ECs included are too low to reliably compare the 
distribution of somatic aberrations between CRCs 
and ECs. 
For two related sLS patients (sLS-25 and sLS-
26, sisters) the same pathogenic MSH2 mutation was 
found in both normal and tumor tissues, indicating 
a germline predisposition. From these patients no 
blood DNA was available as a source of constitutional 
DNA, since both patients were deceased at time of 
germline mutation analysis. Four of their healthy 
children were tested and no germline mutations in 
MLH1, MSH2 or MSH6 were found, indicating that 
these children did not inherit the MSH2 germline 
mutation from their mothers. This exemplifies that 
mutation analysis of normal and tumor DNA isolated 
from archival FFPE tissue can be a valuable approach 
for LS testing in patients from whom no blood DNA 
is available. 
In the tumors of 21 sLS patients, two (likely) 
deleterious somatic aberrations were detected, 
either two mutations or one mutation and LOH. It is 
likely that these aberrations are located on different 
alleles, causing bi-allelic inactivation of the MMR 
gene involved. For 12/16 tumors with a mutation 
and LOH, loss of the wild-type allele could indeed be 
confirmed by Sanger sequencing. These tumors may 
now be considered not to be associated to Lynch 
syndrome. As these patients are no longer suspect 
for LS, extensive colonoscopic surveillance similar 
to that needed in LS patients is no longer required. 
The starting age and frequency of colonoscopies for 
these patients and their relatives can now be solely 
based on family history. 
Some of the sLS patients included in the 
current study were previously involved in the 
prospective multicenter LIMO study (Figure 1), in 
which all consecutive CRC and EC patients≤70 years 
were screened for LS7,8. In total, 1117 CRCs and 179 
ECs were screened and germline mutation analysis 
was performed for 52 suspected LS patients: 34 (65%) 
patients had a germline MMR mutation or VUS and 
for 18 (35%) patients no mutations were detected. 
We screened the tumors of these 18 patients without 
germline MMR mutations for somatic aberrations of 
the MMR genes: 12 tumors (10 CRCs and two ECs) had 
a likely sporadic origin, and for six tumors (five CRCs 
and one EC) the results were inconclusive (Figure 6). 
Thus, 12/52 (23%) patients who were referred to the 
Clinical Genetics Department and tested for germline 
MMR gene mutations actually had (likely) sporadic 
tumors.
 Only two tumors showed the absence of one 
of the MMR alleles by copy number analysis, whereas 
LOH was found in 65 tumors. This suggests that the 
LOH detected is due to copy-neutral LOH (cnLOH). 
Previous studies have reported that cnLOH is an 
important mutational event in the carcinogenesis 
of microsatellite-unstable tumors and usually 
confined to the locus harboring pathogenic MMR 
gene mutations21,23. Interestingly, cnLOH was less 
frequently observed in tumors of MSH6 mutation 
carriers21,23, which corresponds to our findings in LS 
patients, where LOH is observed in only 11/21 (52%) 
of tumors of MSH6 mutation carriers, but in 13/21 
(62%), 10/13 (77%) and 5/6 (83%) of tumors of MLH1, 
MSH2 and PMS2 mutation carriers, respectively. This 
suggests that the second hit in MSH6-affected tumors 
is less often loss of the wild-type allele, but may be a 
second somatic mutation. An alternative explanation 
for the absence of copy number alterations is that 
only a small part of the chromosome is lost, which 
is not detected by our FISH probes. In 15/65 (23%) 
tumors we indeed found indications for partial LOH 
of the involved MMR gene. 
BRAF mutation status is regularly used to 
distinguish LS-associated tumors from sporadic 
microsatellite unstable colon cancer, as BRAF 
mutations are correlated with MLH1 methylation 
and are strong predictors of MMR gene mutation-
negative status24,25. In none of the tumors from LS 
patients was a BRAF V600E mutation detected; 
however, one germline MSH6 mutation carrier 
showed a BRAF D594G mutation in the tumor. The 
same mutation was detected in the tumor of a sLS 
patient. This mutation appears to be a low-activity 
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mutant26 and has been described previously in 
CRC27,28, but the significance of this mutant in the 
screening for LS is unknown. In total, BRAF mutation 
status was determined in 15 likely sporadic MLH1-
deficient tumors of sLS patients; interestingly, 3/15 
(20%) showed a BRAF mutation (V600E, K601E and 
D594G). As these tumors showed no MLH1 promoter 
hypermethylation, BRAF screening could be valuable 
in this subgroup of patients to predict the sporadic 
origin of the tumors. 
In 12/40 (30%) tumors of sLS patients, no or 
only one somatic mutation was found in the tumor. 
Obviously, some aberrations escaped detection by 
our analyses, so no final diagnosis with regard to LS 
could be made for these cases. Other mechanisms, 
such as mutations in untranslated or (deep) intronic 
regions, large deletions or alterations in other genes 
that are involved in regulation or expression of the 
MMR genes, might be involved in these tumors. 
Recently, the risk of cancer in families of sLS patients 
without germline mutations was determined by 
Rodriguez-Soler et al.29, who found that the risk of 
CRC is lower in families with sLS than among patients 
with genetically confirmed LS, but significantly 
higher than in cases of truly sporadic CRC. Therefore, 
sLS patients should only be released from cancer 
surveillance programs when two somatic hits are 
detected in the tumor, as any undetected hit could 
be a germline mutation. 
The current study also has some limitations. 
Some somatic aberrations might have escaped 
our detection methods; therefore, the number 
of somatic aberrations of the MMR genes could 
be underestimated. For the LOH analyses, 12/135 
patients showed non-evaluable results, probably 
due to the use of DNA extracted from FFPE tissue. 
Furthermore, 9/135 patients were homozygous for 
all investigated SNPs. As LOH might be confined to 
only a small region of the MMR gene, it could have 
been missed due to insufficient informative markers. 
Additionally, some somatic mutations might have 
been missed due to the design of the PGM primer 
panel, as not all exonic regions were completely 
covered. We did not have a sufficient amount of 
DNA to analyze all tumors of sLS patients for MMR 
mutations using an alternative method, therefore we 
do not know the false-negativity rate for the PGM 
analysis. The tumors of three sLS patients (sLS-2, 
sLS-13 and sLS-38) had non-evaluable PGM results 
(<80% of the target bases were covered>100 times). 
For two of those tumors (sLS-13 and sLS-38), no 
conventional Sanger sequencing could be performed 
as an alternative, due to a limited amount of DNA. 
Despite the low coverage, the tumor of patient sLS-
13 did show one likely benign variant, but Sanger 
sequencing of this region could not be performed 
due to low-quality DNA. As the PGM coverage for 
these patients is very low, potential mutations could 
have been missed. 
In 26/40 (65%) tumors of sLS patients, two 
or more somatic MMR gene aberrations were found. 
For 21 patients this concerned (likely) pathogenic 
mutations, indicating the sporadic origin of the 
tumors. This result indicates that LOH and somatic 
mutation analyses of the MMR genes in tumors of 
sLS patients adds substantially to the final diagnostics 
of these patients and their relatives. Therefore, we 
propose to add somatic molecular analyses of the 
MMR genes to the routine molecular diagnostic 
workflow of tumors of sLS patients. To better 
document the incidence of somatic MMR mutations, 
intronic regions and regions that were not covered 
in the current design should be analyzed as well. 
Implementation of whole-genome sequencing 
might help to identify unknown germline or somatic 
aberrations associated with LS. 
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Supplementary Methods
Microsatellite instability (MSI) analysis, mismatch 
repair (MMR) protein immunohistochemistry 
(IHC) and MLH1, MSH2, and MSH6 promoter 
hypermethylation assay 
MSI analysis was performed on all tumor samples 
using a panel of five mononucleotide microsatellite 
markers (Promega pentaplex assay, Promega, 
Madison, WI). Tumors with more than one unstable 
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marker were categorized as having MSI. IHC for 
the MMR proteins was performed as previously 
described6. For suspected Lynch syndrome (sLS) 
patients, the methylation status of the MLH1, MSH2, 
or MSH6 promoter was determined if the tumor had 
absent MLH1, MSH2, or MSH6 protein expression, 
respectively. Promoter hypermethylation was 
determined by the methylation-specific multiplex 
ligation-dependent probe amplification assay SALSA 
MS-MLPA Kit ME011-100R for MMR genes (MRC-
Holland, Amsterdam, The Netherlands), according to 
standard protocols. 
LOH analysis 
Single PCR - and multiplex PCR assays were designed 
to detect six to nine SNPs in or adjacent to each of 
the MMR genes. The following SNPs were included 
in these assays: rs4476463, rs11712098, rs4441609 
(TRANK1), rs3774341, rs4234259, rs9876116 
(MLH1), rs199279, rs11709385, rs2434132 (ITGA9); 
rs3815865, rs10209586, rs2347794, rs7607076, 
rs6757035, rs3732183, rs3764960, rs2059520, 
rs11684737 (MSH2); rs3136228, rs3136245, 
rs3136265, rs3136282, rs2348244, rs3136329, 
rs2020911, rs3136354, rs3136359 (MSH6); 
rs62455883 (RNF216), rs62456178, rs12702462, 
rs2286681, rs2286680, and rs12112229 (PMS2). 
Labelled fragments were detected on an ABI 3730xl 
genetic analyzer (Applied Biosystems, Foster City, 
CA). Data was analyzed with Genemarker v2.4.0 
software (SoftGenetics, State college, PA). 
Mutation analysis of the MMR genes and BRAF
Mutation analysis with the Ion Torrent Personal 
Genome machine (PGM) was performed with 
suppliers materials and protocols (Life Technologies, 
Carlsbad, CA). DNA concentrations were measured 
with the Qubit 2.0 Fluorometer and 2.5 to 10 ng DNA 
input was used. Libraries were made using the Ion 
AmpliSeq Library Kit 2.0-384 LV according to the Ion 
Ampliseq Library Preparation User Guide. Template 
was prepared using the Ion OneTouch 200 Template 
Kit v2 DL and sequencing was performed with the 
Ion PGM Sequencing 200 Kit v2 on an Ion 316, 316 
v2, or 318 chip. Data was analysed with Variant 
Caller v3.6 (Life Technologies). Using ANNOVAR30 in 
a local Galaxy pipeline31-33, variants were annotated 
with RefSeq and additional information about the 
variant was obtained using dbsnp137NonFlagged, 
COSMIC64, ESP6500_ALL, and 1000g2012apr_ALL. 
All Sanger sequence analyses were performed with 
M13 tailed custom made primers, as previously 
described18. Data was analyzed with Mutation 
Surveyor v4.0 software (SoftGenetics). For the BRAF 
mutation specific PCR labelled fragments were 
detected as described for the SNaPshot analysis. 
Sequences of all primers and probes are available on 
request.
Predicting pathogenicity for somatic MMR variants
For all missense variants and in-frame deletions the 
Consensus InSIGHT classification was searched19,20. 
Furthermore, Align-GVGD34, SIFT35, Mutation Taster36 
and Grantham scores37 were calculated using Alamut 
software v2.3 (Interactive Biosoftware, Rouen, 
France). Additionally, all variants were analysed by 
PolyPhen-238, FATHMM39, CHASM40, and PROVEAN41. 
Variants with a consensus InSIGHT classification 
were classified accordingly. For variants not classified 
by InSIGHT, a literature search was performed and 
classification was based on in silico tool predictions 
and functional data if available
Supplementary material on the internet
Supplementary Table 1. All results for suspected 
LS patients (sLS), Lynch syndrome (LS) patients and 
patients with sporadic tumors.
http://www.niekgeurts.nl/proefschrift/Chapter 9 - 
Supplementary Table 1.xls
Supplementary Table 2. Prediction of pathogenicity 
for missense variants and in-frame deletions of 
MLH1, MSH2, and MSH6.
http://www.niekgeurts.nl/proefschrift/Chapter 9 - 
Supplementary Table 2.xls
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Summary
The studies in the first part of this thesis focus on 
tumor clonality determinations. Unique DNA markers 
or somatic DNA aberrations can be used to reliably 
define tumor origin or the clonal relationships 
between multiple tumors in the same patient 
(multiple primary tumors or metastasized disease). 
These DNA analyses help with the differential 
diagnosis and facilitate selecting the appropriate 
treatment for the patient. Studies in the second 
part address molecular analyses in the context of 
hereditary testing. As certain hereditary syndromes 
are characterized by specific somatic aberrations, 
screening tumors for these aberrations helps to 
decide whether or not the patient should be referred 
for genetic counseling. Furthermore, determining the 
sporadic origin of a tumor in a patient suspected of a 
hereditary syndrome can facilitate proper diagnosis 
for the patient and its relatives. The main findings are 
summarized below.
Part I - Clonality determinations
In chapter 2, a patient with a colorectal carcinoma 
metastasis in a transplanted liver, detected 18 
months after transplantation, is described. Although 
donor-related tumors are very rare in transplantation 
patients1-4, the diagnostic question was raised 
whether this tumor could originate from the donor, 
as a colonoscopy was negative for the index patient. 
DNA short tandem repeat genotyping of tumor tissue 
indicated unequivocally that the tumor cells were of 
donor origin. These results show that considering 
the possibility of a donor-related tumor in patients 
who received a tissue transplant is crucial for proper 
therapeutic decision-making.
 In chapter 3, immunoglobulin heavy (IGH) 
and Ƙ light chain (IGK) gene rearrangements were 
studied in patients with successive B-cell lymphomas 
to determine whether these were recurrences or 
unrelated primary lymphomas. After initial treatment, 
25 to 85% of patients with malignant lymphoma 
relapse following a period of complete remission5-8. A 
second occurrence of lymphoma is usually considered 
a recurrence, however, it may also be an unrelated 
primary lymphoma, with different treatment options. 
IGH and IGK rearrangements were studied for 36 
patients with multiple lymphomas, diagnosed within 
a 5- to 15-year time interval. Lymphoma relapses 
were mostly recurrences of the primary tumor (89-
94% of cases). Therefore, routine investigation of the 
possible clonal relationship between two successive 
lymphoma is not warranted. For specific subtypes of 
lymphoma molecular analysis might be valuable, for 
example for diffuse large B-cell lymphoma (DLBCL), 
as the only two successive lymphomas that were 
unrelated primary lymphomas concerned DLBCL.
 In chapter 4, the potential use of the 
mitochondrial DNA (mtDNA) D310 marker for 
clonality determinations of clinically challenging 
synchronous or metachronous tumors was examined 
for a wide range of tumor types. Sanger sequencing 
of the D310 mononucleotide repeat was performed 
on a diagnostic cohort of 382 patients with 857 
tumors that were previously analyzed using routine 
molecular analysis on genomic DNA. For 26% of 
patients a D310 mutation was detected in at least 
one of their tumors, for these patients the D310 
can be used to determine the clonal relationship 
between their multiple tumors. However, clonality 
assessments based on mtDNA and genomic DNA 
were only concordant in 71% of patients. Although 
D310 mutation status might aid in clonality 
determinations, as a single assay it has limited 
predictive value. To further evaluate the potential 
contribution of mtDNA markers to the assessment 
of tumor clonality, next generation sequencing (NGS) 
assays can be complemented with mtDNA markers, 
such as the D310 repeat.
 In chapter 5, the accuracy and additional 
value of targeted NGS for determining the clonal 
relationship between two lung lesions from the same 
patient was examined. Histological and molecular 
subtyping of non-small cell lung cancer (NSCLC) is 
important for predicting survival and drug response, 
however, up to 8% of NSCLC is multifocal9-12. The two 
tumors of this patient showed different activating 
EGFR mutations, EGFR amplification status, TP53 
mutation status and loss of heterozygosity patterns by 
routine analysis. Targeted NGS was performed using 
the commercially available AmpliSeq Cancer Panel, 
which targets hotspot regions of 50 genes frequently 
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mutated in multiple tumor types. With NGS, all 
conventional detected mutations were confirmed, 
and an additional variant, in a gene not covered 
by routine analysis, was detected. NGS accurately 
determined the multifocal NSCLC of this patient as 
two unrelated primary tumors. Additionally, these 
results suggest that multifocal NSCLC should be 
considered as potentially multiple primary tumors 
and stratification for targeted therapy based on 
molecular markers should be performed on all tumor 
foci present.
 In chapter 6, the value of targeted NGS in 
the diagnostic workup of BRCA1/2 gene mutation 
carriers with more than one tumor location was 
evaluated. Female BRCA1/2 gene mutations carriers 
have a high cumulative lifetime risk for developing 
breast and ovarian cancer (55-85% and 10-60%, 
respectively)13-16 and therefore are often diagnosed 
with multiple tumors. It is of clinical importance to 
determine the clonal relationships between these 
tumors, as the primary tumor guides treatment and 
determines prognosis17,18. For this study, conventional 
histopathological revision was performed on 
the multiple tumors of 42 patients, resulting in a 
conclusive result on tumor origins for 38 patients. 
For 14 patients targeted NGS was performed, using 
a custom made primer panel for the detection of 
mutations as well as DNA copy number changes. For 
all 14 patients, NGS could unequivocally determine 
the clonal relationships between the multiple tumors. 
For 10 of these patients conventional histopathology 
also yielded a conclusive result, which matched the 
molecular outcomes in all cases.
Part II - Molecular diagnostics
in the context of hereditary testing
In chapter 7, β-catenin immunohistochemistry 
(IHC) and CTNNB1 mutations were analyzed in 18 
pediatric desmoid tumors to identify possible APC 
germline mutation carriers. In 11 tumors, abnormal 
nuclear β-catenin accumulation was detected, 
indicative for an APC or CTNNB1 mutation. 7/11 
tumors showed somatic CTNNB1 mutations. In two 
tumors with abnormal β-catenin staining and no 
CTNNB1 mutation, an APC mutation was detected, 
which appeared to be germline. This illustrates 
that β-catenin IHC and CTNNB1 mutation analysis 
are useful tools in selecting pediatric patients with 
desmoid tumors for germline testing of APC.
 In chapter 8, a pitfall in the current screening 
strategy for mismatch repair deficiency (MMR-D) 
is presented. A family was identified in which both 
the mother and the father were germline PMS2 
mutation carriers, resulting in a 25% chance for their 
children to be biallelic germline PMS2 mutation 
carriers. Biallelic germline MMR gene mutations are 
associated with constitutional MMR-D (CMMR-D)19. 
Diagnostic strategies for selection of patients for 
genetic counseling for CMMR-D or Lynch syndrome 
(LS), include microsatellite instability (MSI) testing 
and/or MMR protein IHC in tumor tissue20. The index 
patient and his sister had biallelic PMS2 mutations, 
which were confirmed to be derived from the father 
and mother. The brain tumors of both the index 
patient and his sister showed absence of PMS2 
expression. However, MSI analysis showed MSI only 
for 2/5 markers in the tumor of the index patient, 
and no MSI in the tumor of the sister. These data 
show that in case of a clinical suspicion of CMMR-D, 
MSI analysis is suboptimal and should be routinely 
combined with MMR protein IHC.
 In chapter 9, somatic aberrations of the 
MMR genes were analyzed in microsatellite-unstable 
tumors of 40 suspected LS patients tested negative 
for germline MMR gene mutations. Approximately 
35% of suspected LS patients test negative for 
germline MMR gene mutations, hampering 
conclusive LS diagnosis21,22. Tumors were analyzed 
for somatic MMR gene mutations and for loss of 
heterozygosity using a custom made targeted NGS 
panel and a custom made SNaPshot assay. Half of 
the suspected LS patients negative for germline 
MMR gene mutations appeared to have sporadic 
tumors due to two somatic MMR gene aberrations. 
As a result these patients are no longer suspected 
of LS and therefore analysis of somatic MMR gene 
aberrations adds substantially to the final diagnosis 
of these patients and their relatives. Based on our 
results and literature23,24, we advise to add somatic 
molecular analysis of the MMR genes to the routine 
molecular workflow of suspected LS patients.
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Discussion
Next generation sequencing: 
possibilities and challenges
The introduction of targeted NGS into the molecular 
pathology laboratory has led to many changes, and 
multiple chapters in this thesis are based on NGS 
technology. One of the most important features of 
NGS for molecular pathology is that it enables the 
simultaneous testing of multiple DNA fragments 
using a limited amount of DNA input (only 10 ng 
for the Ion Torrent PGM). With conventional Sanger 
sequencing between 1 and 10 DNA fragments were 
tested for each tumor, depending on the tumor 
type. For example, mutation analysis of BRAF was 
performed for melanoma, KRAS and EGFR for non-
small cell lung carcinoma, and KIT and PDGFRA for 
gastrointestinal stromal tumors. With NGS mutation 
analysis, most molecular pathology laboratories in 
the Netherlands use one general diagnostic panel, 
including all clinically relevant mutations for multiple 
tumor types. Especially in the academic hospitals 
NGS panels are often augmented with additional 
genomic fragments (genes), which might become 
diagnostically relevant in the (near) future. Using 
large NGS panels in diagnostics sometimes results 
in unexpected findings and/or detection of genomic 
variants of unknown significance. Appropriate 
evaluation of these findings with bio-informaticians, 
pathologists and clinicians is a major challenge. 
 An advantage of NGS is the high sensitivity 
compared to Sanger sequencing, which results in the 
detection of variants present in a low percentage 
of the cells from which DNA has been isolated. For 
some analyses this is very useful, for example when 
it is impossible to obtain DNA from a high percentage 
of neoplastic cells. Furthermore, some mutations 
associated with resistance to targeted therapies are 
only detected in low allele frequencies, and might 
therefore escape detection using Sanger sequencing. 
This high sensitivity however also creates a new 
dilemma: what percentage of the tumor cells need 
to carry a specific mutation for the tumor to be 
responsive to targeted therapy?
 For clonality determinations, NGS obviously 
has a great advantage over Sanger sequencing. As 
many genes can be tested in one NGS analysis, the 
chance to detect mutations in the tumors is largely 
increased. This is especially true for tumors of 
unknown primary, as the chance to detect mutations 
with Sanger sequencing depends on selection of 
the appropriate genes. Additionally, copy number 
aberrations can be analyzed simultaneously 
in the same NGS panel using single nucleotide 
polymorphisms (SNPs). The NGS panel used for 
clonality determinations at the department of 
Pathology of the Erasmus MC was previously 
described and targets the entire open reading frame 
of CDKN2A, PTEN and TP53, multiple hotspots sites 
for 27 different genes and 143 SNPs at 15 different 
loci for the detection of copy number aberrations. 
Use of this panel often results in detection of 
multiple aberrations, mutations as well as copy 
number aberrations. This increase in the number 
of detected aberrations per tumor can however 
also complicate interpretation. Frequently, common 
aberrations as well as differences between two 
tumors are detected. Biologically this makes sense; 
two independent primary tumors can by chance 
develop the same aberrations. Especially hotspot 
mutations or identical copy number aberrations are 
found in many different tumor types. On the other 
hand, metastatic disease might be heterogeneous 
and result in additional aberrations in one or more 
of the tumor localizations. Classification of tumors as 
clonally related or not depends on critical evaluation 
of all identified DNA aberrations in the context of the 
clinical and pathological characteristics.
 For somatic testing in the context of hereditary 
testing, to detect somatic aberrations that suggest a 
sporadic origin of the tumor, introduction of NGS was 
essential. Many hereditary syndromes are caused by 
mutations in tumor suppressor genes, which need 
a second hit before the gene is inactivated. Tumor 
suppressor genes can harbor all types of inactivating 
mutations including missense, nonsense, frameshift 
and splice site mutations, but also larger aberrations 
like exon and whole gene deletions. Tumor suppressor 
genes usually do not have mutation ‘hotpots’, 
therefore, testing for aberrations generally involves 
screening the complete coding sequence, including 
the intron-exon boundaries. Routinely sequencing 
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these genes in DNA isolated from formalin fixed 
paraffin embedded (FFPE) tissue is challenging, but 
since the introduction of NGS no longer impossible. 
Now large tumor suppressor genes, like the MMR 
genes, are routinely tested for somatic mutations 
facilitating proper diagnosis for patients and their 
families. A continuing challenge in somatic testing of 
tumor suppressor genes using NGS is to detect entire 
exon deletions and other large genomic aberrations. 
This can be tested with an additional multiplex 
ligation-dependent probe amplification analysis, but 
a combined NGS approach would be more efficient 
and would require less DNA input. 
Beyond next generation sequencing
In this thesis different techniques are described, 
including short tandem repeat genotyping, IGH and 
IGK rearrangement analysis, Sanger sequencing, 
MSI analysis, and targeted NGS. This wide range of 
techniques is illustrative of the current molecular 
pathology laboratory, where many different types of 
analyses are performed on a daily basis. Especially in 
academic hospitals, these analyses are continuously 
adapted according to the most recent experimental, 
clinical and technical findings and/or (experimental) 
treatments available. Technological developments 
are an important factor in the ability to incorporate 
all these new analyses into a routine diagnostic 
setting. Below, some technological advancements 
potentially relevant for future molecular pathology 
are discussed.
Whole exome sequencing (WES) / whole genome 
sequencing (WGS)
With the introduction of NGS into the routine 
diagnostic setting, possibilities for mutation analysis 
seem endless. Most molecular pathology laboratories 
started with relative small targeted NGS panels, mainly 
composed of clinically relevant genes. However, as 
the costs for NGS are dropping, the question arises 
whether molecular pathology laboratories should be 
performing WES or WGS instead. This would result 
in detecting all (potentially) relevant aberrations, 
without having to select the appropriate genes in 
advance. The advantages of WES/WGS for research 
purposes are obvious, as unexpected mutations 
will only be detected using these approaches. For 
diagnostic purposes WEG/WGS will undoubtedly 
result in frequent off-target findings that might be 
difficult to interpret in a clinical setting, however, it 
is possible to only analyze the data of genes relevant 
for the specific diagnostic question. The advantage 
compared to targeted sequencing is obvious, if any 
other genes become relevant in the future, the data is 
already there. A challenge for the application of WES/
WGS in solid tumors diagnostics might be generating 
good quality data using DNA isolated from FFPE tissue.
RNA-seq
The current application of NGS in molecular pathology 
laboratories is mostly DNA sequencing. However, the 
same platforms can be used for RNA sequencing, 
which can especially be useful for the detection of 
gene fusions resulting from genomic translocations. 
An illustrative example is the Ion Ampliseq RNA fusion 
lung cancer research panel from Life Technologies 
(Thermo Fischer Scientific, Waltham, Massachusetts), 
which targets over 70 fusion transcripts in one 
assay. This assay detects known fusion partners, 
as well as indicates potential translocations with 
unknown fusion partners. With conventional in situ 
hybridization (ISH, break-apart probes) usually only 
a break in one of the target genes is detected, which 
is however generally sufficient for clinical purposes. 
Additionally, methods are available for NGS-based 
gene fusion detection without prior knowledge of 
the fusion partner (FusionPlex, ArcherDX, Boulder, 
Colorado).
RNA scope
In ISH a labeled nucleic acid (DNA or RNA) 
complementary probe is used to detect with 
subcellular resolution specific DNA or RNA sequences 
in a tissue section. Currently, most routine diagnostic 
ISH assays are based on detection of DNA aberrations 
because of the low sensitivity and/or specificity of RNA 
ISH. RNA scope (Advanced Cell Diagnostics, Hayward, 
California) is a novel RNA ISH method that visualizes, 
down to single molecules, specific RNA sequences in 
individual cells and enables semi-quantitative in situ 
gene expression analysis. Multiplexing of different 
target genes with RNA scope is also possible.
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Methylation profiling
DNA methylation denotes the conversion of a 
cytosine to 5-methylcytosine, which typically occurs 
at CpG sites (a cytosine 5’ of a guanine). Many genes 
have CpG islands associated with the promoter 
regions, and methylation of these CpG sites can lead 
to inhibition of transcriptional activity. As particular 
tumor types are characterized by specific methylation 
patterns, methylation profiling can be used for tumor 
classification. This is especially useful for tumors that 
are difficult to classify using conventional criteria, like 
for pediatric brain tumors25. 
One of the main limitations of the techniques 
mentioned above is the requirement of a sufficient 
amount of tumor tissue. Removing a piece of tumor 
tissue is invasive and difficult for certain tumor types. 
Furthermore, a biopsy might suffer from sample 
bias due to molecular heterogeneity within the 
tumor. Recently, several less invasive techniques for 
molecular profiling of a tumor are being established, 
some of which are discussed below. 
Circulating tumor cells (CTCs) 
and circulating tumor DNA (ctDNA)
Two main approaches for tumor analysis based on 
blood are the analysis of CTCs and ctDNA. CTCs are 
tumor cells that have shed from a tumor, circulate 
in the bloodstream and can give rise to metastases 
in distant organs. ctDNA is thought to enter the 
bloodstream following apoptosis or necrosis of 
tumor cells. Both DNA from CTCs as well as ctDNA 
can be used for analysis of the genetic profile of 
the tumor. The main challenge in analyzing CTCs or 
ctDNA is the high abundance of circulating normal 
cells and cell free DNA from normal cells (non-tumor 
cells). However, very sensitive detection methods are 
available for detecting specific mutations at low allele 
frequencies, like the Droplet Digital PCR (Bio-Rad, 
Hercules, California). For example, the EGFR T790M 
resistance mutation can be monitored by analyzing 
CTCs or ctDNA26,27.
RNA-seq of platelets
Blood platelets are circulating anucleated cell 
fragments and involved in the systemic and local 
response to tumor growth. When platelets are 
exposed to tumor cells their RNA profile is altered in 
a specific manner. These so called tumor-educated 
platelets have diagnostic potential as they harbor 
unique RNA profiles depending on the tumor type 
present in the patient28,29. A recent study showed 
that blood platelets provide a valuable platform for 
detecting and subtyping multiple types of cancer30.
Molecular pathology in clinical decision-making
Different disciplines are involved in clinical decision-
making and for the clinical scientist in molecular 
pathology the main interactions are with pathologists, 
clinicians and clinical geneticists. Traditionally, a 
pathologist authorizes molecular results before being 
reported to the clinic. In some hospitals however, 
including the Erasmus MC in Rotterdam, the clinical 
scientist in molecular pathology reports the results 
of molecular testing for targeted treatment directly 
to the requesting clinician, without interference of a 
pathologist. The main reason for this is the need to 
report the results as quickly as possible to the clinic 
in order to avoid any delay in start of the treatment. 
However, also for these tests, involvement of a 
pathologist is imperative to indicate the appropriate 
tissue region for testing and identifying the tumor 
cells from which DNA should be isolated. For many 
complex molecular analyses, like tumor clonality 
determinations and other differential diagnostic 
questions, the requesting pathologist is in the lead 
and integrates the molecular results with clinical, 
histopathological and immunohistochemical findings 
to make an optimal diagnosis.
 In the last few years many clinical scientists 
in molecular pathology in the Netherlands have 
become involved in multidisciplinary meetings with 
pathologists and/or clinicians. In these meetings 
specific patients with unusual molecular profiles are 
discussed, not limited to the molecular details, but 
also including treatment options and outcome. These 
meetings underscore the importance of molecular 
testing in patient care, and are mutually instructive 
for both clinicians and clinical scientists in molecular 
pathology. As more and more targeted treatment 
possibilities are developed, close collaboration 
between pathologists, clinicians and clinical scientists 
123i Chapter 10 Summery and general discussion
in molecular pathology is crucial to keep up to date 
and to deliver the best patient care possible. 
 In the Netherlands, germline testing is only 
performed after counseling by clinical geneticists. For 
certain hereditary syndromes, like Lynch syndrome, 
tumors are first screened for somatic aberrations 
to determine whether or not a patient should be 
referred to clinical genetics. Lately however, the strict 
separation between somatic and germline testing is 
fading, which is exemplified by BRCA testing in ovarian 
cancer. Patients with ovarian cancer have a high 
risk of being a germline BRCA1 or BRCA2 mutation 
carrier31 and are therefore conventionally counseled 
and tested for mutations by clinical genetics. Recently 
however, somatic BRCA mutations have become of 
interest because ovarian tumors with either germline 
or somatic BRCA mutations appear to respond well 
to PARP inhibitors32,33. The most efficient workflow is 
to first test the tumor for mutations, as both somatic 
and germline mutations can be detected in tumor 
DNA, and thus double testing is avoided. Based on 
these results patients can be stratified for treatment. 
Subsequently, patients with mutation positive tumors 
need to be referred to clinical genetics for counseling 
and germline testing for the specific mutations, as 
these are potentially germline. In several hospitals in 
the Netherlands the molecular pathology laboratory 
is already performing primary testing of ovarian 
cancer for BRCA mutations. As clinical geneticists are 
very experienced in both testing genes associated 
with hereditary syndromes as well as interpreting the 
variants detected, their involvement in implementing 
somatic testing of these genes is essential.
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Pathologie is de medische discipline die ziektes 
diagnosticeert door middel van het onderzoeken 
van weefsels, cellen en lichaamsvloeistoffen. Deze 
diagnose is vaak de basis voor de juiste behandeling 
van de patiënt. Kleine gekleurde weefselfragmenten 
worden onder de microscoop bekeken om de 
cellulaire en nucleaire details te beoordelen. Indien 
nodig worden aanvullend immunohistochemische 
kleuringen gemaakt, die de aan- of afwezigheid van 
specifieke cellulaire of extracellulaire componenten 
kunnen aantonen. Voor de beoordeling van tumoren 
worden deze onderzoeken steeds vaker aangevuld met 
moleculair onderzoek. Moleculaire pathologie helpt 
bij het vaststellen van de juiste diagnose, prognose 
en/of behandeling van patiënten met kanker door 
middel van het analyseren van DNA (en eventueel 
RNA) afwijkingen. DNA is een complex molecuul dat 
alle informatie bevat benodigd voor de ontwikkeling, 
het functioneren en de reproductie van levende 
organismen. Deze informatie wordt gecodeerd 
door vier verschillende basen: adenine, thymine, 
guanine en cytosine. Humaan DNA is verdeeld over 
23 chromosoom paren die zich in de kern van de 
cel bevinden, daarnaast is een kleine hoeveelheid 
DNA aanwezig in de mitochondriën. Humaan DNA 
bestaat uit ongeveer 3 miljard basen, die grotendeels 
identiek zijn voor alle individuen. Ongeveer 0,5% van 
het DNA verschilt tussen individuen. Meestal zijn dit 
‘neutrale varianten’ zonder functionele betekenis, 
bijvoorbeeld veranderingen van één base (SNPs, 
single nucleotide repeats) of veranderingen in korte 
herhalingen van basen (STRs, short tandem repeats).
 Kanker ontstaat door DNA mutaties, welke in 
tegenstelling tot neutrale varianten een pathogeen 
effect hebben. Tumoren verkrijgen mutaties door 
een vorm van genomische instabiliteit, bijvoorbeeld 
chromosomale instabiliteit (CIN) of microsatelliet 
instabiliteit (MSI). CIN wordt gekenmerkt door grote 
deleties of toenames van hele chromosomen of 
delen daarvan, MSI door de aanwezigheid van vele 
mutaties, voornamelijk in korte herhalingen van 
basen. Tijdens het ontstaan van een tumor zorgt deze 
instabiliteit voor de activatie van proto-oncogenen 
en de inactivatie van tumorsuppressorgenen. De 
meeste tumoren zijn het resultaat van verkregen 
(somatische) mutaties, deze mutaties kunnen in elke 
cel van het lichaam ontstaan. Een minderheid van 
de tumoren ontstaat in de context van een erfelijk 
kanker syndroom, waarbij een mutatie geërfd wordt 
van een van de ouders. Deze geërfde mutaties 
worden kiembaanmutaties genoemd, en zijn meestal 
aanwezig in alle cellen van het aangedane individu. 
De aanwezigheid van deze kiembaanmutatie 
verhoogt de kans dat het aangedane individu kanker 
zal ontwikkelen.
Diagnostische moleculaire pathologie
Er zijn verschillende indicaties voor het testen van het 
DNA van tumoren op de aanwezigheid van somatisch 
afwijkingen:
Het selecteren van patiënten 
voor (gerichte) behandeling
Voor verschillende tumorsoorten 
zijn gerichte behandelingen mogelijk 
wanneer specifieke DNA afwijkingen 
aan- of afwezig zijn. 
Differentiaal diagnostisch
Sommige tumorsoorten worden 
gekenmerkt door de aanwezigheid van 
specifieke DNA afwijkingen. Wanneer 
histopathologisch onderzoek niet 
conclusief is, kan het al dan niet 
aantonen van deze kenmerkende afwijkingen helpen 
bij het stellen van de juiste diagnose.
In het kader van erfelijk onderzoek
Erfelijke syndromen worden 
soms gekenmerkt door specifieke 
somatische afwijkingen. Het 
aantonen van deze afwijkingen 
kan ondersteunend zijn in de 
beslissing om een patiënt door te sturen voor 
erfelijkheidsonderzoek bij de afdeling klinische 
genetica.
De moleculaire diagnostiek is de afgelopen jaren 
een steeds belangrijkere rol gaan spelen in de 
patiëntenzorg. Sinds 2013 bestaat er dan ook binnen 
?
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de Nederlandse Vereniging voor Pathologie (NVVP) 
een 2-jarige opleiding tot klinisch moleculair bioloog 
in de pathologie (KMBP). Richtlijnen vastgesteld in 
2014 door de NVVP stellen dat elk laboratorium dat 
moleculaire diagnostiek verricht binnen Nederland 
een KMBP in dienst moet hebben, of tenminste 
toegang moet hebben tot KMBP expertise. Dit is 
belangrijk omdat de moleculaire pathologie een 
snel veranderend veld is; dagelijks worden nieuwe 
ontdekkingen en technieken in de routine diagnostiek 
geïmplementeerd. Een van de meest belangrijke 
recente veranderingen in de moleculaire pathologie 
is de introductie van next generation sequencing 
(NGS). Het principe van NGS is dat, in tegenstelling 
tot bij Sanger sequentie analyse, miljoenen korte 
DNA fragmenten tegelijkertijd kunnen worden 
geanalyseerd. Daardoor is het mogelijk om een 
grote hoeveelheid genen te analyseren met een 
hoge sensitiviteit, zelfs wanneer slechts een kleine 
hoeveelheid weefsel voor analyse beschikbaar is. 
Aanvullend kan NGS ook gebruikt worden voor 
het detecteren van DNA copy number afwijkingen 
(deleties of toenames van DNA), door het analyseren 
van SNPs of fragment coverage. 
Deel I - Clonaliteits-analyses
Sommige patiënten hebben 
meerdere tumoren, tegelijkertijd of 
met enige tijd tussen het ontstaan 
van de tumoren. Deze tumoren 
kunnen onafhankelijke primaire 
tumoren zijn, het is echter ook mogelijk dat het een 
primaire tumor betreft met een uitzaaiing daarvan. 
Voor optimale behandeling van de patiënt is het 
belangrijk dit onderscheid te kunnen maken, echter 
dit is niet altijd mogelijk op basis van de klinische en 
histopathologische kenmerken. Omdat elke tumor 
specifieke verkregen (somatische) afwijkingen heeft, 
kan analyse van deze afwijkingen bijdragen aan het 
stellen van de juiste diagnose. Wanneer meerdere 
tumoren dezelfde afwijkingen hebben suggereert 
dit een gezamenlijke origine, terwijl aanwezigheid 
van verschillende afwijkingen erop wijst dat de 
tumoren onafhankelijke entiteiten zijn. Naast 
somatische afwijkingen kunnen ook andere unieke 
karakteristieken van de cel geanalyseerd worden. 
Voor de meeste clonaliteits-analyses binnen de 
moleculaire pathologie worden tumoren gescreend 
voor zowel mutaties in multipele genen als voor DNA 
copy number afwijkingen.
 In hoofdstuk 2 wordt een patiënt beschreven 
met een uitzaaiing van een colorectaal carcinoom in 
een getransplanteerde lever. Vanwege een negatieve 
coloscopie rees de vraag of de tumor van deze patiënt 
wellicht van donor-origine kon zijn. Unieke patiënt 
specifieke DNA markers (STRs) zijn geanalyseerd om 
te bepalen of de uitzaaiing van donor of receptor 
origine was, de tumorcellen bleken van donor origine 
te zijn. Deze resultaten laten zien dat ondanks dat 
donor gerelateerde tumoren erg zeldzaam zijn, het 
voor de juiste behandeling cruciaal is deze optie te 
overwegen. 
 Clonale markers met een hoge voorspellende 
waarde zijn immuunglobuline zware (IGH) en Ƙ 
lichte keten (IGK) herschikkingen bij lymfomen. 
Deze DNA herschikkingen zijn niet tumor-
specifiek, alle lymfocyten hebben unieke IGH en 
IGK herschikkingen. Wanneer echter een lymfoom 
ontstaat uit een van deze lymfocyten, zullen alle 
lymfoom cellen dezelfde unieke herschikte DNA 
sequentie bevatten. In hoofdstuk 3 zijn IGH en 
IGK herschikkingen bestudeerd in patiënten met 
meerdere B-cel lymfomen om te bepalen of het 
multipele primaire lymfomen of een primaire tumor 
met een of meerdere uitzaaiing(en) betrof. Na 
initiële behandeling wordt 25-85% van de patiënten 
met maligne lymfomen opnieuw met een lymfoom 
gediagnosticeerd, welke meestal beschouwd 
wordt als dezelfde origine. Voor deze studie zijn 36 
patiënten geselecteerd met 5-15 jaar tussen het 
ontstaan van de opeenvolgende lymfomen, omdat 
vooral bij een lange periode de kans bestaat dat het 
meerdere primaire tumoren betreft. In 89-94% van 
de gevallen bleken de multipele lymfomen echter 
dezelfde origine te hebben. Dit onderzoek toont 
daarom aan dat het routinematig onderzoeken van 
de clonale relatie tussen meerdere opeenvolgende 
lymfomen niet geïndiceerd is. Dit is mogelijk wel 
het geval voor specifieke subtypes lymfomen, zoals 
diffuus grootcellige B-cel lymfomen.
 Naast genomisch DNA bevatten humane 
cellen ook mitochondriaal DNA (mtDNA), waarin voor 
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meerdere tumortypen afwijkingen zijn beschreven. 
In hoofdstuk 4 wordt de mogelijkheid onderzocht om 
mtDNA afwijkingen te gebruiken voor clonaliteits-
analyse bij patiënten met meerdere tumoren. 
Sanger sequentie analyse van de D310 repeat, een 
van de meest voorkomende mtDNA afwijkingen, 
is daarvoor uitgevoerd op een diagnostisch cohort 
van 382 patiënten met in totaal 857 tumoren, welke 
eerder zijn onderzocht met de routine moleculaire 
analyse op genomisch DNA. D310 mutaties werden 
gedetecteerd in één of meerdere tumoren van 26% 
van de patiënten, voor deze patiënten kan D310 
als clonaliteits-marker worden gebruikt. Echter, 
de clonaliteits bepalingen op basis van mtDNA 
en genomisch DNA kwamen slechts tot hetzelfde 
resultaat in 71% van de patiënten. Deze studie 
toont aan dat D310 mutatie analyse kan helpen bij 
clonaliteits-analyses, maar als afzonderlijke test een 
beperkte voorspellende waarde heeft. Om verder 
te kijken naar de waarde van mtDNA analyse in 
clonaliteits-analyses, zouden NGS assays aangevuld 
kunnen worden met mtDNA markers, zoals de D310 
repeat.
 In hoofdstuk 5 wordt de juistheid en de 
additionele waarde van targeted NGS onderzocht 
voor het bepalen van de clonale relatie tussen 
twee long laesies van een patiënt. Het sub-typeren 
van niet-kleincellige longtumoren door middel van 
histologie en moleculair onderzoek is belangrijk voor 
het voorspellen van prognose en therapierespons. De 
twee tumoren van de index patiënt lieten verschillende 
activerende EGFR mutaties, EGFR amplificatie 
status, TP53 mutatie status en chromosomale 
verliezen zien met routine moleculaire analyse. 
Met NGS, waarmee gescreend wordt op mutaties 
in de hotspots van 50 genen, werden alle eerder 
gevonden mutaties bevestigd. Aanvullend werd een 
extra variant gevonden in een gen wat niet gecoverd 
werd door de routine analyse. Concluderend werden 
de tumoren met behulp van NGS analyse correct als 
onafhankelijke primaire tumoren beschouwd. Deze 
studie toont tevens aan multifocale niet-kleincellige 
longtumoren als mogelijk meerdere onafhankelijke 
primaire tumoren moeten worden beschouwd, en 
dat moleculaire screening voor therapiekeuze op alle 
laesies zou moeten worden uitgevoerd.
 In hoofdstuk 6 werd de waarde van targeted 
NGS voor de diagnostiek van patiënten met BRCA1 
of BRCA2 kiembaanmutaties en twee of meerdere 
tumoren geëvalueerd. Vrouwelijke BRCA1 of 
BRCA2 kiembaandragers hebben een hoge kans op 
het ontwikkelen van borst- en ovariumkanker, en 
ontwikkelen daarom vaak meerdere tumoren. Het 
is belangrijk de clonale relatie tussen deze tumoren 
te bepalen, aangezien de behandeling en prognose 
bepaald worden aan de hand van de primaire tumor. 
Voor deze studie is routine histopathologie verricht 
op de tumoren van 42 patiënten, waarbij voor 
38 patiënten een conclusief resultaat verkregen 
werd. Voor 14 patiënten is vervolgens targeted 
NGS uitgevoerd, met behulp van een custom made 
panel voor het detecteren van zowel mutaties als 
copy number veranderingen. Voor alle 14 patiënten 
konden de relaties tussen de verschillende tumoren 
eenduidig bepaald worden met behulp van NGS. 
Voor 10 van deze patiënten was ook een conclusief 
resultaat aanwezig op basis van histopathologie, 
welk overeenkwam met het NGS resultaat voor alle 
patiënten. Deze studie toont aan dat voor de meeste 
BRCA1 en BRCA2 mutatiedraagsters met meerdere 
tumoren routine histopathologisch onderzoek 
voldoende is om de origine van de tumoren te 
bepalen, en dat NGS analyse een waardevolle 
aanvulling is wanneer histopathologisch onderzoek 
niet conclusief is.
Deel II - Moleculaire pathologie 
in het kader van erfelijk onderzoek
Wanneer een patiënt mogelijk drager 
is van kiembaanmutatie wordt deze 
binnen Nederland gecounseld door 
de klinische genetica. Een verdenking 
op een kiembaanmutatie kan 
bijvoorbeeld gebaseerd zijn op een jonge leeftijd bij 
diagnose, het hebben van meerdere tumoren en/
of familie geschiedenis. Het aantonen van specifieke 
somatische afwijkingen kan onderdeel uitmaken 
van de voorscreening van tumoren die mogelijk 
ontstaan zijn in het kader van een erfelijke afwijking. 
Ook wanneer patiënten al worden gecounseld kan 
somatische analyse geïndiceerd zijn, bijvoorbeeld 
om meer informatie te krijgen over de mogelijke 
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pathogeniciteit van kiembaanvarianten. Tevens kan 
het aantonen van somatische afwijkingen soms 
helpen bij het uitsluiten van een erfelijke oorzaak 
van een tumor. onderzoek
 Familiare adenomateuze polyposis (FAP) is 
een erfelijke aandoening waarbij een groot aantal 
poliepen in de dikke darm voorkomen, waaruit 
darmkanker kan ontstaan. FAP wordt veroorzaakt 
door kiembaan mutaties in APC. Desmoid tumoren 
(tumoren van de weke delen) kunnen een eerste 
manifestatie zijn van FAP, echter, het testen voor 
kiembaan APC mutaties wordt niet standaard 
uitgevoerd bij kinderen met desmoid tumoren. 
In hoofdstuk 7 wordt met behulp van β-catenine 
immunohistochemie (IHC) en CTNNB1 mutatie analyse 
gezocht naar mogelijke APC kiembaan mutatiedragers 
bij 18 kinderen met desmoid tumoren. In 11 tumoren 
werd afwijkende β-catenine aankleuring gevonden, 
indicatief voor een APC of CTNNB1 mutatie, 7 van 
deze tumoren hadden somatische CTNNB1 mutaties. 
In twee tumoren met afwijkende β-catenine 
aankleuring maar geen CTNNB1 mutatie, werd een 
kiembaan APC mutatie gedetecteerd. Dit onderzoek 
laat zien dat de combinatie van β-catenine IHC en 
CTNNB1 mutatie analyse een goede strategie is om 
patiënten te selecteren voor kiembaan APC analyse. 
 Lynch syndroom (LS) is een erfelijke 
aandoening waarbij patiënten een hoge kans hebben 
op het ontwikkelen van meerdere typen tumoren, 
waaronder colorectale en endometrium tumoren. 
LS wordt veroorzaakt door kiembaanmutaties in 
één van de vier mismatch repair (MMR) genen. 
De voorscreening voor LS bestaat uit analyse van 
een tumor door middel van immunohistochemisch 
onderzoek naar expressie van de vier MMR eiwitten 
en/of DNA microsatelliet instabiliteit (MSI, een 
kenmerk van LS) analyse. In hoofdstuk 8 wordt een 
pitfall van deze screeningsstrategie besproken voor 
een familie met biallelische PMS2 mutaties. Deze 
studie beschrijft een patiënt en zijn zus met beide 
biallelische PMS2 mutaties, afkomstig van de vader 
en moeder. De hersentumoren van beide patiënten 
toonden afwezigheid van PMS2 expressie, passend bij 
de afwijkingen. Echter, MSI analyse toonde MSI voor 
slechts 2/5 markers in de tumor van de index patiënt, 
en geen MSI in de tumor van de zus. Deze resultaten 
laten zien dat bij verdenking op een biallelische MMR 
afwijking, MSI analyse gecombineerd zou moeten 
worden met MMR eiwit IHC. 
 Patiënten verdacht voor het hebben 
van LS worden getest op de aanwezigheid van 
kiembaanmutaties in de MMR genen. Bij 35% van 
deze patiënten wordt echter geen kiembaanmutatie 
gevonden. In hoofdstuk 9 zijn de microsatelliet 
instabiele tumoren van 40 patiënten, verdacht voor 
LS maar zonder kiembaan MMR mutatie, getest voor 
somatische afwijkingen van de MMR genen met 
behulp van targeted NGS en SNaPshot analyse. De 
helft van de patiënten bleek sporadische tumoren te 
hebben die ontstaan zijn door twee somatische MMR-
gen afwijkingen. Op basis van deze bevindingen zijn 
die patiënten niet langer verdacht voor het hebben 
van LS. Deze studie laat zien dat somatische MMR-gen 
analyse substantieel kan bijdragen aan de diagnose 
van patiënten verdacht voor LS en hun familieleden. 
Op basis van onze resultaten en literatuur adviseren 
we daarom om somatische MMR-gen analyse toe 
te voegen aan de routine workflow van patiënten 
verdacht voor LS.
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plaatjes, posters en nu dit mooie proefschrift. Noa en Otis: de wereld is mooier met jullie.
Stellingen
Behorende bij het proefschrift
Next Generation Diagnostic Molecular Pathology
1. Wanneer een patiënt gediagnosticeerd wordt met twee opeenvolgende lymfomen is de kans groot 
dat dit dezelfde entiteit betreft, zelfs na lange tijd. (dit proefschrift)
2. Multifocale niet-kleincellige longtumoren moeten beschouwd worden als potentieel multiple 
primaire tumoren. (dit proefschrift)
3. Voor de meeste BRCA1 en BRCA2 mutatiedraagsters met meerdere tumoren is routine 
histopathologisch onderzoek voldoende om de origine van de tumoren te bepalen. (dit proefschrift)
4. Targeted NGS is een geschikte methode om de clonale relatie tussen meerdere tumoren te bepalen. 
(dit proefschrift)
5. Het aantonen van somatische afwijkingen in een tumor kan helpen bij het uitsluiten van een erfelijke 
oorzaak. (dit proefschrift)
6. Moleculaire diagnostiek is waarschijnlijkheidsdiagnostiek.
7. Verrijken voor tumorcellen door middel van microdissectie komt de uiteindelijke interpretatie van de 
moleculaire resultaten ten goede.
8. De capaciteit voor het genereren van NGS data is vele malen groter dan ons vermogen deze data te 
interpreteren (Nekrutenko et al. Nature Reviews Genetics, 2012)
9. Kanker is geen oorlog die over 20 jaar is gewonnen. (Hans Clevers)
10. Een microscoop kan wel 40x vergroten, maar als je er voor de 41e  keer doorheen kijkt doet hij het ook 
nog gewoon. (aangepast van Herman Finkers)
11. Ik hoop maar dat er roze koeken zijn. (Spinvis)
Willemina RR Geurts-Giele, 2016
